{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:41:21Z","timestamp":1792194081114,"version":"4.4.0"},"reference-count":478,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300212"],"award-info":[{"award-number":["82300212"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403198"],"award-info":[{"award-number":["82403198"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"DOI":"10.1186\/s40364-026-01019-6","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:02:19Z","timestamp":1792166539000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dynamic regulation of H3K9 modifications in cancer: pathogenesis and targeted therapies"],"prefix":"10.1186","volume":"14","author":[{"given":"Yuanyuan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qihui","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxiu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodan","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"issue":"10","key":"1019_CR1","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/2159-8290.CD-24-0296","volume":"14","author":"M Esteller","year":"2024","unstructured":"Esteller M, Dawson MA, Kadoch C, Rassool FV, Jones PA, Baylin SB. The Epigenetic Hallmarks of Cancer. Cancer Discov. 2024;14(10):1783\u2013809.","journal-title":"Cancer Discov"},{"key":"1019_CR2","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1146\/annurev.genet.032608.103928","volume":"43","author":"EI Campos","year":"2009","unstructured":"Campos EI, Reinberg D. Histones: annotating chromatin. Annu Rev Genet. 2009;43:559\u201399.","journal-title":"Annu Rev Genet"},{"issue":"9","key":"1019_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41576-022-00468-7","volume":"23","author":"G Millan-Zambrano","year":"2022","unstructured":"Millan-Zambrano G, Burton A, Bannister AJ, Schneider R. Histone post-translational modifications - cause and consequence of genome function. Nat Rev Genet. 2022;23(9):563\u201380.","journal-title":"Nat Rev Genet"},{"issue":"3","key":"1019_CR4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1042\/BCJ20200170","volume":"478","author":"BC Taylor","year":"2021","unstructured":"Taylor BC, Young NL. Combinations of histone post-translational modifications. Biochem J. 2021;478(3):511\u201332.","journal-title":"Biochem J"},{"key":"1019_CR5","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.semcancer.2020.07.015","volume":"83","author":"ME Neganova","year":"2022","unstructured":"Neganova ME, Klochkov SG, Aleksandrova YR, Aliev G. Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress. Semin Cancer Biol. 2022;83:452\u201371.","journal-title":"Semin Cancer Biol"},{"issue":"9","key":"1019_CR6","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41580-022-00483-w","volume":"23","author":"J Padeken","year":"2022","unstructured":"Padeken J, Methot SP, Gasser SM. Establishment of H3K9-methylated heterochromatin and its functions in tissue differentiation and maintenance. Nat Rev Mol Cell Biol. 2022;23(9):623\u201340.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"1019_CR7","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41392-024-02030-9","volume":"9","author":"Y Chen","year":"2024","unstructured":"Chen Y, Liang R, Li Y, Jiang L, Ma D, Luo Q, Song G. Chromatin accessibility: biological functions, molecular mechanisms and therapeutic application. Signal Transduct Target Ther. 2024;9(1):340.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1019_CR8","doi-asserted-by":"publisher","first-page":"3561","DOI":"10.1038\/s41467-024-47900-6","volume":"15","author":"Z Niu","year":"2024","unstructured":"Niu Z, Chen C, Wang S, Lu C, Wu Z, Wang A, Mo J, Zhang J, Han Y, Yuan Y, et al. HBO1 catalyzes lysine lactylation and mediates histone H3K9la to regulate gene transcription. Nat Commun. 2024;15(1):3561.","journal-title":"Nat Commun"},{"issue":"2","key":"1019_CR9","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.molcel.2016.03.036","volume":"62","author":"Z Xie","year":"2016","unstructured":"Xie Z, Zhang D, Chung D, Tang Z, Huang H, Dai L, Qi S, Li J, Colak G, Chen Y, et al. Metabolic Regulation of Gene Expression by Histone Lysine beta-Hydroxybutyrylation. Mol Cell. 2016;62(2):194\u2013206.","journal-title":"Mol Cell"},{"key":"1019_CR10","doi-asserted-by":"crossref","first-page":"101249","DOI":"10.1016\/j.molmet.2021.101249","volume":"53","author":"Z Yang","year":"2021","unstructured":"Yang Z, He M, Austin J, Pfleger J, Abdellatif M. Histone H3K9 butyrylation is regulated by dietary fat and stress via an Acyl-CoA dehydrogenase short chain-dependent mechanism. Mol Metab. 2021;53:101249.","journal-title":"Mol Metab"},{"key":"1019_CR11","doi-asserted-by":"crossref","unstructured":"Yuan M, Li S, Chen S, Zhu M, Yu R, Huang J, et al. ACSS2-mediated lysine crotonylation attenuates senescence and enhances the therapeutic efficacy of adipose-derived stem cells in inflammatory bowel disease. Cell Regen. 2026;15(1):11.","DOI":"10.1186\/s13619-026-00285-x"},{"issue":"2","key":"1019_CR12","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/cbic.201000545","volume":"12","author":"S Krishnan","year":"2011","unstructured":"Krishnan S, Horowitz S, Trievel RC. Structure and function of histone H3 lysine 9 methyltransferases and demethylases. ChemBioChem. 2011;12(2):254\u201363.","journal-title":"ChemBioChem"},{"issue":"2","key":"1019_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/emboj.2010.318","volume":"30","author":"Q Jin","year":"2011","unstructured":"Jin Q, Yu LR, Wang L, Zhang Z, Kasper LH, Lee JE, Wang C, Brindle PK, Dent SY, Ge K. Distinct roles of GCN5\/PCAF-mediated H3K9ac and CBP\/p300-mediated H3K18\/27ac in nuclear receptor transactivation. EMBO J. 2011;30(2):249\u201362.","journal-title":"EMBO J"},{"issue":"5","key":"1019_CR14","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.cell.2009.06.049","volume":"138","author":"Z Wang","year":"2009","unstructured":"Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W, Zhao K. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell. 2009;138(5):1019\u201331.","journal-title":"Cell"},{"issue":"1","key":"1019_CR15","doi-asserted-by":"crossref","first-page":"14690","DOI":"10.1038\/s41598-018-32927-9","volume":"8","author":"RDW Kelly","year":"2018","unstructured":"Kelly RDW, Chandru A, Watson PJ, Song Y, Blades M, Robertson NS, Jamieson AG, Schwabe JWR, Cowley SM. Histone deacetylase (HDAC) 1 and 2 complexes regulate both histone acetylation and crotonylation in vivo. Sci Rep. 2018;8(1):14690.","journal-title":"Sci Rep"},{"issue":"6824","key":"1019_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/35065138","volume":"410","author":"AJ Bannister","year":"2001","unstructured":"Bannister AJ, Zegerman P, Partridge JF, Miska EA, Thomas JO, Allshire RC, Kouzarides T. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature. 2001;410(6824):120\u20134.","journal-title":"Nature"},{"key":"1019_CR17","doi-asserted-by":"crossref","unstructured":"Ni Y, Shi M, Liu L, Lin D, Zeng H, Ong C, et al. G9a in Cancer: mechanisms, therapeutic advancements, and clinical implications. Cancers (Basel) 2024;16(12):2175.","DOI":"10.3390\/cancers16122175"},{"issue":"1","key":"1019_CR18","doi-asserted-by":"crossref","first-page":"188498","DOI":"10.1016\/j.bbcan.2020.188498","volume":"1875","author":"N Saha","year":"2021","unstructured":"Saha N, Muntean AG. Insight into the multi-faceted role of the SUV family of H3K9 methyltransferases in carcinogenesis and cancer progression. Biochim Biophys Acta Rev Cancer. 2021;1875(1):188498.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"5","key":"1019_CR19","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/med.21955","volume":"43","author":"YQ Song","year":"2023","unstructured":"Song YQ, Yang GJ, Ma DL, Wang W, Leung CH. The role and prospect of lysine-specific demethylases in cancer chemoresistance. Med Res Rev. 2023;43(5):1438\u201369.","journal-title":"Med Res Rev"},{"key":"1019_CR20","doi-asserted-by":"crossref","unstructured":"Jeon YH, Seo H, Youn JW, Yoo J, Lee SW, Oh SY, et al. Histone deacetylases in cancer metabolic reprogramming. Exp Mol Med. 2026;58(9):2812\u201324.","DOI":"10.1038\/s12276-026-01820-1"},{"issue":"1","key":"1019_CR21","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1038\/s41467-018-07077-1","volume":"9","author":"SP Rowbotham","year":"2018","unstructured":"Rowbotham SP, Li F, Dost AFM, Louie SM, Marsh BP, Pessina P, Anbarasu CR, Brainson CF, Tuminello SJ, Lieberman A, et al. H3K9 methyltransferases and demethylases control lung tumor-propagating cells and lung cancer progression. Nat Commun. 2018;9(1):4559.","journal-title":"Nat Commun"},{"issue":"2","key":"1019_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrm.2016.140","volume":"18","author":"BR Sabari","year":"2017","unstructured":"Sabari BR, Zhang D, Allis CD, Zhao Y. Metabolic regulation of gene expression through histone acylations. Nat Rev Mol Cell Biol. 2017;18(2):90\u2013101.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"11","key":"1019_CR23","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1038\/nrm1761","volume":"6","author":"C Martin","year":"2005","unstructured":"Martin C, Zhang Y. The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol. 2005;6(11):838\u201349.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"1019_CR24","first-page":"165","volume":"14","author":"Y Li","year":"2023","unstructured":"Li Y, Ge K, Li T, Cai R, Chen Y. The engagement of histone lysine methyltransferases with nucleosomes: structural basis, regulatory mechanisms, and therapeutic implications. Protein Cell. 2023;14(3):165\u201379.","journal-title":"Protein Cell"},{"issue":"8","key":"1019_CR25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrm4029","volume":"16","author":"C Mozzetta","year":"2015","unstructured":"Mozzetta C, Boyarchuk E, Pontis J, Ait-Si-Ali S. Sound of silence: the properties and functions of repressive Lys methyltransferases. Nat Rev Mol Cell Biol. 2015;16(8):499\u2013513.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"1019_CR26","doi-asserted-by":"crossref","first-page":"e8570","DOI":"10.1371\/journal.pone.0008570","volume":"5","author":"H Wu","year":"2010","unstructured":"Wu H, Min J, Lunin VV, Antoshenko T, Dombrovski L, Zeng H, Allali-Hassani A, Campagna-Slater V, Vedadi M, Arrowsmith CH, et al. Structural biology of human H3K9 methyltransferases. PLoS ONE. 2010;5(1):e8570.","journal-title":"PLoS ONE"},{"issue":"1","key":"1019_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biochi.2006.07.009","volume":"89","author":"P Volkel","year":"2007","unstructured":"Volkel P, Angrand PO. The control of histone lysine methylation in epigenetic regulation. Biochimie. 2007;89(1):1\u201320.","journal-title":"Biochimie"},{"issue":"3","key":"1019_CR28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0092-8674(01)00542-6","volume":"107","author":"AH Peters","year":"2001","unstructured":"Peters AH, O\u2019Carroll D, Scherthan H, Mechtler K, Sauer S, Schofer C, Weipoltshammer K, Pagani M, Lachner M, Kohlmaier A, et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell. 2001;107(3):323\u201337.","journal-title":"Cell"},{"issue":"1","key":"1019_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/ng1278","volume":"36","author":"M Garcia-Cao","year":"2004","unstructured":"Garcia-Cao M, O\u2019Sullivan R, Peters AH, Jenuwein T, Blasco MA. Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases. Nat Genet. 2004;36(1):94\u20139.","journal-title":"Nat Genet"},{"issue":"8","key":"1019_CR30","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1101\/gad.2027411","volume":"25","author":"Y Shinkai","year":"2011","unstructured":"Shinkai Y, Tachibana M. H3K9 methyltransferase G9a and the related molecule GLP. Genes Dev. 2011;25(8):781\u20138.","journal-title":"Genes Dev"},{"issue":"51","key":"1019_CR31","doi-asserted-by":"crossref","first-page":"53248","DOI":"10.1074\/jbc.M409604200","volume":"279","author":"D Patnaik","year":"2004","unstructured":"Patnaik D, Chin HG, Esteve PO, Benner J, Jacobsen SE, Pradhan S. Substrate specificity and kinetic mechanism of mammalian G9a histone H3 methyltransferase. J Biol Chem. 2004;279(51):53248\u201358.","journal-title":"J Biol Chem"},{"issue":"1","key":"1019_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/ni.3046","volume":"16","author":"C Schliehe","year":"2015","unstructured":"Schliehe C, Flynn EK, Vilagos B, Richson U, Swaminanthan S, Bosnjak B, Bauer L, Kandasamy RK, Griesshammer IM, Kosack L, et al. The methyltransferase Setdb2 mediates virus-induced susceptibility to bacterial superinfection. Nat Immunol. 2015;16(1):67\u201374.","journal-title":"Nat Immunol"},{"issue":"6","key":"1019_CR33","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.stem.2011.04.004","volume":"8","author":"MM Karimi","year":"2011","unstructured":"Karimi MM, Goyal P, Maksakova IA, Bilenky M, Leung D, Tang JX, Shinkai Y, Mager DL, Jones S, Hirst M, et al. DNA methylation and SETDB1\/H3K9me3 regulate predominantly distinct sets of genes, retroelements, and chimeric transcripts in mESCs. Cell Stem Cell. 2011;8(6):676\u201387.","journal-title":"Cell Stem Cell"},{"issue":"6","key":"1019_CR34","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1093\/nar\/gkt1377","volume":"42","author":"LM Congdon","year":"2014","unstructured":"Congdon LM, Sims JK, Tuzon CT, Rice JC. The PR-Set7 binding domain of Riz1 is required for the H4K20me1-H3K9me1 trans-tail \u2018histone code\u2019 and Riz1 tumor suppressor function. Nucleic Acids Res. 2014;42(6):3580\u20139.","journal-title":"Nucleic Acids Res"},{"key":"1019_CR35","doi-asserted-by":"crossref","unstructured":"Biferali B, Bianconi V, Perez DF, Kronawitter SP, Marullo F, Maggio R, et al. Prdm16-mediated H3K9 methylation controls fibro-adipogenic progenitors identity during skeletal muscle repair. Sci Adv. 2021;7(23):eabd9371.","DOI":"10.1126\/sciadv.abd9371"},{"issue":"5","key":"1019_CR36","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nrm3327","volume":"13","author":"SM Kooistra","year":"2012","unstructured":"Kooistra SM, Helin K. Molecular mechanisms and potential functions of histone demethylases. Nat Rev Mol Cell Biol. 2012;13(5):297\u2013311.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1019_CR37","doi-asserted-by":"crossref","unstructured":"Shi YG, Tsukada Y. The discovery of histone demethylases. Cold Spring Harb Perspect Biol. 2013;5(9):a017947.","DOI":"10.1101\/cshperspect.a017947"},{"issue":"7078","key":"1019_CR38","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/nature04433","volume":"439","author":"Y Tsukada","year":"2006","unstructured":"Tsukada Y, Fang J, Erdjument-Bromage H, Warren ME, Borchers CH, Tempst P, Zhang Y. Histone demethylation by a family of JmjC domain-containing proteins. Nature. 2006;439(7078):811\u20136.","journal-title":"Nature"},{"issue":"3","key":"1019_CR39","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cell.2006.03.028","volume":"125","author":"JR Whetstine","year":"2006","unstructured":"Whetstine JR, Nottke A, Lan F, Huarte M, Smolikov S, Chen Z, Spooner E, Li E, Zhang G, Colaiacovo M, et al. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell. 2006;125(3):467\u201381.","journal-title":"Cell"},{"issue":"10","key":"1019_CR40","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1158\/0008-5472.CAN-12-4300","volume":"73","author":"WL Berry","year":"2013","unstructured":"Berry WL, Janknecht R. KDM4\/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Cancer Res. 2013;73(10):2936\u201342.","journal-title":"Cancer Res"},{"issue":"3","key":"1019_CR41","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cell.2006.03.027","volume":"125","author":"K Yamane","year":"2006","unstructured":"Yamane K, Toumazou C, Tsukada Y, Erdjument-Bromage H, Tempst P, Wong J, Zhang Y. JHDM2A, a JmjC-containing H3K9 demethylase, facilitates transcription activation by androgen receptor. Cell. 2006;125(3):483\u201395.","journal-title":"Cell"},{"issue":"1","key":"1019_CR42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1541-7786.MCR-20-0404","volume":"19","author":"Y Sui","year":"2021","unstructured":"Sui Y, Gu R, Janknecht R. Crucial Functions of the JMJD1\/KDM3 Epigenetic Regulators in Cancer. Mol Cancer Res. 2021;19(1):3\u201313.","journal-title":"Mol Cancer Res"},{"issue":"21","key":"1019_CR43","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1002\/chem.201900492","volume":"25","author":"SS Chaturvedi","year":"2019","unstructured":"Chaturvedi SS, Ramanan R, Waheed SO, Ainsley J, Evison M, Ames JM, Schofield CJ, Karabencheva-Christova TG, Christov CZ. Conformational Dynamics Underlies Different Functions of Human KDM7 Histone Demethylases. Chemistry. 2019;25(21):5422\u20136.","journal-title":"Chemistry"},{"issue":"6","key":"1019_CR44","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ncb2228","volume":"13","author":"A Baba","year":"2011","unstructured":"Baba A, Ohtake F, Okuno Y, Yokota K, Okada M, Imai Y, Ni M, Meyer CA, Igarashi K, Kanno J, et al. PKA-dependent regulation of the histone lysine demethylase complex PHF2-ARID5B. Nat Cell Biol. 2011;13(6):668\u201375.","journal-title":"Nat Cell Biol"},{"key":"1019_CR45","doi-asserted-by":"crossref","unstructured":"Liu L, Rodriguez-Mateo C, Huang P, Huang A, Lieu A, Mao M, Chung M, Yang S, Yu K, Charville GW, et al. Hairless regulates heterochromatin maintenance and muscle stem cell function as a histone demethylase antagonist. Proc Natl Acad Sci USA. 2021;118(37).","DOI":"10.1073\/pnas.2025281118"},{"issue":"4","key":"1019_CR46","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1096\/fj.13-237677","volume":"28","author":"L Liu","year":"2014","unstructured":"Liu L, Kim H, Casta A, Kobayashi Y, Shapiro LS, Christiano AM. Hairless is a histone H3K9 demethylase. FASEB J. 2014;28(4):1534\u201342.","journal-title":"FASEB J"},{"issue":"14","key":"1019_CR47","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1021\/acs.chemrev.8b00008","volume":"118","author":"M Luo","year":"2018","unstructured":"Luo M. Chemical and Biochemical Perspectives of Protein Lysine Methylation. Chem Rev. 2018;118(14):6656\u2013705.","journal-title":"Chem Rev"},{"issue":"3","key":"1019_CR48","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/cr.2011.22","volume":"21","author":"AJ Bannister","year":"2011","unstructured":"Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011;21(3):381\u201395.","journal-title":"Cell Res"},{"issue":"3","key":"1019_CR49","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/nsmb.1384","volume":"15","author":"RE Collins","year":"2008","unstructured":"Collins RE, Northrop JP, Horton JR, Lee DY, Zhang X, Stallcup MR, Cheng X. The ankyrin repeats of G9a and GLP histone methyltransferases are mono- and dimethyllysine binding modules. Nat Struct Mol Biol. 2008;15(3):245\u201350.","journal-title":"Nat Struct Mol Biol"},{"key":"1019_CR50","doi-asserted-by":"publisher","unstructured":"Liu N, Zhang Z, Wu H, Jiang Y, Meng L, Xiong J, et al. Recognition of H3K9 methylation by GLP is required for efficient establishment of H3K9 methylation, rapid target gene repression, and mouse viability. Genes Dev. 2015;29(4):379\u201393. https:\/\/doi.org\/10.1371\/journal.pgen.1002017.","DOI":"10.1371\/journal.pgen.1002017"},{"issue":"3","key":"1019_CR51","doi-asserted-by":"crossref","first-page":"e1002017","DOI":"10.1371\/journal.pgen.1002017","volume":"7","author":"N Koester-Eiserfunke","year":"2011","unstructured":"Koester-Eiserfunke N, Fischle W. H3K9me2\/3 binding of the MBT domain protein LIN-61 is essential for Caenorhabditis elegans vulva development. PLoS Genet. 2011;7(3):e1002017.","journal-title":"PLoS Genet"},{"issue":"12","key":"1019_CR52","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1038\/cr.2011.176","volume":"21","author":"J Zhang","year":"2011","unstructured":"Zhang J, Gao Q, Li P, Liu X, Jia Y, Wu W, Li J, Dong S, Koseki H, Wong J. S phase-dependent interaction with DNMT1 dictates the role of UHRF1 but not UHRF2 in DNA methylation maintenance. Cell Res. 2011;21(12):1723\u201339.","journal-title":"Cell Res"},{"issue":"7454","key":"1019_CR53","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nature12178","volume":"498","author":"JA Law","year":"2013","unstructured":"Law JA, Du J, Hale CJ, Feng S, Krajewski K, Palanca AM, Strahl BD, Patel DJ, Jacobsen SE. Polymerase IV occupancy at RNA-directed DNA methylation sites requires SHH1. Nature. 2013;498(7454):385\u20139.","journal-title":"Nature"},{"issue":"2","key":"1019_CR54","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1042\/BJ20090870","volume":"423","author":"CA Musselman","year":"2009","unstructured":"Musselman CA, Mansfield RE, Garske AL, Davrazou F, Kwan AH, Oliver SS, O\u2019Leary H, Denu JM, Mackay JP, Kutateladze TG. Binding of the CHD4 PHD2 finger to histone H3 is modulated by covalent modifications. Biochem J. 2009;423(2):179\u201387.","journal-title":"Biochem J"},{"issue":"3","key":"1019_CR55","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.molcel.2005.06.011","volume":"19","author":"CR Vakoc","year":"2005","unstructured":"Vakoc CR, Mandat SA, Olenchock BA, Blobel GA. Histone H3 lysine 9 methylation and HP1gamma are associated with transcription elongation through mammalian chromatin. Mol Cell. 2005;19(3):381\u201391.","journal-title":"Mol Cell"},{"issue":"21","key":"1019_CR56","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1158\/0008-5472.CAN-14-3735","volume":"75","author":"M Liu","year":"2015","unstructured":"Liu M, Huang F, Zhang D, Ju J, Wu XB, Wang Y, Wang Y, Wu Y, Nie M, Li Z, et al. Heterochromatin protein HP1gamma promotes colorectal cancer progression and is regulated by miR-30a. Cancer Res. 2015;75(21):4593\u2013604.","journal-title":"Cancer Res"},{"issue":"27","key":"1019_CR57","doi-asserted-by":"crossref","first-page":"24300","DOI":"10.1074\/jbc.M111.234104","volume":"286","author":"N Nady","year":"2011","unstructured":"Nady N, Lemak A, Walker JR, Avvakumov GV, Kareta MS, Achour M, Xue S, Duan S, Allali-Hassani A, Zuo X, et al. Recognition of multivalent histone states associated with heterochromatin by UHRF1 protein. J Biol Chem. 2011;286(27):24300\u201311.","journal-title":"J Biol Chem"},{"issue":"2","key":"1019_CR58","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1128\/MCB.01598-07","volume":"28","author":"P Karagianni","year":"2008","unstructured":"Karagianni P, Amazit L, Qin J, Wong J. ICBP90, a novel methyl K9 H3 binding protein linking protein ubiquitination with heterochromatin formation. Mol Cell Biol. 2008;28(2):705\u201317.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"1019_CR59","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41392-022-01245-y","volume":"7","author":"S Shang","year":"2022","unstructured":"Shang S, Liu J, Hua F. Protein acylation: mechanisms, biological functions and therapeutic targets. Signal Transduct Target Ther. 2022;7(1):396.","journal-title":"Signal Transduct Target Ther"},{"issue":"35","key":"1019_CR60","doi-asserted-by":"crossref","first-page":"14456","DOI":"10.1074\/jbc.M117.802074","volume":"292","author":"LA Gates","year":"2017","unstructured":"Gates LA, Shi J, Rohira AD, Feng Q, Zhu B, Bedford MT, Sagum CA, Jung SY, Qin J, Tsai MJ, et al. Acetylation on histone H3 lysine 9 mediates a switch from transcription initiation to elongation. J Biol Chem. 2017;292(35):14456\u201372.","journal-title":"J Biol Chem"},{"issue":"1","key":"1019_CR61","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/s41467-017-01384-9","volume":"8","author":"J Simithy","year":"2017","unstructured":"Simithy J, Sidoli S, Yuan ZF, Coradin M, Bhanu NV, Marchione DM, Klein BJ, Bazilevsky GA, McCullough CE, Magin RS, et al. Characterization of histone acylations links chromatin modifications with metabolism. Nat Commun. 2017;8(1):1141.","journal-title":"Nat Commun"},{"issue":"2","key":"1019_CR62","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41573-024-01080-6","volume":"24","author":"MM Zhou","year":"2025","unstructured":"Zhou MM, Cole PA. Targeting lysine acetylation readers and writers. Nat Rev Drug Discov. 2025;24(2):112\u201333.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"1019_CR63","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1053\/j.gastro.2020.10.008","volume":"160","author":"SO Aseem","year":"2021","unstructured":"Aseem SO, Jalan-Sakrikar N, Chi C, Navarro-Corcuera A, De Assuncao TM, Hamdan FH, Chowdhury S, Banales JM, Johnsen SA, Shah VH, et al. Epigenomic Evaluation of Cholangiocyte Transforming Growth Factor-beta Signaling Identifies a Selective Role for Histone 3 Lysine 9 Acetylation in Biliary Fibrosis. Gastroenterology. 2021;160(3):889\u2013905. e810.","journal-title":"Gastroenterology"},{"issue":"1","key":"1019_CR64","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12951-023-02012-z","volume":"21","author":"J Li","year":"2023","unstructured":"Li J, Ye F, Xu X, Xu P, Wang P, Zheng G, Ye G, Yu W, Su Z, Lin J, et al. Targeting macrophage M1 polarization suppression through PCAF inhibition alleviates autoimmune arthritis via synergistic NF-kappaB and H3K9Ac blockade. J Nanobiotechnol. 2023;21(1):280.","journal-title":"J Nanobiotechnol"},{"issue":"3","key":"1019_CR65","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.gendis.2018.10.002","volume":"6","author":"W Zhou","year":"2019","unstructured":"Zhou W, Jiang D, Tian J, Liu L, Lu T, Huang X, Sun H. Acetylation of H3K4, H3K9, and H3K27 mediated by p300 regulates the expression of GATA4 in cardiocytes. Genes Dis. 2019;6(3):318\u201325.","journal-title":"Genes Dis"},{"issue":"3","key":"1019_CR66","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s13238-016-0324-z","volume":"8","author":"S Zeng","year":"2017","unstructured":"Zeng S, Wang Y, Zhang T, Bai L, Wang Y, Duan C. E3 ligase UHRF2 stabilizes the acetyltransferase TIP60 and regulates H3K9ac and H3K14ac via RING finger domain. Protein Cell. 2017;8(3):202\u201318.","journal-title":"Protein Cell"},{"issue":"17","key":"1019_CR67","doi-asserted-by":"crossref","first-page":"e70028","DOI":"10.1096\/fj.202401151R","volume":"38","author":"T Qu","year":"2024","unstructured":"Qu T, Cha L, Liu H, Tian L, Hu X, Zou H, Feng Y, Sun C, Cao J, Guo W, et al. Circ_0005397 inhibits ferroptosis of pancreatic cancer cells by up-regulating PCBP2 through KAT6A\/H3K9Ac. FASEB J. 2024;38(17):e70028.","journal-title":"FASEB J"},{"issue":"3","key":"1019_CR68","doi-asserted-by":"crossref","first-page":"108262","DOI":"10.1016\/j.jbc.2025.108262","volume":"301","author":"RN Sengupta","year":"2025","unstructured":"Sengupta RN, Brodsky O, Bingham P, Diehl WC, Ferre R, Greasley SE, Johnson E, Kraus M, Lieberman W, Meier JL, et al. Modulation of the substrate preference of a MYST acetyltransferase by a scaffold protein. J Biol Chem. 2025;301(3):108262.","journal-title":"J Biol Chem"},{"issue":"1","key":"1019_CR69","doi-asserted-by":"publisher","first-page":"7409","DOI":"10.1038\/s41467-025-62743-5","volume":"16","author":"H Li","year":"2025","unstructured":"Li H, He Y, Jiang J, Liu Z, Liu Y, Shi Q, Ding J, Li H, Sun W, Hu X, et al. CRISPR screening reveals that RNA helicase DDX41 triggers ribosome biogenesis and cancer progression through R-loop-mediated RPL\/RPS transcription. Nat Commun. 2025;16(1):7409.","journal-title":"Nat Commun"},{"issue":"6","key":"1019_CR70","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","volume":"13","author":"T Liang","year":"2023","unstructured":"Liang T, Wang F, Elhassan RM, Cheng Y, Tang X, Chen W, Fang H, Hou X. Targeting histone deacetylases for cancer therapy: Trends and challenges. Acta Pharm Sin B. 2023;13(6):2425\u201363.","journal-title":"Acta Pharm Sin B"},{"key":"1019_CR71","doi-asserted-by":"crossref","first-page":"107813","DOI":"10.1016\/j.phrs.2025.107813","volume":"217","author":"X Wang","year":"2025","unstructured":"Wang X, Luo H. The roles of histone acetylation key enzymes HAT, HDAC and BET proteins in neuropathic pain: Selection of drug targets. Pharmacol Res. 2025;217:107813.","journal-title":"Pharmacol Res"},{"issue":"4","key":"1019_CR72","doi-asserted-by":"crossref","first-page":"a018713","DOI":"10.1101\/cshperspect.a018713","volume":"6","author":"E Seto","year":"2014","unstructured":"Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol. 2014;6(4):a018713.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1019_CR73","doi-asserted-by":"crossref","unstructured":"Gandhi S, Mitterhoff R, Rapoport R, Farago M, Greenberg A, Hodge L, et al. Mitotic H3K9ac is controlled by phase-specific activity of HDAC2, HDAC3, and SIRT1. Life Sci Alliance. 2022;5(10):e202201433.","DOI":"10.26508\/lsa.202201433"},{"issue":"12","key":"1019_CR74","doi-asserted-by":"crossref","first-page":"6811","DOI":"10.1021\/jacs.2c13512","volume":"145","author":"ZA Wang","year":"2023","unstructured":"Wang ZA, Markert JW, Whedon SD, Yapa Abeywardana M, Lee K, Jiang H, Suarez C, Lin H, Farnung L, Cole PA. Structural Basis of Sirtuin 6-Catalyzed Nucleosome Deacetylation. J Am Chem Soc. 2023;145(12):6811\u201322.","journal-title":"J Am Chem Soc"},{"issue":"5532","key":"1019_CR75","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1126\/science.1063127","volume":"293","author":"T Jenuwein","year":"2001","unstructured":"Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293(5532):1074\u201380.","journal-title":"Science"},{"issue":"4","key":"1019_CR76","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nrm2145","volume":"8","author":"KK Lee","year":"2007","unstructured":"Lee KK, Workman JL. Histone acetyltransferase complexes: one size doesn\u2019t fit all. Nat Rev Mol Cell Biol. 2007;8(4):284\u201395.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"1019_CR77","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.str.2017.03.010","volume":"25","author":"A Khan","year":"2017","unstructured":"Khan A, Bridgers JB, Strahl BD. Expanding the Reader Landscape of Histone Acylation. Structure. 2017;25(4):571\u20133.","journal-title":"Structure"},{"issue":"10","key":"1019_CR78","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/s41594-019-0309-8","volume":"26","author":"N Zaware","year":"2019","unstructured":"Zaware N, Zhou MM. Bromodomain biology and drug discovery. Nat Struct Mol Biol. 2019;26(10):870\u20139.","journal-title":"Nat Struct Mol Biol"},{"issue":"3","key":"1019_CR79","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cell.2014.09.049","volume":"159","author":"Y Li","year":"2014","unstructured":"Li Y, Wen H, Xi Y, Tanaka K, Wang H, Peng D, Ren Y, Jin Q, Dent SY, Li W, et al. AF9 YEATS domain links histone acetylation to DOT1L-mediated H3K79 methylation. Cell. 2014;159(3):558\u201371.","journal-title":"Cell"},{"issue":"7303","key":"1019_CR80","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/nature09139","volume":"466","author":"L Zeng","year":"2010","unstructured":"Zeng L, Zhang Q, Li S, Plotnikov AN, Walsh MJ, Zhou MM. Mechanism and regulation of acetylated histone binding by the tandem PHD finger of DPF3b. Nature. 2010;466(7303):258\u201362.","journal-title":"Nature"},{"issue":"5","key":"1019_CR81","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/s41580-021-00441-y","volume":"23","author":"M Shvedunova","year":"2022","unstructured":"Shvedunova M, Akhtar A. Modulation of cellular processes by histone and non-histone protein acetylation. Nat Rev Mol Cell Biol. 2022;23(5):329\u201349.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1019_CR82","doi-asserted-by":"crossref","unstructured":"Lai CY, Hsieh MC, Chou D, Lin KH, Wang HH, Yang PS, Lin TB, Peng HY. The transcription factor Tbx5-dependent epigenetic modification contributes to neuropathic allodynia by activating TRPV1 expression in the dorsal horn. J Neurosci. 2024;44(39).","DOI":"10.1523\/JNEUROSCI.0497-24.2024"},{"issue":"17","key":"1019_CR83","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1128\/MCB.23.17.6086-6102.2003","volume":"23","author":"I Le Masson","year":"2003","unstructured":"Le Masson I, Yu DY, Jensen K, Chevalier A, Courbeyrette R, Boulard Y, Smith MM, Mann C. Yaf9, a novel NuA4 histone acetyltransferase subunit, is required for the cellular response to spindle stress in yeast. Mol Cell Biol. 2003;23(17):6086\u2013102.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"1019_CR84","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1139\/O08-111","volume":"87","author":"JM Schulze","year":"2009","unstructured":"Schulze JM, Wang AY, Kobor MS. YEATS domain proteins: a diverse family with many links to chromatin modification and transcription. Biochem Cell Biol. 2009;87(1):65\u201375.","journal-title":"Biochem Cell Biol"},{"issue":"7644","key":"1019_CR85","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nature21687","volume":"543","author":"L Wan","year":"2017","unstructured":"Wan L, Wen H, Li Y, Lyu J, Xi Y, Hoshii T, Joseph JK, Wang X, Loh YE, Erb MA, et al. ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia. Nature. 2017;543(7644):265\u20139.","journal-title":"Nature"},{"issue":"7779","key":"1019_CR86","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-019-1678-1","volume":"574","author":"D Zhang","year":"2019","unstructured":"Zhang D, Tang Z, Huang H, Zhou G, Cui C, Weng Y, Liu W, Kim S, Lee S, Perez-Neut M, et al. Metabolic regulation of gene expression by histone lactylation. Nature. 2019;574(7779):575\u201380.","journal-title":"Nature"},{"issue":"19","key":"1019_CR87","doi-asserted-by":"crossref","first-page":"e2309290","DOI":"10.1002\/advs.202309290","volume":"11","author":"Q Yue","year":"2024","unstructured":"Yue Q, Wang Z, Shen Y, Lan Y, Zhong X, Luo X, Yang T, Zhang M, Zuo B, Zeng T, et al. Histone H3K9 Lactylation Confers Temozolomide Resistance in Glioblastoma via LUC7L2-Mediated MLH1 Intron Retention. Adv Sci (Weinh). 2024;11(19):e2309290.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"1019_CR88","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s13059-022-02775-y","volume":"23","author":"E Galle","year":"2022","unstructured":"Galle E, Wong CW, Ghosh A, Desgeorges T, Melrose K, Hinte LC, Castellano-Castillo D, Engl M, de Sousa JA, Ruiz-Ojeda FJ, et al. H3K18 lactylation marks tissue-specific active enhancers. Genome Biol. 2022;23(1):207.","journal-title":"Genome Biol"},{"key":"1019_CR89","doi-asserted-by":"crossref","first-page":"156426","DOI":"10.1016\/j.metabol.2025.156426","volume":"175","author":"Y Ma","year":"2026","unstructured":"Ma Y, Feng S, Jiang Y, Jiang J, Liu R, Ma Y, Yin X, Bian H, Zhu R. SLC22A6-dependent lactylation of H3K9 aggravates endothelial dysfunction and atherosclerosis. Metabolism. 2026;175:156426.","journal-title":"Metabolism"},{"key":"1019_CR90","doi-asserted-by":"crossref","first-page":"1559744","DOI":"10.3389\/fphar.2025.1559744","volume":"16","author":"Y Dai","year":"2025","unstructured":"Dai Y, Wang S, Luo J, Yu H, Du Q, Hou S, Liu M, Jiang S, Xu H, Ye S, et al. Gastrodin attenuates rheumatoid arthritis by targeting KAT8 to inhibit the lactylation of H3K9. Front Pharmacol. 2025;16:1559744.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1019_CR91","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41580-025-00876-7","volume":"27","author":"X Sheng","year":"2026","unstructured":"Sheng X, Lin H, Cole PA, Zhao Y. Biochemistry and regulation of histone lysine L-lactylation. Nat Rev Mol Cell Biol. 2026;27(2):95\u2013109.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"1019_CR92","doi-asserted-by":"crossref","first-page":"eabi6696","DOI":"10.1126\/sciadv.abi6696","volume":"8","author":"C Moreno-Yruela","year":"2022","unstructured":"Moreno-Yruela C, Zhang D, Wei W, Baek M, Liu W, Gao J, Dankova D, Nielsen AL, Bolding JE, Yang L, et al. Class I histone deacetylases (HDAC1-3) are histone lysine delactylases. Sci Adv. 2022;8(3):eabi6696.","journal-title":"Sci Adv"},{"issue":"1","key":"1019_CR93","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13059-024-03308-5","volume":"25","author":"W Fan","year":"2024","unstructured":"Fan W, Zeng S, Wang X, Wang G, Liao D, Li R, He S, Li W, Huang J, Li X, et al. A feedback loop driven by H3K9 lactylation and HDAC2 in endothelial cells regulates VEGF-induced angiogenesis. Genome Biol. 2024;25(1):165.","journal-title":"Genome Biol"},{"issue":"5","key":"1019_CR94","doi-asserted-by":"crossref","first-page":"100973","DOI":"10.1016\/j.mcpro.2025.100973","volume":"24","author":"C Chen","year":"2025","unstructured":"Chen C, Zhang Y, Zang Y, Fan Z, Han Y, Bai X, Wang A, Zhang J, Wang J, Zhang K. SIRT3 Functions as an Eraser of Histone H3K9 Lactylation to Modulate Transcription for Inhibiting the Progression of Esophageal Cancer. Mol Cell Proteom. 2025;24(5):100973.","journal-title":"Mol Cell Proteom"},{"issue":"12","key":"1019_CR95","doi-asserted-by":"crossref","first-page":"110795","DOI":"10.1016\/j.jbc.2025.110795","volume":"301","author":"GA Nickel","year":"2025","unstructured":"Nickel GA, Pederson NJ, Faheem, Yang Z, Bulf J, Diehl KL. Sirtuin 6 is a histone delactylase. J Biol Chem. 2025;301(12):110795.","journal-title":"J Biol Chem"},{"issue":"2","key":"1019_CR96","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cmet.2024.10.015","volume":"37","author":"R Zhu","year":"2025","unstructured":"Zhu R, Ye X, Lu X, Xiao L, Yuan M, Zhao H, Guo D, Meng Y, Han H, Luo S, et al. ACSS2 acts as a lactyl-CoA synthetase and couples KAT2A to function as a lactyltransferase for histone lactylation and tumor immune evasion. Cell Metab. 2025;37(2):361\u201376. e367.","journal-title":"Cell Metab"},{"key":"1019_CR97","doi-asserted-by":"crossref","unstructured":"Huang H, Zhang D, Weng Y, Delaney K, Tang Z, Yan C, et al. The regulatory enzymes and protein substrates for the lysine beta-hydroxybutyrylation pathway. Sci Adv. 2021;7(9):eabe2771.","DOI":"10.1126\/sciadv.abe2771"},{"issue":"33","key":"1019_CR98","doi-asserted-by":"crossref","first-page":"eadv8448","DOI":"10.1126\/sciadv.adv8448","volume":"11","author":"S Wang","year":"2025","unstructured":"Wang S, Niu Z, Zhang Y, Liu R, Zhu R, Sun Y, Han Y, Wang A, Zhang J, Zhang H, et al. ACSS2 coupled with KAT7 regulates histone beta-hydroxybutyrylation to enhance transcription. Sci Adv. 2025;11(33):eadv8448.","journal-title":"Sci Adv"},{"issue":"5","key":"1019_CR99","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1074\/mcp.M700021-MCP200","volume":"6","author":"Y Chen","year":"2007","unstructured":"Chen Y, Sprung R, Tang Y, Ball H, Sangras B, Kim SC, Falck JR, Peng J, Gu W, Zhao Y. Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol Cell Proteom. 2007;6(5):812\u20139.","journal-title":"Mol Cell Proteom"},{"issue":"4","key":"1019_CR100","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s42255-024-00992-2","volume":"6","author":"LA Gates","year":"2024","unstructured":"Gates LA, Reis BS, Lund PJ, Paul MR, Leboeuf M, Djomo AM, Nadeem Z, Lopes M, Vitorino FN, Unlu G, et al. Histone butyrylation in the mouse intestine is mediated by the microbiota and associated with regulation of gene expression. Nat Metab. 2024;6(4):697\u2013707.","journal-title":"Nat Metab"},{"issue":"14","key":"1019_CR101","doi-asserted-by":"crossref","first-page":"8037","DOI":"10.1093\/nar\/gkab607","volume":"49","author":"Y Xiao","year":"2021","unstructured":"Xiao Y, Li W, Yang H, Pan L, Zhang L, Lu L, Chen J, Wei W, Ye J, Li J, et al. HBO1 is a versatile histone acyltransferase critical for promoter histone acylations. Nucleic Acids Res. 2021;49(14):8037\u201359.","journal-title":"Nucleic Acids Res"},{"key":"1019_CR102","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev-physiol-021115-105045","volume":"78","author":"SM Houten","year":"2016","unstructured":"Houten SM, Violante S, Ventura FV, Wanders RJ. The Biochemistry and Physiology of Mitochondrial Fatty Acid beta-Oxidation and Its Genetic Disorders. Annu Rev Physiol. 2016;78:23\u201344.","journal-title":"Annu Rev Physiol"},{"issue":"6","key":"1019_CR103","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.cell.2011.08.008","volume":"146","author":"M Tan","year":"2011","unstructured":"Tan M, Luo H, Lee S, Jin F, Yang JS, Montellier E, Buchou T, Cheng Z, Rousseaux S, Rajagopal N, et al. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell. 2011;146(6):1016\u201328.","journal-title":"Cell"},{"issue":"4","key":"1019_CR104","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.stem.2020.12.009","volume":"28","author":"Y Fang","year":"2021","unstructured":"Fang Y, Xu X, Ding J, Yang L, Doan MT, Karmaus PWF, Snyder NW, Zhao Y, Li JL, Li X. Histone crotonylation promotes mesoendodermal commitment of human embryonic stem cells. Cell Stem Cell. 2021;28(4):748\u2013e763747.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"1019_CR105","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1038\/s41467-024-47315-3","volume":"15","author":"L Li","year":"2024","unstructured":"Li L, Xiang T, Guo J, Guo F, Wu Y, Feng H, Liu J, Tao S, Fu P, Ma L. Inhibition of ACSS2-mediated histone crotonylation alleviates kidney fibrosis via IL-1beta-dependent macrophage activation and tubular cell senescence. Nat Commun. 2024;15(1):3200.","journal-title":"Nat Commun"},{"key":"1019_CR106","doi-asserted-by":"crossref","first-page":"101903","DOI":"10.1016\/j.molmet.2024.101903","volume":"81","author":"N Zeaiter","year":"2024","unstructured":"Zeaiter N, Belot L, Cunin V, Nahed RA, Tokarska-Schlattner M, Le Gouellec A, Petosa C, Khochbin S, Schlattner U. Acetyl-CoA synthetase (ACSS2) does not generate butyryl- and crotonyl-CoA. Mol Metab. 2024;81:101903.","journal-title":"Mol Metab"},{"issue":"2","key":"1019_CR107","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.molcel.2016.03.028","volume":"62","author":"Y Li","year":"2016","unstructured":"Li Y, Sabari BR, Panchenko T, Wen H, Zhao D, Guan H, Wan L, Huang H, Tang Z, Zhao Y, et al. Molecular Coupling of Histone Crotonylation and Active Transcription by AF9 YEATS Domain. Mol Cell. 2016;62(2):181\u201393.","journal-title":"Mol Cell"},{"issue":"13","key":"1019_CR108","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.jmb.2017.03.010","volume":"429","author":"D Zhao","year":"2017","unstructured":"Zhao D, Li Y, Xiong X, Chen Z, Li H. YEATS Domain-A Histone Acylation Reader in Health and Disease. J Mol Biol. 2017;429(13):1994\u20132002.","journal-title":"J Mol Biol"},{"key":"1019_CR109","doi-asserted-by":"crossref","first-page":"117500","DOI":"10.1016\/j.bmc.2023.117500","volume":"95","author":"N Bilgin","year":"2023","unstructured":"Bilgin N, Turkmen VA, Hammami N, Christensen NR, Hintzen JCJ, Mecinovic J. Reading and erasing of histone crotonyllysine mimics by the AF9 YEATS domain and SIRT2 deacylase. Bioorg Med Chem. 2023;95:117500.","journal-title":"Bioorg Med Chem"},{"issue":"6","key":"1019_CR110","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.molcel.2019.09.029","volume":"76","author":"GJ Gowans","year":"2019","unstructured":"Gowans GJ, Bridgers JB, Zhang J, Dronamraju R, Burnetti A, King DA, Thiengmany AV, Shinsky SA, Bhanu NV, Garcia BA, et al. Recognition of Histone Crotonylation by Taf14 Links Metabolic State to Gene Expression. Mol Cell. 2019;76(6):909\u201321. e903.","journal-title":"Mol Cell"},{"issue":"6","key":"1019_CR111","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nchembio.2065","volume":"12","author":"FH Andrews","year":"2016","unstructured":"Andrews FH, Shinsky SA, Shanle EK, Bridgers JB, Gest A, Tsun IK, Krajewski K, Shi X, Strahl BD, Kutateladze TG. The Taf14 YEATS domain is a reader of histone crotonylation. Nat Chem Biol. 2016;12(6):396\u20138.","journal-title":"Nat Chem Biol"},{"issue":"8071","key":"1019_CR112","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-025-08971-7","volume":"643","author":"S Park","year":"2025","unstructured":"Park S, Merino-Urteaga R, Karwacki-Neisius V, Carrizo GE, Athreya A, Marin-Gonzalez A, Benning NA, Park J, Mitchener MM, Bhanu NV, et al. Native nucleosomes intrinsically encode genome organization principles. Nature. 2025;643(8071):572\u201381.","journal-title":"Nature"},{"issue":"1","key":"1019_CR113","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1080\/19491034.2022.2143106","volume":"13","author":"AR Mansisidor","year":"2022","unstructured":"Mansisidor AR, Risca VI. Chromatin accessibility: methods, mechanisms, and biological insights. Nucleus. 2022;13(1):236\u201376.","journal-title":"Nucleus"},{"issue":"11","key":"1019_CR114","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/nrm3890","volume":"15","author":"P Tessarz","year":"2014","unstructured":"Tessarz P, Kouzarides T. Histone core modifications regulating nucleosome structure and dynamics. Nat Rev Mol Cell Biol. 2014;15(11):703\u20138.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"1019_CR115","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nrm2640","volume":"10","author":"AV Probst","year":"2009","unstructured":"Probst AV, Dunleavy E, Almouzni G. Epigenetic inheritance during the cell cycle. Nat Rev Mol Cell Biol. 2009;10(3):192\u2013206.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"12","key":"1019_CR116","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41589-025-02023-x","volume":"21","author":"J Han","year":"2025","unstructured":"Han J, Wu M, Liu T, Huang J. Decoding replication stress responses through post-translational modifications. Nat Chem Biol. 2025;21(12):1859\u201372.","journal-title":"Nat Chem Biol"},{"issue":"9","key":"1019_CR117","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1101\/gr.201244.115","volume":"26","author":"R Bar-Ziv","year":"2016","unstructured":"Bar-Ziv R, Voichek Y, Barkai N. Chromatin dynamics during DNA replication. Genome Res. 2016;26(9):1245\u201356.","journal-title":"Genome Res"},{"issue":"2","key":"1019_CR118","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1083\/jcb.200601113","volume":"174","author":"R Wu","year":"2006","unstructured":"Wu R, Singh PB, Gilbert DM. Uncoupling global and fine-tuning replication timing determinants for mouse pericentric heterochromatin. J Cell Biol. 2006;174(2):185\u201394.","journal-title":"J Cell Biol"},{"issue":"7","key":"1019_CR119","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/s41556-023-01167-z","volume":"25","author":"V Gaggioli","year":"2023","unstructured":"Gaggioli V, Lo CSY, Reveron-Gomez N, Jasencakova Z, Domenech H, Nguyen H, Sidoli S, Tvardovskiy A, Uruci S, Slotman JA, et al. Dynamic de novo heterochromatin assembly and disassembly at replication forks ensures fork stability. Nat Cell Biol. 2023;25(7):1017\u201332.","journal-title":"Nat Cell Biol"},{"issue":"1","key":"1019_CR120","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/nar\/gkw848","volume":"45","author":"R Wu","year":"2017","unstructured":"Wu R, Wang Z, Zhang H, Gan H, Zhang Z. H3K9me3 demethylase Kdm4d facilitates the formation of pre-initiative complex and regulates DNA replication. Nucleic Acids Res. 2017;45(1):169\u201380.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"1019_CR121","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/s41556-021-00776-w","volume":"23","author":"SP Methot","year":"2021","unstructured":"Methot SP, Padeken J, Brancati G, Zeller P, Delaney CE, Gaidatzis D, Kohler H, van Oudenaarden A, Grosshans H, Gasser SM. H3K9me selectively blocks transcription factor activity and ensures differentiated tissue integrity. Nat Cell Biol. 2021;23(11):1163\u201375.","journal-title":"Nat Cell Biol"},{"issue":"4","key":"1019_CR122","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2007.05.009","volume":"129","author":"A Barski","year":"2007","unstructured":"Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. High-resolution profiling of histone methylations in the human genome. Cell. 2007;129(4):823\u201337.","journal-title":"Cell"},{"key":"1019_CR123","doi-asserted-by":"crossref","unstructured":"Ninova M, Fejes Toth K, Aravin AA. The control of gene expression and cell identity by H3K9 trimethylation. Development. 2019;146(19).","DOI":"10.1242\/dev.181180"},{"issue":"9","key":"1019_CR124","doi-asserted-by":"crossref","first-page":"e1002954","DOI":"10.1371\/journal.pgen.1002954","volume":"8","author":"NC Riddle","year":"2012","unstructured":"Riddle NC, Jung YL, Gu T, Alekseyenko AA, Asker D, Gui H, Kharchenko PV, Minoda A, Plachetka A, Schwartz YB, et al. Enrichment of HP1a on Drosophila chromosome 4 genes creates an alternate chromatin structure critical for regulation in this heterochromatic domain. PLoS Genet. 2012;8(9):e1002954.","journal-title":"PLoS Genet"},{"issue":"46","key":"1019_CR125","doi-asserted-by":"crossref","first-page":"18845","DOI":"10.1073\/pnas.1213951109","volume":"109","author":"CP Chaturvedi","year":"2012","unstructured":"Chaturvedi CP, Somasundaram B, Singh K, Carpenedo RL, Stanford WL, Dilworth FJ, Brand M. Maintenance of gene silencing by the coordinate action of the H3K9 methyltransferase G9a\/KMT1C and the H3K4 demethylase Jarid1a\/KDM5A. Proc Natl Acad Sci U S A. 2012;109(46):18845\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"1019_CR126","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.molcel.2019.06.034","volume":"75","author":"JP Etchegaray","year":"2019","unstructured":"Etchegaray JP, Zhong L, Li C, Henriques T, Ablondi E, Nakadai T, Van Rechem C, Ferrer C, Ross KN, Choi JE, et al. The Histone Deacetylase SIRT6 Restrains Transcription Elongation via Promoter-Proximal Pausing. Mol Cell. 2019;75(4):683\u2013e699687.","journal-title":"Mol Cell"},{"issue":"2","key":"1019_CR127","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.molcel.2015.02.029","volume":"58","author":"BR Sabari","year":"2015","unstructured":"Sabari BR, Tang Z, Huang H, Yong-Gonzalez V, Molina H, Kong HE, Dai L, Shimada M, Cross JR, Zhao Y, et al. Intracellular crotonyl-CoA stimulates transcription through p300-catalyzed histone crotonylation. Mol Cell. 2015;58(2):203\u201315.","journal-title":"Mol Cell"},{"key":"1019_CR128","doi-asserted-by":"crossref","first-page":"102405","DOI":"10.1016\/j.ceb.2024.102405","volume":"90","author":"JA Downs","year":"2024","unstructured":"Downs JA, Gasser SM. Chromatin remodeling and spatial concerns in DNA double-strand break repair. Curr Opin Cell Biol. 2024;90:102405.","journal-title":"Curr Opin Cell Biol"},{"issue":"25","key":"1019_CR129","doi-asserted-by":"crossref","first-page":"9169","DOI":"10.1073\/pnas.1403565111","volume":"111","author":"MK Ayrapetov","year":"2014","unstructured":"Ayrapetov MK, Gursoy-Yuzugullu O, Xu C, Xu Y, Price BD. DNA double-strand breaks promote methylation of histone H3 on lysine 9 and transient formation of repressive chromatin. Proc Natl Acad Sci U S A. 2014;111(25):9169\u201374.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"1019_CR130","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/ncb1982","volume":"11","author":"Y Sun","year":"2009","unstructured":"Sun Y, Jiang X, Xu Y, Ayrapetov MK, Moreau LA, Whetstine JR, Price BD. Histone H3 methylation links DNA damage detection to activation of the tumour suppressor Tip60. Nat Cell Biol. 2009;11(11):1376\u201382.","journal-title":"Nat Cell Biol"},{"issue":"14","key":"1019_CR131","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1158\/0008-5472.CAN-18-3767","volume":"79","author":"H Ji","year":"2019","unstructured":"Ji H, Zhou Y, Zhuang X, Zhu Y, Wu Z, Lu Y, Li S, Zeng Y, Lu QR, Huo Y, et al. HDAC3 Deficiency Promotes Liver Cancer through a Defect in H3K9ac\/H3K9me3 Transition. Cancer Res. 2019;79(14):3676\u201388.","journal-title":"Cancer Res"},{"issue":"1","key":"1019_CR132","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/ncb1343","volume":"8","author":"R Murr","year":"2006","unstructured":"Murr R, Loizou JI, Yang YG, Cuenin C, Li H, Wang ZQ, Herceg Z. Histone acetylation by Trrap-Tip60 modulates loading of repair proteins and repair of DNA double-strand breaks. Nat Cell Biol. 2006;8(1):91\u20139.","journal-title":"Nat Cell Biol"},{"issue":"4","key":"1019_CR133","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/s41419-020-2405-4","volume":"11","author":"L Fan","year":"2020","unstructured":"Fan L, Xu S, Zhang F, Cui X, Fazli L, Gleave M, Clark DJ, Yang A, Hussain A, Rassool F, et al. Histone demethylase JMJD1A promotes expression of DNA repair factors and radio-resistance of prostate cancer cells. Cell Death Dis. 2020;11(4):214.","journal-title":"Cell Death Dis"},{"issue":"9","key":"1019_CR134","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1093\/nar\/gkaa196","volume":"48","author":"I Alonso-de Vega","year":"2020","unstructured":"Alonso-de Vega I, Paz-Cabrera MC, Rother MB, Wiegant WW, Checa-Rodriguez C, Hernandez-Fernaud JR, Huertas P, Freire R, van Attikum H, Smits VAJ. PHF2 regulates homology-directed DNA repair by controlling the resection of DNA double strand breaks. Nucleic Acids Res. 2020;48(9):4915\u201327.","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"1019_CR135","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.molcel.2022.03.031","volume":"82","author":"ER Abu-Zhayia","year":"2022","unstructured":"Abu-Zhayia ER, Bishara LA, Machour FE, Barisaac AS, Ben-Oz BM, Ayoub N. CDYL1-dependent decrease in lysine crotonylation at DNA double-strand break sites functionally uncouples transcriptional silencing and repair. Mol Cell. 2022;82(10):1940\u201355. e1947.","journal-title":"Mol Cell"},{"key":"1019_CR136","doi-asserted-by":"crossref","first-page":"117347","DOI":"10.1016\/j.taap.2025.117347","volume":"499","author":"X Xie","year":"2025","unstructured":"Xie X, Wen C, Peng Q, Xiang D, Pan X, Lan X, Chen Z, Hua X, Wang G, Huang C. H3K9\/18 lactylation regulates DNA damage due to nickel exposure in human bronchial epithelial cells. Toxicol Appl Pharmacol. 2025;499:117347.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"1019_CR137","doi-asserted-by":"publisher","first-page":"135","DOI":"10.15252\/embr.201744250","volume":"19","author":"D Du","year":"2018","unstructured":"Du D, Katsuno Y, Meyer D, Budi EH, Chen SH, Koeppen H, Wang H, Akhurst RJ, Derynck R. Smad3-mediated recruitment of the methyltransferase SETDB1\/ESET controls Snail1 expression and epithelial-mesenchymal transition. EMBO Rep. 2018;19(1):135\u201355.","journal-title":"EMBO Rep"},{"issue":"1","key":"1019_CR138","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1038\/s41467-021-22575-5","volume":"12","author":"A Fortuny","year":"2021","unstructured":"Fortuny A, Chansard A, Caron P, Chevallier O, Leroy O, Renaud O, Polo SE. Imaging the response to DNA damage in heterochromatin domains reveals core principles of heterochromatin maintenance. Nat Commun. 2021;12(1):2428.","journal-title":"Nat Commun"},{"issue":"2","key":"1019_CR139","doi-asserted-by":"crossref","first-page":"e13092","DOI":"10.1111\/acel.13092","volume":"19","author":"AJ Price","year":"2020","unstructured":"Price AJ, Manjegowda MC, Kain J, Anandh S, Bochkis IM. Hdac3, Setdb1, and Kap1 mark H3K9me3\/H3K14ac bivalent regions in young and aged liver. Aging Cell. 2020;19(2):e13092.","journal-title":"Aging Cell"},{"issue":"1","key":"1019_CR140","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1038\/s41467-017-02259-9","volume":"8","author":"RZ Jurkowska","year":"2017","unstructured":"Jurkowska RZ, Qin S, Kungulovski G, Tempel W, Liu Y, Bashtrykov P, Stiefelmaier J, Jurkowski TP, Kudithipudi S, Weirich S, et al. H3K14ac is linked to methylation of H3K9 by the triple Tudor domain of SETDB1. Nat Commun. 2017;8(1):2057.","journal-title":"Nat Commun"},{"issue":"22","key":"1019_CR141","doi-asserted-by":"crossref","first-page":"13690","DOI":"10.1093\/nar\/gkae1053","volume":"52","author":"TT Chandrasekaran","year":"2024","unstructured":"Chandrasekaran TT, Choudalakis M, Brohm A, Weirich S, Kouroukli AG, Ammerpohl O, Rathert P, Bashtrykov P, Jeltsch A. SETDB1 activity is globally directed by H3K14 acetylation via its Triple Tudor Domain. Nucleic Acids Res. 2024;52(22):13690\u2013705.","journal-title":"Nucleic Acids Res"},{"issue":"7071","key":"1019_CR142","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/nature04254","volume":"438","author":"T Hirota","year":"2005","unstructured":"Hirota T, Lipp JJ, Toh BH, Peters JM. Histone H3 serine 10 phosphorylation by Aurora B causes HP1 dissociation from heterochromatin. Nature. 2005;438(7071):1176\u201380.","journal-title":"Nature"},{"issue":"7071","key":"1019_CR143","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/nature04219","volume":"438","author":"W Fischle","year":"2005","unstructured":"Fischle W, Tseng BS, Dormann HL, Ueberheide BM, Garcia BA, Shabanowitz J, Hunt DF, Funabiki H, Allis CD. Regulation of HP1-chromatin binding by histone H3 methylation and phosphorylation. Nature. 2005;438(7071):1116\u201322.","journal-title":"Nature"},{"key":"1019_CR144","doi-asserted-by":"crossref","unstructured":"Chen N, Bandau S, Nair Pushkala Kumari RR, Prevo B, Sasaki T, Web S, di Sanzo S, Shapira D, Voelker-Albert M, Gilbert DM, et al. RIF1 orchestrates a multi-step restoration of post-replicative H3K9me3. bioRxiv 2025.","DOI":"10.1101\/2025.07.14.664777"},{"issue":"8","key":"1019_CR145","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1093\/nar\/gkac259","volume":"50","author":"M Udugama","year":"2022","unstructured":"Udugama M, Vinod B, Chan FL, Hii L, Garvie A, Collas P, Kalitsis P, Steer D, Das PP, Tripathi P, et al. Histone H3.3 phosphorylation promotes heterochromatin formation by inhibiting H3K9\/K36 histone demethylase. Nucleic Acids Res. 2022;50(8):4500\u201314.","journal-title":"Nucleic Acids Res"},{"issue":"8090","key":"1019_CR146","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s41586-025-09624-5","volume":"647","author":"Y Huang","year":"2025","unstructured":"Huang Y, Sun Y, Qi H, Jiang Q, Li J, Chang M, Li X, Shu L, Duan X, Wang Y, et al. A conserved H3K14ub-driven H3K9me3 for chromatin compartmentalization. Nature. 2025;647(8090):786\u201397.","journal-title":"Nature"},{"issue":"19","key":"1019_CR147","doi-asserted-by":"crossref","first-page":"7357","DOI":"10.1073\/pnas.0401866101","volume":"101","author":"G Liang","year":"2004","unstructured":"Liang G, Lin JC, Wei V, Yoo C, Cheng JC, Nguyen CT, Weisenberger DJ, Egger G, Takai D, Gonzales FA, et al. Distinct localization of histone H3 acetylation and H3-K4 methylation to the transcription start sites in the human genome. Proc Natl Acad Sci U S A. 2004;101(19):7357\u201362.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1019_CR148","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s13402-024-00976-0","volume":"47","author":"J Zhu","year":"2024","unstructured":"Zhu J, Qiu X, Jin X, Nie X, Ou S, Wu G, Shen J, Zhang R. ZNF468-mediated epigenetic upregulation of VEGF-C facilitates lymphangiogenesis and lymphatic metastasis in ESCC via PI3K\/Akt and ERK1\/2 signaling pathways. Cell Oncol (Dordr). 2024;47(5):1927\u201342.","journal-title":"Cell Oncol (Dordr)"},{"key":"1019_CR149","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1186\/1471-2164-13-424","volume":"13","author":"K Karmodiya","year":"2012","unstructured":"Karmodiya K, Krebs AR, Oulad-Abdelghani M, Kimura H, Tora L. H3K9 and H3K14 acetylation co-occur at many gene regulatory elements, while H3K14ac marks a subset of inactive inducible promoters in mouse embryonic stem cells. BMC Genomics. 2012;13:424.","journal-title":"BMC Genomics"},{"issue":"7","key":"1019_CR150","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/ng.154","volume":"40","author":"Z Wang","year":"2008","unstructured":"Wang Z, Zang C, Rosenfeld JA, Schones DE, Barski A, Cuddapah S, Cui K, Roh TY, Peng W, Zhang MQ, et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet. 2008;40(7):897\u2013903.","journal-title":"Nat Genet"},{"issue":"5","key":"1019_CR151","doi-asserted-by":"crossref","first-page":"e1008770","DOI":"10.1371\/journal.pgen.1008770","volume":"16","author":"SM Praestholm","year":"2020","unstructured":"Praestholm SM, Siersbaek MS, Nielsen R, Zhu X, Hollenberg AN, Cheng SY, Grontved L. Multiple mechanisms regulate H3 acetylation of enhancers in response to thyroid hormone. PLoS Genet. 2020;16(5):e1008770.","journal-title":"PLoS Genet"},{"issue":"4","key":"1019_CR152","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.cell.2012.07.018","volume":"150","author":"W Yang","year":"2012","unstructured":"Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, Aldape K, Hunter T, Alfred Yung WK, Lu Z. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell. 2012;150(4):685\u201396.","journal-title":"Cell"},{"issue":"1","key":"1019_CR153","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1038\/s41467-019-10648-5","volume":"10","author":"A Frapporti","year":"2019","unstructured":"Frapporti A, Miro Pina C, Arnaiz O, Holoch D, Kawaguchi T, Humbert A, Eleftheriou E, Lombard B, Loew D, Sperling L, et al. The Polycomb protein Ezl1 mediates H3K9 and H3K27 methylation to repress transposable elements in Paramecium. Nat Commun. 2019;10(1):2710.","journal-title":"Nat Commun"},{"issue":"24","key":"1019_CR154","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1016\/j.molcel.2022.11.010","volume":"82","author":"KW Fong","year":"2022","unstructured":"Fong KW, Zhao JC, Lu X, Kim J, Piunti A, Shilatifard A, Yu J. PALI1 promotes tumor growth through competitive recruitment of PRC2 to G9A-target chromatin for dual epigenetic silencing. Mol Cell. 2022;82(24):4611\u201326. e4617.","journal-title":"Mol Cell"},{"issue":"18","key":"1019_CR155","doi-asserted-by":"crossref","first-page":"7541","DOI":"10.1073\/pnas.1017374108","volume":"108","author":"L Shi","year":"2011","unstructured":"Shi L, Sun L, Li Q, Liang J, Yu W, Yi X, Yang X, Li Y, Han X, Zhang Y, et al. Histone demethylase JMJD2B coordinates H3K4\/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc Natl Acad Sci U S A. 2011;108(18):7541\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"26","key":"1019_CR156","doi-asserted-by":"crossref","first-page":"9509","DOI":"10.1073\/pnas.1321843111","volume":"111","author":"SC Kerr","year":"2014","unstructured":"Kerr SC, Ruppersburg CC, Francis JW, Katz DJ. SPR-5 and MET-2 function cooperatively to reestablish an epigenetic ground state during passage through the germ line. Proc Natl Acad Sci U S A. 2014;111(26):9509\u201314.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1019_CR157","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nrg2540","volume":"10","author":"H Cedar","year":"2009","unstructured":"Cedar H, Bergman Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet. 2009;10(5):295\u2013304.","journal-title":"Nat Rev Genet"},{"issue":"9","key":"1019_CR158","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nrm4043","volume":"16","author":"J Du","year":"2015","unstructured":"Du J, Johnson LM, Jacobsen SE, Patel DJ. DNA methylation pathways and their crosstalk with histone methylation. Nat Rev Mol Cell Biol. 2015;16(9):519\u201332.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"1019_CR159","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/nar\/gkg332","volume":"31","author":"F Fuks","year":"2003","unstructured":"Fuks F, Hurd PJ, Deplus R, Kouzarides T. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res. 2003;31(9):2305\u201312.","journal-title":"Nucleic Acids Res"},{"issue":"14","key":"1019_CR160","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S0960-9822(03)00432-9","volume":"13","author":"B Lehnertz","year":"2003","unstructured":"Lehnertz B, Ueda Y, Derijck AA, Braunschweig U, Perez-Burgos L, Kubicek S, Chen T, Li E, Jenuwein T, Peters AH. Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin. Curr Biol. 2003;13(14):1192\u2013200.","journal-title":"Curr Biol"},{"issue":"11","key":"1019_CR161","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/nsmb.2391","volume":"19","author":"SB Rothbart","year":"2012","unstructured":"Rothbart SB, Krajewski K, Nady N, Tempel W, Xue S, Badeaux AI, Barsyte-Lovejoy D, Martinez JY, Bedford MT, Fuchs SM, et al. Association of UHRF1 with methylated H3K9 directs the maintenance of DNA methylation. Nat Struct Mol Biol. 2012;19(11):1155\u201360.","journal-title":"Nat Struct Mol Biol"},{"key":"1019_CR162","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/ncomms2562","volume":"4","author":"X Liu","year":"2013","unstructured":"Liu X, Gao Q, Li P, Zhao Q, Zhang J, Li J, Koseki H, Wong J. UHRF1 targets DNMT1 for DNA methylation through cooperative binding of hemi-methylated DNA and methylated H3K9. Nat Commun. 2013;4:1563.","journal-title":"Nat Commun"},{"issue":"2","key":"1019_CR163","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.molcel.2024.11.009","volume":"85","author":"Y Liu","year":"2025","unstructured":"Liu Y, Hrit JA, Chomiak AA, Stransky S, Hoffman JR, Tiedemann RL, Wiseman AK, Kariapper LS, Dickson BM, Worden EJ, et al. DNA hypomethylation promotes UHRF1-and SUV39H1\/H2-dependent crosstalk between H3K18ub and H3K9me3 to reinforce heterochromatin states. Mol Cell. 2025;85(2):394\u2013412. e312.","journal-title":"Mol Cell"},{"issue":"10","key":"1019_CR164","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.1096\/fj.201700645RRRRR","volume":"32","author":"G Kim","year":"2018","unstructured":"Kim G, Kim JY, Lim SC, Lee KY, Kim O, Choi HS. SUV39H1\/DNMT3A-dependent methylation of the RB1 promoter stimulates PIN1 expression and melanoma development. FASEB J. 2018;32(10):5647\u201360.","journal-title":"FASEB J"},{"issue":"6","key":"1019_CR165","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1016\/j.molcel.2022.02.006","volume":"82","author":"W Xu","year":"2022","unstructured":"Xu W, He C, Kaye EG, Li J, Mu M, Nelson GM, Dong L, Wang J, Wu F, Shi YG, et al. Dynamic control of chromatin-associated m(6)A methylation regulates nascent RNA synthesis. Mol Cell. 2022;82(6):1156\u201368. e1157.","journal-title":"Mol Cell"},{"issue":"7849","key":"1019_CR166","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41586-021-03210-1","volume":"591","author":"W Xu","year":"2021","unstructured":"Xu W, Li J, He C, Wen J, Ma H, Rong B, Diao J, Wang L, Wang J, Wu F, et al. METTL3 regulates heterochromatin in mouse embryonic stem cells. Nature. 2021;591(7849):317\u201321.","journal-title":"Nature"},{"issue":"9","key":"1019_CR167","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/s41588-020-0677-3","volume":"52","author":"Y Li","year":"2020","unstructured":"Li Y, Xia L, Tan K, Ye X, Zuo Z, Li M, Xiao R, Wang Z, Liu X, Deng M, et al. N(6)-Methyladenosine co-transcriptionally directs the demethylation of histone H3K9me2. Nat Genet. 2020;52(9):870\u20137.","journal-title":"Nat Genet"},{"issue":"1","key":"1019_CR168","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.stem.2020.04.001","volume":"27","author":"J Wang","year":"2020","unstructured":"Wang J, Li Y, Wang P, Han G, Zhang T, Chang J, Yin R, Shan Y, Wen J, Xie X, et al. Leukemogenic Chromatin Alterations Promote AML Leukemia Stem Cells via a KDM4C-ALKBH5-AXL Signaling Axis. Cell Stem Cell. 2020;27(1):81\u2013e9788.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"1019_CR169","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41419-025-07608-x","volume":"16","author":"S Chen","year":"2025","unstructured":"Chen S, Wang Y, Zhang J, Liu B, Liu W, Cao G, Li R, Li H, Zhai N, Song X, et al. YTHDC1 phase separation drives the nuclear export of m(6)A-modified lncNONMMUT062668.2 through the transport complex SRSF3-ALYREF-XPO5 to aggravate pulmonary fibrosis. Cell Death Dis. 2025;16(1):279.","journal-title":"Cell Death Dis"},{"issue":"3","key":"1019_CR170","doi-asserted-by":"crossref","first-page":"168129","DOI":"10.1016\/j.bbadis.2025.168129","volume":"1872","author":"Z Fan","year":"2026","unstructured":"Fan Z, Ni B, Duan Z, Ling F, Zhang J, Sun J, Yu H, Xu J, Chen Z, Shen B, et al. H3K9 lactylation drives FTO-mediated NRF2 suppression to exacerbate bladder epithelial ferroptosis and inflammation in diabetic bladder dysfunction. Biochim Biophys Acta Mol Basis Dis. 2026;1872(3):168129.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"1019_CR171","doi-asserted-by":"crossref","unstructured":"Flavahan WA, Gaskell E, Bernstein BE. Epigenetic plasticity and the hallmarks of cancer. Science. 2017;357(6348):eaal2380.","DOI":"10.1126\/science.aal2380"},{"key":"1019_CR172","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.canlet.2020.02.004","volume":"476","author":"C Lu","year":"2020","unstructured":"Lu C, Klement JD, Yang D, Albers T, Lebedyeva IO, Waller JL, Liu K. SUV39H1 regulates human colon carcinoma apoptosis and cell cycle to promote tumor growth. Cancer Lett. 2020;476:87\u201396.","journal-title":"Cancer Lett"},{"issue":"1","key":"1019_CR173","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12964-024-01687-7","volume":"22","author":"B Pan","year":"2024","unstructured":"Pan B, Liu C, Su J, Xia C. Activation of AMPK inhibits cervical cancer growth by hyperacetylation of H3K9 through PCAF. Cell Commun Signal. 2024;22(1):306.","journal-title":"Cell Commun Signal"},{"key":"1019_CR174","doi-asserted-by":"crossref","unstructured":"Weirich S, Khella MS, Jeltsch A. Structure, activity and function of the Suv39h1 and Suv39h2 Protein Lysine Methyltransferases. Life (Basel) 2021;11(7):703.","DOI":"10.3390\/life11070703"},{"issue":"4","key":"1019_CR175","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/neuonc\/noad222","volume":"26","author":"DE Xin","year":"2024","unstructured":"Xin DE, Liao Y, Rao R, Ogurek S, Sengupta S, Xin M, Bayat AE, Seibel WL, Graham RT, Koschmann C, et al. Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201. Neuro Oncol. 2024;26(4):735\u201348.","journal-title":"Neuro Oncol"},{"issue":"45","key":"1019_CR176","doi-asserted-by":"publisher","first-page":"3306","DOI":"10.1038\/s41388-024-03164-4","volume":"43","author":"M Li","year":"2024","unstructured":"Li M, Sun F, Wang J, Lu S, Que Y, Song M, Chen H, Xiong X, Xie W, Zhu J, et al. SUV39H1 epigenetically modulates the MCPIP1-AURKA signaling axis to enhance neuroblastoma tumorigenesis. Oncogene. 2024;43(45):3306\u201320.","journal-title":"Oncogene"},{"issue":"2","key":"1019_CR177","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.cell.2020.11.042","volume":"184","author":"JZ Shen","year":"2021","unstructured":"Shen JZ, Qiu Z, Wu Q, Finlay D, Garcia G, Sun D, Rantala J, Barshop W, Hope JL, Gimple RC, et al. FBXO44 promotes DNA replication-coupled repetitive element silencing in cancer cells. Cell. 2021;184(2):352\u201369. e323.","journal-title":"Cell"},{"issue":"4","key":"1019_CR178","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.apsb.2021.10.025","volume":"12","author":"HI Tsai","year":"2022","unstructured":"Tsai HI, Wu Y, Huang R, Su D, Wu Y, Liu X, Wang L, Xu Z, Pang Y, Sun C, et al. PHF6 functions as a tumor suppressor by recruiting methyltransferase SUV39H1 to nucleolar region and offers a novel therapeutic target for PHF6-muntant leukemia. Acta Pharm Sin B. 2022;12(4):1913\u201327.","journal-title":"Acta Pharm Sin B"},{"issue":"50","key":"1019_CR179","doi-asserted-by":"publisher","first-page":"7239","DOI":"10.1038\/s41388-020-01495-6","volume":"39","author":"Y Chu","year":"2020","unstructured":"Chu Y, Chen Y, Guo H, Li M, Wang B, Shi D, Cheng X, Guan J, Wang X, Xue C, et al. SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia. Oncogene. 2020;39(50):7239\u201352.","journal-title":"Oncogene"},{"issue":"2","key":"1019_CR180","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/nar\/gkp991","volume":"38","author":"YJ Yang","year":"2010","unstructured":"Yang YJ, Han JW, Youn HD, Cho EJ. The tumor suppressor, parafibromin, mediates histone H3 K9 methylation for cyclin D1 repression. Nucleic Acids Res. 2010;38(2):382\u201390.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"1019_CR181","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/0008-5472.CAN-16-1567","volume":"77","author":"Z Feng","year":"2017","unstructured":"Feng Z, Wang L, Sun Y, Jiang Z, Domsic J, An C, Xing B, Tian J, Liu X, Metz DC, et al. Menin and Daxx Interact to Suppress Neuroendocrine Tumors through Epigenetic Control of the Membrane Metallo-Endopeptidase. Cancer Res. 2017;77(2):401\u201311.","journal-title":"Cancer Res"},{"issue":"1","key":"1019_CR182","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13148-018-0562-4","volume":"10","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Li B, Wang J, Xiong Y, Wang K, Qi Y, Sun H, Wu L, Yang L. Identification of SUV39H2 as a potential oncogene in lung adenocarcinoma. Clin Epigenetics. 2018;10(1):129.","journal-title":"Clin Epigenetics"},{"issue":"11","key":"1019_CR183","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1002\/tox.24370","volume":"39","author":"J You","year":"2024","unstructured":"You J, Xue H, Chao C, Zhang Z, Tan X, Wang X, Li H. Histone Methyltransferase SUV39H2 Supports Nasopharyngeal Carcinoma Cell Metastasis by Regulation of SIRT1. Environ Toxicol. 2024;39(11):4974\u201383.","journal-title":"Environ Toxicol"},{"issue":"1","key":"1019_CR184","first-page":"325","volume":"41","author":"L Piao","year":"2019","unstructured":"Piao L, Yuan X, Zhuang M, Qiu X, Xu X, Kong R, Liu Z. Histone methyltransferase SUV39H2 serves oncogenic roles in osteosarcoma. Oncol Rep. 2019;41(1):325\u201332.","journal-title":"Oncol Rep"},{"issue":"2","key":"1019_CR185","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12032-023-02252-x","volume":"41","author":"D Sun","year":"2024","unstructured":"Sun D, Guo J, Liang W, Chen Y, Wei S, Li A, Wang L, Chen X. Histone methyltransferase SUV39H2 regulates apoptosis and chemosensitivity in prostate cancer through AKT\/FOXO signaling pathway. Med Oncol. 2024;41(2):44.","journal-title":"Med Oncol"},{"key":"1019_CR186","doi-asserted-by":"crossref","unstructured":"Poulard C, Noureddine LM, Pruvost L, Le Romancer M. Structure, activity, and function of the protein lysine methyltransferase G9a. Life (Basel). 2021;11(10):1082.","DOI":"10.3390\/life11101082"},{"issue":"1","key":"1019_CR187","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12935-024-03441-y","volume":"24","author":"AE Silva-Carvalho","year":"2024","unstructured":"Silva-Carvalho AE, Filiu-Braga LDC, Bogea GMR, de Assis AJB, Pittella-Silva F, Saldanha-Araujo F. GLP and G9a histone methyltransferases as potential therapeutic targets for lymphoid neoplasms. Cancer Cell Int. 2024;24(1):243.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"1019_CR188","doi-asserted-by":"crossref","first-page":"111063","DOI":"10.1016\/j.jbc.2025.111063","volume":"302","author":"B Zhang","year":"2026","unstructured":"Zhang B, Jiang J, Sun W, Hu S, Chen P, Li L, Jiang M, Chen J, Zeng J, Cai D, et al. CtBP1\/2 oligomerization promotes G9a-Mediated transcriptional repression. J Biol Chem. 2026;302(2):111063.","journal-title":"J Biol Chem"},{"issue":"4","key":"1019_CR189","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/hep.31141","volume":"72","author":"W Ma","year":"2020","unstructured":"Ma W, Han C, Zhang J, Song K, Chen W, Kwon H, Wu T. The Histone Methyltransferase G9a Promotes Cholangiocarcinogenesis Through Regulation of the Hippo Pathway Kinase LATS2 and YAP Signaling Pathway. Hepatology. 2020;72(4):1283\u201397.","journal-title":"Hepatology"},{"issue":"3","key":"1019_CR190","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1158\/1541-7786.MCR-21-0536","volume":"20","author":"J Zhang","year":"2022","unstructured":"Zhang J, Chen W, Ma W, Song K, Lee S, Han C, Wu T. Epigenetic Silencing of 15-Hydroxyprostaglandin Dehydrogenase by Histone Methyltransferase EHMT2\/G9a in Cholangiocarcinoma. Mol Cancer Res. 2022;20(3):350\u201360.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"1019_CR191","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41467-017-00350-9","volume":"8","author":"YF Wang","year":"2017","unstructured":"Wang YF, Zhang J, Su Y, Shen YY, Jiang DX, Hou YY, Geng MY, Ding J, Chen Y. G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin. Nat Commun. 2017;8(1):274.","journal-title":"Nat Commun"},{"issue":"8","key":"1019_CR192","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1158\/1541-7786.MCR-16-0424","volume":"15","author":"THW Dobson","year":"2017","unstructured":"Dobson THW, Hatcher RJ, Swaminathan J, Das CM, Shaik S, Tao RH, Milite C, Castellano S, Taylor PH, Sbardella G, et al. Regulation of USP37 Expression by REST-Associated G9a-Dependent Histone Methylation. Mol Cancer Res. 2017;15(8):1073\u201384.","journal-title":"Mol Cancer Res"},{"issue":"7339","key":"1019_CR193","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nature09806","volume":"471","author":"CJ Ceol","year":"2011","unstructured":"Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, Fritsch L, Lin WM, Hollmann TJ, Ferre F, et al. The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset. Nature. 2011;471(7339):513\u20137.","journal-title":"Nature"},{"issue":"5","key":"1019_CR194","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41419-020-2561-6","volume":"11","author":"N Cao","year":"2020","unstructured":"Cao N, Yu Y, Zhu H, Chen M, Chen P, Zhuo M, Mao Y, Li L, Zhao Q, Wu M, et al. SETDB1 promotes the progression of colorectal cancer via epigenetically silencing p21 expression. Cell Death Dis. 2020;11(5):351.","journal-title":"Cell Death Dis"},{"issue":"16","key":"1019_CR195","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.7150\/jca.20482","volume":"8","author":"K Chen","year":"2017","unstructured":"Chen K, Zhang F, Ding J, Liang Y, Zhan Z, Zhan Y, Chen LH, Ding Y. Histone Methyltransferase SETDB1 Promotes the Progression of Colorectal Cancer by Inhibiting the Expression of TP53. J Cancer. 2017;8(16):3318\u201330.","journal-title":"J Cancer"},{"issue":"4","key":"1019_CR196","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/path.4482","volume":"235","author":"QY Sun","year":"2015","unstructured":"Sun QY, Ding LW, Xiao JF, Chien W, Lim SL, Hattori N, Goodglick L, Chia D, Mah V, Alavi M, et al. SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway. J Pathol. 2015;235(4):559\u201370.","journal-title":"J Pathol"},{"issue":"21","key":"1019_CR197","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1038\/onc.2013.239","volume":"33","author":"M Rodriguez-Paredes","year":"2014","unstructured":"Rodriguez-Paredes M, Martinez de Paz A, Simo-Riudalbas L, Sayols S, Moutinho C, Moran S, Villanueva A, Vazquez-Cedeira M, Lazo PA, Carneiro F, et al. Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis. Oncogene. 2014;33(21):2807\u201313.","journal-title":"Oncogene"},{"issue":"4","key":"1019_CR198","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.celrep.2018.03.124","volume":"23","author":"CH Lin","year":"2018","unstructured":"Lin CH, Wong SH, Kurzer JH, Schneidawind C, Wei MC, Duque-Afonso J, Jeong J, Feng X, Cleary ML. SETDB2 Links E2A-PBX1 to Cell-Cycle Dysregulation in Acute Leukemia through CDKN2C Repression. Cell Rep. 2018;23(4):1166\u201377.","journal-title":"Cell Rep"},{"key":"1019_CR199","doi-asserted-by":"crossref","first-page":"117135","DOI":"10.1016\/j.bcp.2025.117135","volume":"241","author":"X Shi","year":"2025","unstructured":"Shi X, An Z, Cheng S, Yao J, Zhang Y, Zhang L, Cheng X, Cui Y, Wang Y. SETDB2 participates in iron metabolism in esophageal squamous cell carcinoma via H3K9me3-mediated TFRC silencing. Biochem Pharmacol. 2025;241:117135.","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"1019_CR200","doi-asserted-by":"crossref","first-page":"7258","DOI":"10.1002\/cam4.5451","volume":"12","author":"G Yuan","year":"2023","unstructured":"Yuan G, Hu B, Ma J, Zhang C, Xie H, Wei T, Yang Y, Ni B. Histone lysine methyltransferase SETDB2 suppresses NRF2 to restrict tumor progression and modulates chemotherapy sensitivity in lung adenocarcinoma. Cancer Med. 2023;12(6):7258\u201372.","journal-title":"Cancer Med"},{"issue":"12","key":"1019_CR201","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1038\/s12276-020-00542-2","volume":"52","author":"B Perillo","year":"2020","unstructured":"Perillo B, Tramontano A, Pezone A, Migliaccio A. LSD1: more than demethylation of histone lysine residues. Exp Mol Med. 2020;52(12):1936\u201347.","journal-title":"Exp Mol Med"},{"issue":"4","key":"1019_CR202","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1016\/j.apsb.2024.01.005","volume":"14","author":"M Li","year":"2024","unstructured":"Li M, Dai M, Cheng B, Li S, Guo E, Fu J, Ma T, Yu B. Strategies that regulate LSD1 for novel therapeutics. Acta Pharm Sin B. 2024;14(4):1494\u2013507.","journal-title":"Acta Pharm Sin B"},{"issue":"18","key":"1019_CR203","doi-asserted-by":"crossref","first-page":"7054","DOI":"10.7150\/thno.102037","volume":"14","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Guo N, Zhu H, Liu M, Hao J, Wang S, Guo T, Mamun M, Pang J, Liu Q, et al. Unlocking the dual role of LSD1 in tumor immunity: innate and adaptive pathways. Theranostics. 2024;14(18):7054\u201371.","journal-title":"Theranostics"},{"issue":"4","key":"1019_CR204","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/onc.2017.353","volume":"37","author":"Y He","year":"2018","unstructured":"He Y, Zhao Y, Wang L, Bohrer LR, Pan Y, Wang L, Huang H. LSD1 promotes S-phase entry and tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation. Oncogene. 2018;37(4):534\u201343.","journal-title":"Oncogene"},{"issue":"3","key":"1019_CR205","doi-asserted-by":"crossref","first-page":"942","DOI":"10.3892\/ijo.2017.3849","volume":"50","author":"C Chen","year":"2017","unstructured":"Chen C, Wang Y, Wang S, Liu Y, Zhang J, Xu Y, Zhang Z, Bao W, Wu S. LSD1 sustains estrogen-driven endometrial carcinoma cell proliferation through the PI3K\/AKT pathway via di-demethylating H3K9 of cyclin D1. Int J Oncol. 2017;50(3):942\u201352.","journal-title":"Int J Oncol"},{"issue":"2","key":"1019_CR206","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.celrep.2018.03.051","volume":"23","author":"S Li","year":"2018","unstructured":"Li S, Ali S, Duan X, Liu S, Du J, Liu C, Dai H, Zhou M, Zhou L, Yang L, et al. JMJD1B Demethylates H4R3me2s and H3K9me2 to Facilitate Gene Expression for Development of Hematopoietic Stem and Progenitor Cells. Cell Rep. 2018;23(2):389\u2013403.","journal-title":"Cell Rep"},{"key":"1019_CR207","doi-asserted-by":"crossref","first-page":"10258","DOI":"10.1038\/ncomms10258","volume":"7","author":"H Ohguchi","year":"2016","unstructured":"Ohguchi H, Hideshima T, Bhasin MK, Gorgun GT, Santo L, Cea M, Samur MK, Mimura N, Suzuki R, Tai YT, et al. The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. Nat Commun. 2016;7:10258.","journal-title":"Nat Commun"},{"issue":"11","key":"1019_CR208","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41389-019-0174-7","volume":"8","author":"Z Li","year":"2019","unstructured":"Li Z, Xia J, Fang M, Xu Y. Epigenetic regulation of lung cancer cell proliferation and migration by the chromatin remodeling protein BRG1. Oncogenesis. 2019;8(11):66.","journal-title":"Oncogenesis"},{"issue":"4","key":"1019_CR209","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41418-024-01436-w","volume":"32","author":"H Hong","year":"2025","unstructured":"Hong H, Han H, Wang L, Cao W, Hu M, Li J, Wang J, Yang Y, Xu X, Li G, et al. ABCF1-K430-Lactylation promotes HCC malignant progression via transcriptional activation of HIF1 signaling pathway. Cell Death Differ. 2025;32(4):613\u201331.","journal-title":"Cell Death Differ"},{"issue":"27","key":"1019_CR210","doi-asserted-by":"crossref","first-page":"10606","DOI":"10.1074\/jbc.RA118.001730","volume":"293","author":"K Peng","year":"2018","unstructured":"Peng K, Su G, Ji J, Yang X, Miao M, Mo P, Li M, Xu J, Li W, Yu C. Histone demethylase JMJD1A promotes colorectal cancer growth and metastasis by enhancing Wnt\/beta-catenin signaling. J Biol Chem. 2018;293(27):10606\u201319.","journal-title":"J Biol Chem"},{"issue":"5","key":"1019_CR211","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1093\/nar\/gky1317","volume":"47","author":"HY Wang","year":"2019","unstructured":"Wang HY, Long QY, Tang SB, Xiao Q, Gao C, Zhao QY, Li QL, Ye M, Zhang L, Li LY, et al. Histone demethylase KDM3A is required for enhancer activation of hippo target genes in colorectal cancer. Nucleic Acids Res. 2019;47(5):2349\u201364.","journal-title":"Nucleic Acids Res"},{"issue":"14","key":"1019_CR212","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1128\/MCB.00133-12","volume":"32","author":"JY Kim","year":"2012","unstructured":"Kim JY, Kim KB, Eom GH, Choe N, Kee HJ, Son HJ, Oh ST, Kim DW, Pak JH, Baek HJ, et al. KDM3B is the H3K9 demethylase involved in transcriptional activation of lmo2 in leukemia. Mol Cell Biol. 2012;32(14):2917\u201333.","journal-title":"Mol Cell Biol"},{"issue":"1","key":"1019_CR213","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1080\/10428194.2017.1324156","volume":"59","author":"X Xu","year":"2018","unstructured":"Xu X, Nagel S, Quentmeier H, Wang Z, Pommerenke C, Dirks WG, Macleod RAF, Drexler HG, Hu Z. KDM3B shows tumor-suppressive activity and transcriptionally regulates HOXA1 through retinoic acid response elements in acute myeloid leukemia. Leuk Lymphoma. 2018;59(1):204\u201313.","journal-title":"Leuk Lymphoma"},{"key":"1019_CR214","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12935-019-0979-7","volume":"19","author":"X Wang","year":"2019","unstructured":"Wang X, Fan H, Xu C, Jiang G, Wang H, Zhang J. KDM3B suppresses APL progression by restricting chromatin accessibility and facilitating the ATRA-mediated degradation of PML\/RARalpha. Cancer Cell Int. 2019;19:256.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"1019_CR215","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1756-9966-30-90","volume":"30","author":"BX Li","year":"2011","unstructured":"Li BX, Zhang MC, Luo CL, Yang P, Li H, Xu HM, Xu HF, Shen YW, Xue AM, Zhao ZQ. Effects of RNA interference-mediated gene silencing of JMJD2A on human breast cancer cell line MDA-MB-231 in vitro. J Exp Clin Cancer Res. 2011;30(1):90.","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"1019_CR216","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3892\/etm.2012.662","volume":"4","author":"BX Li","year":"2012","unstructured":"Li BX, Luo CL, Li H, Yang P, Zhang MC, Xu HM, Xu HF, Shen YW, Xue AM, Zhao ZQ. Effects of siRNA-mediated knockdown of jumonji domain containing 2A on proliferation, migration and invasion of the human breast cancer cell line MCF-7. Exp Ther Med. 2012;4(4):755\u201361.","journal-title":"Exp Ther Med"},{"issue":"4","key":"1019_CR217","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1002\/jcb.24009","volume":"113","author":"TD Kim","year":"2012","unstructured":"Kim TD, Shin S, Berry WL, Oh S, Janknecht R. The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells. J Cell Biochem. 2012;113(4):1368\u201376.","journal-title":"J Cell Biochem"},{"issue":"1","key":"1019_CR218","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.canlet.2013.04.009","volume":"336","author":"M Kogure","year":"2013","unstructured":"Kogure M, Takawa M, Cho HS, Toyokawa G, Hayashi K, Tsunoda T, Kobayashi T, Daigo Y, Sugiyama M, Atomi Y, et al. Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)\/S transition. Cancer Lett. 2013;336(1):76\u201384.","journal-title":"Cancer Lett"},{"key":"1019_CR219","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12935-020-01177-z","volume":"20","author":"M Li","year":"2020","unstructured":"Li M, Cheng J, Ma Y, Guo H, Shu H, Huang H, Kuang Y, Yang T. The histone demethylase JMJD2A promotes glioma cell growth via targeting Akt-mTOR signaling. Cancer Cell Int. 2020;20:101.","journal-title":"Cancer Cell Int"},{"issue":"6","key":"1019_CR220","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41419-021-03738-0","volume":"12","author":"ME Massett","year":"2021","unstructured":"Massett ME, Monaghan L, Patterson S, Mannion N, Bunschoten RP, Hoose A, Marmiroli S, Liskamp RMJ, Jorgensen HG, Vetrie D, et al. A KDM4A-PAF1-mediated epigenomic network is essential for acute myeloid leukemia cell self-renewal and survival. Cell Death Dis. 2021;12(6):573.","journal-title":"Cell Death Dis"},{"issue":"12","key":"1019_CR221","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1158\/1940-6207.CAPR-11-0290","volume":"4","author":"G Toyokawa","year":"2011","unstructured":"Toyokawa G, Cho HS, Iwai Y, Yoshimatsu M, Takawa M, Hayami S, Maejima K, Shimizu N, Tanaka H, Tsunoda T, et al. The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6. Cancer Prev Res (Phila). 2011;4(12):2051\u201361.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"10","key":"1019_CR222","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.neo.2016.08.005","volume":"18","author":"X Yuan","year":"2016","unstructured":"Yuan X, Kong J, Ma Z, Li N, Jia R, Liu Y, Zhou F, Zhan Q, Liu G, Gao S. KDM4C, a H3K9me3 Histone Demethylase, is Involved in the Maintenance of Human ESCC-Initiating Cells by Epigenetically Enhancing SOX2 Expression. Neoplasia. 2016;18(10):594\u2013609.","journal-title":"Neoplasia"},{"issue":"3","key":"1019_CR223","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/ncb1546","volume":"9","author":"M Wissmann","year":"2007","unstructured":"Wissmann M, Yin N, Muller JM, Greschik H, Fodor BD, Jenuwein T, Vogler C, Schneider R, Gunther T, Buettner R, et al. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nat Cell Biol. 2007;9(3):347\u201353.","journal-title":"Nat Cell Biol"},{"issue":"4","key":"1019_CR224","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1053\/j.gastro.2018.11.036","volume":"156","author":"K Peng","year":"2019","unstructured":"Peng K, Kou L, Yu L, Bai C, Li M, Mo P, Li W, Yu C. Histone Demethylase JMJD2D Interacts With beta-Catenin to Induce Transcription and Activate Colorectal Cancer Cell Proliferation and Tumor Growth in Mice. Gastroenterology. 2019;156(4):1112\u201326.","journal-title":"Gastroenterology"},{"issue":"1","key":"1019_CR225","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-018-0861-6","volume":"17","author":"F Hu","year":"2018","unstructured":"Hu F, Li H, Liu L, Xu F, Lai S, Luo X, Hu J, Yang X. Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1beta\/VEGFA signalling. Mol Cancer. 2018;17(1):107.","journal-title":"Mol Cancer"},{"issue":"2","key":"1019_CR226","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41418-019-0381-y","volume":"27","author":"Y Wang","year":"2020","unstructured":"Wang Y, Chen W, Lian J, Zhang H, Yu B, Zhang M, Wei F, Wu J, Jiang J, Jia Y, et al. The lncRNA PVT1 regulates nasopharyngeal carcinoma cell proliferation via activating the KAT2A acetyltransferase and stabilizing HIF-1alpha. Cell Death Differ. 2020;27(2):695\u2013710.","journal-title":"Cell Death Differ"},{"issue":"Pt 4","key":"1019_CR227","doi-asserted-by":"crossref","first-page":"134580","DOI":"10.1016\/j.ijbiomac.2024.134580","volume":"277","author":"Q Wang","year":"2024","unstructured":"Wang Q, Ma C, Mao H, Wang J. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates the ZNF334 gene to inhibit the growth of colorectal cancer. Int J Biol Macromol. 2024;277(Pt 4):134580.","journal-title":"Int J Biol Macromol"},{"issue":"2","key":"1019_CR228","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/iub.2158","volume":"72","author":"L Shao","year":"2020","unstructured":"Shao L, Sun W, Wang Z, Dong W, Qin Y. Long noncoding RNA SAMMSON promotes papillary thyroid carcinoma progression through p300\/Sp1 axis and serves as a novel diagnostic and prognostic biomarker. IUBMB Life. 2020;72(2):237\u201346.","journal-title":"IUBMB Life"},{"issue":"3","key":"1019_CR229","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1158\/2159-8290.CD-20-1459","volume":"12","author":"F Yan","year":"2022","unstructured":"Yan F, Li J, Milosevic J, Petroni R, Liu S, Shi Z, Yuan S, Reynaga JM, Qi Y, Rico J, et al. KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs. Cancer Discov. 2022;12(3):792\u2013811.","journal-title":"Cancer Discov"},{"issue":"1","key":"1019_CR230","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-024-01551-8","volume":"17","author":"MQ Shi","year":"2024","unstructured":"Shi MQ, Xu Y, Fu X, Pan DS, Lu XP, Xiao Y, Jiang YZ. Advances in targeting histone deacetylase for treatment of solid tumors. J Hematol Oncol. 2024;17(1):37.","journal-title":"J Hematol Oncol"},{"key":"1019_CR231","doi-asserted-by":"crossref","first-page":"119504","DOI":"10.1016\/j.lfs.2021.119504","volume":"277","author":"MJ Ramaiah","year":"2021","unstructured":"Ramaiah MJ, Tangutur AD, Manyam RR. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. Life Sci. 2021;277:119504.","journal-title":"Life Sci"},{"key":"1019_CR232","doi-asserted-by":"crossref","unstructured":"Park SH, Kim H, Kwak S, Jeong JH, Lee J, Hwang JT, et al. HDAC3-ERalpha Selectively Regulates TNF-alpha-Induced Apoptotic Cell Death in MCF-7 Human Breast Cancer Cells via the p53 Signaling Pathway. Cells. 2020;9(5):1280.","DOI":"10.3390\/cells9051280"},{"issue":"6","key":"1019_CR233","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1158\/1078-0432.CCR-07-0990","volume":"14","author":"W Weichert","year":"2008","unstructured":"Weichert W, Roske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, Gekeler V, Boehm M, Beckers T, Denkert C. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res. 2008;14(6):1669\u201377.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"1019_CR234","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1182\/bloodadvances.2022007998","volume":"7","author":"TH Lai","year":"2023","unstructured":"Lai TH, Ozer HG, Gasparini P, Nigita G, Distefano R, Yu L, Ravikrishnan J, Yilmaz S, Gallegos J, Shukla S, et al. HDAC1 regulates the chromatin landscape to control transcriptional dependencies in chronic lymphocytic leukemia. Blood Adv. 2023;7(12):2897\u2013911.","journal-title":"Blood Adv"},{"issue":"28","key":"1019_CR235","doi-asserted-by":"publisher","first-page":"5686","DOI":"10.1038\/s41388-019-0822-6","volume":"38","author":"D Jiao","year":"2019","unstructured":"Jiao D, Huan Y, Zheng J, Wei M, Zheng G, Han D, Wu J, Xi W, Wei F, Yang AG, et al. UHRF1 promotes renal cell carcinoma progression through epigenetic regulation of TXNIP. Oncogene. 2019;38(28):5686\u201399.","journal-title":"Oncogene"},{"key":"1019_CR236","doi-asserted-by":"crossref","unstructured":"Huang J, Zhang F, Hu G, Pan Y, Sun W, Jiang L, et al. SIRT1 suppresses pituitary tumor progression by downregulating PTTG1 expression. Oncol Rep. 2022;48(2):143.","DOI":"10.3892\/or.2022.8354"},{"issue":"9","key":"1019_CR237","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1182\/blood-2015-06-649970","volume":"127","author":"M Cea","year":"2016","unstructured":"Cea M, Cagnetta A, Adamia S, Acharya C, Tai YT, Fulciniti M, Ohguchi H, Munshi A, Acharya P, Bhasin MK, et al. Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood. 2016;127(9):1138\u201350.","journal-title":"Blood"},{"key":"1019_CR238","doi-asserted-by":"crossref","unstructured":"Hawash M. Next-Generation HDAC Inhibitors: advancing zinc-binding group design for enhanced cancer therapy. Cells. 2025;14(24):1997.","DOI":"10.3390\/cells14241997"},{"issue":"1","key":"1019_CR239","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12935-023-03162-8","volume":"23","author":"H Yang","year":"2023","unstructured":"Yang H, Yang S, He J, Li W, Zhang A, Li N, Zhou G, Sun B. Glucose transporter 3 (GLUT3) promotes lactylation modifications by regulating lactate dehydrogenase A (LDHA) in gastric cancer. Cancer Cell Int. 2023;23(1):303.","journal-title":"Cancer Cell Int"},{"key":"1019_CR240","doi-asserted-by":"crossref","first-page":"106270","DOI":"10.1016\/j.phrs.2022.106270","volume":"181","author":"L Pan","year":"2022","unstructured":"Pan L, Feng F, Wu J, Fan S, Han J, Wang S, Yang L, Liu W, Wang C, Xu K. Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells. Pharmacol Res. 2022;181:106270.","journal-title":"Pharmacol Res"},{"issue":"6","key":"1019_CR241","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1002\/mco2.449","volume":"4","author":"J Huang","year":"2023","unstructured":"Huang J, Liang L, Jiang S, Liu Y, He H, Sun X, Li Y, Xie L, Tao Y, Cong L, et al. BDH1-mediated LRRC31 regulation dependent on histone lysine beta-hydroxybutyrylation to promote lung adenocarcinoma progression. MedComm (2020). 2023;4(6):e449.","journal-title":"MedComm (2020)"},{"issue":"1","key":"1019_CR242","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-025-02360-2","volume":"10","author":"H Lee","year":"2025","unstructured":"Lee H, Kim B, Park J, Park S, Yoo G, Yum S, Kang W, Lee JM, Youn H, Youn B. Cancer stem cells: landscape, challenges and emerging therapeutic innovations. Signal Transduct Target Ther. 2025;10(1):248.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1019_CR243","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","volume":"5","author":"L Yang","year":"2020","unstructured":"Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, Zhang G, Wang X, Dong Z, Chen F, et al. Targeting cancer stem cell pathways for cancer therapy. Signal Transduct Target Ther. 2020;5(1):8.","journal-title":"Signal Transduct Target Ther"},{"key":"1019_CR244","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1038\/ncomms5619","volume":"5","author":"Y Tan","year":"2014","unstructured":"Tan Y, Tajik A, Chen J, Jia Q, Chowdhury F, Wang L, Chen J, Zhang S, Hong Y, Yi H, et al. Matrix softness regulates plasticity of tumour-repopulating cells via H3K9 demethylation and Sox2 expression. Nat Commun. 2014;5:4619.","journal-title":"Nat Commun"},{"key":"1019_CR245","doi-asserted-by":"crossref","first-page":"100121","DOI":"10.1074\/jbc.RA120.015335","volume":"296","author":"Y Deng","year":"2021","unstructured":"Deng Y, Li M, Zhuo M, Guo P, Chen Q, Mo P, Li W, Yu C. Histone demethylase JMJD2D promotes the self-renewal of liver cancer stem-like cells by enhancing EpCAM and Sox9 expression. J Biol Chem. 2021;296:100121.","journal-title":"J Biol Chem"},{"issue":"1\u20132","key":"1019_CR246","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11010-014-2077-4","volume":"394","author":"H Tao","year":"2014","unstructured":"Tao H, Li H, Su Y, Feng D, Wang X, Zhang C, Ma H, Hu Q. Histone methyltransferase G9a and H3K9 dimethylation inhibit the self-renewal of glioma cancer stem cells. Mol Cell Biochem. 2014;394(1\u20132):23\u201330.","journal-title":"Mol Cell Biochem"},{"issue":"21","key":"1019_CR247","doi-asserted-by":"crossref","first-page":"6673","DOI":"10.1158\/1078-0432.CCR-17-0882","volume":"23","author":"Z Yang","year":"2017","unstructured":"Yang Z, He L, Lin K, Zhang Y, Deng A, Liang Y, Li C, Wen T. The KMT1A-GATA3-STAT3 Circuit Is a Novel Self-Renewal Signaling of Human Bladder Cancer Stem Cells. Clin Cancer Res. 2017;23(21):6673\u201385.","journal-title":"Clin Cancer Res"},{"issue":"24","key":"1019_CR248","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1182\/blood-2014-11-610907","volume":"125","author":"T Wada","year":"2015","unstructured":"Wada T, Koyama D, Kikuchi J, Honda H, Furukawa Y. Overexpression of the shortest isoform of histone demethylase LSD1 primes hematopoietic stem cells for malignant transformation. Blood. 2015;125(24):3731\u201346.","journal-title":"Blood"},{"issue":"6","key":"1019_CR249","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1053\/j.gastro.2019.08.018","volume":"157","author":"P Dandawate","year":"2019","unstructured":"Dandawate P, Ghosh C, Palaniyandi K, Paul S, Rawal S, Pradhan R, Sayed AAA, Choudhury S, Standing D, Subramaniam D, et al. The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 and Promotes Tumorigenesis in Mice. Gastroenterology. 2019;157(6):1646\u201359. e1611.","journal-title":"Gastroenterology"},{"key":"1019_CR250","doi-asserted-by":"crossref","first-page":"15146","DOI":"10.1038\/ncomms15146","volume":"8","author":"J Li","year":"2017","unstructured":"Li J, Yu B, Deng P, Cheng Y, Yu Y, Kevork K, Ramadoss S, Ding X, Li X, Wang CY. KDM3 epigenetically controls tumorigenic potentials of human colorectal cancer stem cells through Wnt\/beta-catenin signalling. Nat Commun. 2017;8:15146.","journal-title":"Nat Commun"},{"issue":"11","key":"1019_CR251","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1038\/s41375-019-0581-y","volume":"33","author":"M Kahl","year":"2019","unstructured":"Kahl M, Brioli A, Bens M, Perner F, Kresinsky A, Schnetzke U, Hinze A, Sbirkov Y, Stengel S, Simonetti G, et al. The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML. Leukemia. 2019;33(11):2628\u201339.","journal-title":"Leukemia"},{"issue":"1","key":"1019_CR252","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40164-024-00482-x","volume":"13","author":"J Yang","year":"2024","unstructured":"Yang J, Shay C, Saba NF, Teng Y. Cancer metabolism and carcinogenesis. Exp Hematol Oncol. 2024;13(1):10.","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"1019_CR253","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0163-7258(96)00197-0","volume":"73","author":"JM Mato","year":"1997","unstructured":"Mato JM, Alvarez L, Ortiz P, Pajares MA. S-adenosylmethionine synthesis: molecular mechanisms and clinical implications. Pharmacol Ther. 1997;73(3):265\u201380.","journal-title":"Pharmacol Ther"},{"issue":"5","key":"1019_CR254","doi-asserted-by":"crossref","first-page":"513","DOI":"10.4149\/gpb_2017031","volume":"36","author":"R Murin","year":"2017","unstructured":"Murin R, Vidomanova E, Kowtharapu BS, Hatok J, Dobrota D. Role of S-adenosylmethionine cycle in carcinogenesis. Gen Physiol Biophys. 2017;36(5):513\u201320.","journal-title":"Gen Physiol Biophys"},{"key":"1019_CR255","doi-asserted-by":"crossref","unstructured":"Gou D, Liu R, Shan X, Deng H, Chen C, Xiang J, et al. Gluconeogenic enzyme PCK1 supports S-adenosylmethionine biosynthesis and promotes H3K9me3 modification to suppress hepatocellular carcinoma progression. J Clin Invest. 2023;133(13):e161713.","DOI":"10.1172\/JCI161713"},{"issue":"13","key":"1019_CR256","doi-asserted-by":"crossref","first-page":"e112559","DOI":"10.15252\/embj.2022112559","volume":"42","author":"JP Couto","year":"2023","unstructured":"Couto JP, Vulin M, Jehanno C, Coissieux MM, Hamelin B, Schmidt A, Ivanek R, Sethi A, Brautigam K, Frei AL, et al. Nicotinamide N-methyltransferase sustains a core epigenetic program that promotes metastatic colonization in breast cancer. EMBO J. 2023;42(13):e112559.","journal-title":"EMBO J"},{"issue":"1","key":"1019_CR257","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12943-025-02285-y","volume":"24","author":"J Dai","year":"2025","unstructured":"Dai J, Lu X, Zhang C, Qu T, Li W, Su J, Guo R, Yin D, Wu P, Han L, et al. NNMT promotes acquired EGFR-TKI resistance by forming EGR1 and lactate-mediated double positive feedback loops in non-small cell lung cancer. Mol Cancer. 2025;24(1):79.","journal-title":"Mol Cancer"},{"key":"1019_CR258","doi-asserted-by":"crossref","first-page":"108479","DOI":"10.1016\/j.envint.2024.108479","volume":"184","author":"Y Li","year":"2024","unstructured":"Li Y, Liu A, Chen K, Li L, Zhang X, Zou F, Zhang X, Meng X. Sodium butyrate alleviates lead-induced neuroinflammation and improves cognitive and memory impairment through the ACSS2\/H3K9ac\/BDNF pathway. Environ Int. 2024;184:108479.","journal-title":"Environ Int"},{"issue":"2","key":"1019_CR259","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41588-017-0026-3","volume":"50","author":"J Chen","year":"2018","unstructured":"Chen J, Guccini I, Di Mitri D, Brina D, Revandkar A, Sarti M, Pasquini E, Alajati A, Pinton S, Losa M, et al. Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nat Genet. 2018;50(2):219\u201328.","journal-title":"Nat Genet"},{"issue":"4","key":"1019_CR260","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.cmet.2018.12.019","volume":"29","author":"M Lu","year":"2019","unstructured":"Lu M, Zhu WW, Wang X, Tang JJ, Zhang KL, Yu GY, Shao WQ, Lin ZF, Wang SH, Lu L, et al. ACOT12-Dependent Alteration of Acetyl-CoA Drives Hepatocellular Carcinoma Metastasis by Epigenetic Induction of Epithelial-Mesenchymal Transition. Cell Metab. 2019;29(4):886\u2013e900885.","journal-title":"Cell Metab"},{"issue":"7813","key":"1019_CR261","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41586-020-2363-0","volume":"582","author":"PL Sulkowski","year":"2020","unstructured":"Sulkowski PL, Oeck S, Dow J, Economos NG, Mirfakhraie L, Liu Y, Noronha K, Bao X, Li J, Shuch BM, et al. Oncometabolites suppress DNA repair by disrupting local chromatin signalling. Nature. 2020;582(7813):586\u201391.","journal-title":"Nature"},{"issue":"1","key":"1019_CR262","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13046-022-02282-9","volume":"41","author":"B He","year":"2022","unstructured":"He B, Pan H, Zheng F, Chen S, Bie Q, Cao J, Zhao R, Liang J, Wei L, Zeng J, et al. Long noncoding RNA LINC00930 promotes PFKFB3-mediated tumor glycolysis and cell proliferation in nasopharyngeal carcinoma. J Exp Clin Cancer Res. 2022;41(1):77.","journal-title":"J Exp Clin Cancer Res"},{"issue":"27","key":"1019_CR263","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1038\/onc.2017.13","volume":"36","author":"W Wan","year":"2017","unstructured":"Wan W, Peng K, Li M, Qin L, Tong Z, Yan J, Shen B, Yu C. Histone demethylase JMJD1A promotes urinary bladder cancer progression by enhancing glycolysis through coactivation of hypoxia inducible factor 1alpha. Oncogene. 2017;36(27):3868\u201377.","journal-title":"Oncogene"},{"issue":"18","key":"1019_CR264","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1038\/s41388-022-02283-0","volume":"41","author":"C Lu","year":"2022","unstructured":"Lu C, Yang D, Klement JD, Colson YL, Oberlies NH, Pearce CJ, Colby AH, Grinstaff MW, Liu Z, Shi H, et al. H3K9me3 represses G6PD expression to suppress the pentose phosphate pathway and ROS production to promote human mesothelioma growth. Oncogene. 2022;41(18):2651\u201362.","journal-title":"Oncogene"},{"issue":"6","key":"1019_CR265","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.cmet.2013.11.004","volume":"18","author":"J Ding","year":"2013","unstructured":"Ding J, Li T, Wang X, Zhao E, Choi JH, Yang L, Zha Y, Dong Z, Huang S, Asara JM, et al. The histone H3 methyltransferase G9A epigenetically activates the serine-glycine synthesis pathway to sustain cancer cell survival and proliferation. Cell Metab. 2013;18(6):896\u2013907.","journal-title":"Cell Metab"},{"issue":"8","key":"1019_CR266","doi-asserted-by":"crossref","first-page":"e1352","DOI":"10.1002\/ctm2.1352","volume":"13","author":"X He","year":"2023","unstructured":"He X, Zhong X, Fang Y, Hu Z, Chen Z, Wang Y, Huang H, Zhao S, Li D, Wei P. AF9 sustains glycolysis in colorectal cancer via H3K9ac-mediated PCK2 and FBP1 transcription. Clin Transl Med. 2023;13(8):e1352.","journal-title":"Clin Transl Med"},{"issue":"1","key":"1019_CR267","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41419-025-07404-7","volume":"16","author":"M Zhang","year":"2025","unstructured":"Zhang M, Bai J, Yuan H, Duan X, Yu L, Li Y, Li K, Rile S, Wang X, Wang H, et al. BRD1 deficiency affects SREBF1-related lipid metabolism through regulating H3K9ac\/H3K9me3 transition to inhibit HCC progression. Cell Death Dis. 2025;16(1):104.","journal-title":"Cell Death Dis"},{"issue":"12","key":"1019_CR268","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1038\/s41418-025-01533-4","volume":"32","author":"C Zhang","year":"2025","unstructured":"Zhang C, Yu R, Li S, Yuan M, Hu T, Liu J, Ke H, Ye S, Yun J, Huang J, et al. KRAS mutation increases histone H3 lysine 9 lactylation (H3K9la) to promote colorectal cancer progression by facilitating cholesterol transporter GRAMD1A expression. Cell Death Differ. 2025;32(12):2225\u201338.","journal-title":"Cell Death Differ"},{"issue":"1","key":"1019_CR269","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12943-025-02338-2","volume":"24","author":"H Allgayer","year":"2025","unstructured":"Allgayer H, Mahapatra S, Mishra B, Swain B, Saha S, Khanra S, Kumari K, Panda VK, Malhotra D, Patil NS, et al. Epithelial-to-mesenchymal transition (EMT) and cancer metastasis: the status quo of methods and experimental models 2025. Mol Cancer. 2025;24(1):167.","journal-title":"Mol Cancer"},{"issue":"5","key":"1019_CR270","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","volume":"139","author":"JP Thiery","year":"2009","unstructured":"Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871\u201390.","journal-title":"Cell"},{"issue":"5","key":"1019_CR271","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.2353\/ajpath.2009.080545","volume":"174","author":"MW Klymkowsky","year":"2009","unstructured":"Klymkowsky MW, Savagner P. Epithelial-mesenchymal transition: a cancer researcher\u2019s conceptual friend and foe. Am J Pathol. 2009;174(5):1588\u201393.","journal-title":"Am J Pathol"},{"issue":"6","key":"1019_CR272","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrc2131","volume":"7","author":"H Peinado","year":"2007","unstructured":"Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7(6):415\u201328.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"1019_CR273","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.tcb.2013.06.001","volume":"23","author":"B Ell","year":"2013","unstructured":"Ell B, Kang Y. Transcriptional control of cancer metastasis. Trends Cell Biol. 2013;23(12):603\u201311.","journal-title":"Trends Cell Biol"},{"issue":"Suppl 3","key":"1019_CR274","doi-asserted-by":"publisher","first-page":"S1556","DOI":"10.1245\/s10434-015-4379-5","volume":"22","author":"SM Hsiao","year":"2015","unstructured":"Hsiao SM, Chen MW, Chen CA, Chien MH, Hua KT, Hsiao M, Kuo ML, Wei LH. The H3K9 Methyltransferase G9a Represses E-cadherin and is Associated with Myometrial Invasion in Endometrial Cancer. Ann Surg Oncol. 2015;22(Suppl 3):S1556\u20131565.","journal-title":"Ann Surg Oncol"},{"key":"1019_CR275","doi-asserted-by":"crossref","first-page":"216404","DOI":"10.1016\/j.canlet.2023.216404","volume":"575","author":"X Cui","year":"2023","unstructured":"Cui X, Shang X, Xie J, Xie C, Tang Z, Luo Q, Wu C, Wang G, Wang N, He K, et al. Cooperation between IRTKS and deubiquitinase OTUD4 enhances the SETDB1-mediated H3K9 trimethylation that promotes tumor metastasis via suppressing E-cadherin expression. Cancer Lett. 2023;575:216404.","journal-title":"Cancer Lett"},{"issue":"4","key":"1019_CR276","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1172\/JCI57349","volume":"122","author":"C Dong","year":"2012","unstructured":"Dong C, Wu Y, Yao J, Wang Y, Yu Y, Rychahou PG, Evers BM, Zhou BP. G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. J Clin Invest. 2012;122(4):1469\u201386.","journal-title":"J Clin Invest"},{"issue":"1","key":"1019_CR277","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41389-022-00405-7","volume":"11","author":"L Wang","year":"2022","unstructured":"Wang L, Chen J, Zuo Q, Wu C, Yu T, Zheng P, Huang H, Deng J, Fang L, Liu H, et al. Calreticulin enhances gastric cancer metastasis by dimethylating H3K9 in the E-cadherin promoter region mediating by G9a. Oncogenesis. 2022;11(1):29.","journal-title":"Oncogenesis"},{"issue":"21","key":"1019_CR278","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1038\/emboj.2010.239","volume":"29","author":"K Kokura","year":"2010","unstructured":"Kokura K, Sun L, Bedford MT, Fang J. Methyl-H3K9-binding protein MPP8 mediates E-cadherin gene silencing and promotes tumour cell motility and invasion. EMBO J. 2010;29(21):3673\u201387.","journal-title":"EMBO J"},{"key":"1019_CR279","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/ncomms1549","volume":"2","author":"Y Chang","year":"2011","unstructured":"Chang Y, Sun L, Kokura K, Horton JR, Fukuda M, Espejo A, Izumi V, Koomen JM, Bedford MT, Zhang X, et al. MPP8 mediates the interactions between DNA methyltransferase Dnmt3a and H3K9 methyltransferase GLP\/G9a. Nat Commun. 2011;2:533.","journal-title":"Nat Commun"},{"issue":"2","key":"1019_CR280","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.yexcr.2018.01.011","volume":"363","author":"G Yang","year":"2018","unstructured":"Yang G, Zeng X, Wang M, Wu A. The TET2\/E-cadherin\/beta-catenin regulatory loop confers growth and invasion in hepatocellular carcinoma cells. Exp Cell Res. 2018;363(2):218\u201326.","journal-title":"Exp Cell Res"},{"issue":"23","key":"1019_CR281","doi-asserted-by":"crossref","first-page":"6419","DOI":"10.1158\/1078-0432.CCR-13-0254","volume":"19","author":"L Zhao","year":"2013","unstructured":"Zhao L, Li W, Zang W, Liu Z, Xu X, Yu H, Yang Q, Jia J. JMJD2B promotes epithelial-mesenchymal transition by cooperating with beta-catenin and enhances gastric cancer metastasis. Clin Cancer Res. 2013;19(23):6419\u201329.","journal-title":"Clin Cancer Res"},{"issue":"52","key":"1019_CR282","doi-asserted-by":"crossref","first-page":"e2408049121","DOI":"10.1073\/pnas.2408049121","volume":"121","author":"A Sinha","year":"2024","unstructured":"Sinha A, Saini KK, Chandramouli A, Tripathi K, Khan MA, Satrusal SR, Verma A, Mandal B, Rai P, Meena S, et al. ACSL4-mediated H3K9 and H3K27 hyperacetylation upregulates SNAIL to drive TNBC metastasis. Proc Natl Acad Sci U S A. 2024;121(52):e2408049121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"1019_CR283","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/abbs\/gmv107","volume":"47","author":"S Li","year":"2015","unstructured":"Li S, Wu L, Wang Q, Li Y, Wang X. KDM4B promotes epithelial-mesenchymal transition through up-regulation of ZEB1 in pancreatic cancer. Acta Biochim Biophys Sin (Shanghai). 2015;47(12):997\u20131004.","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"issue":"11","key":"1019_CR284","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/onc.2012.169","volume":"32","author":"C Dong","year":"2013","unstructured":"Dong C, Wu Y, Wang Y, Wang C, Kang T, Rychahou PG, Chi YI, Evers BM, Zhou BP. Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer. Oncogene. 2013;32(11):1351\u201362.","journal-title":"Oncogene"},{"issue":"4","key":"1019_CR285","doi-asserted-by":"crossref","first-page":"e12621","DOI":"10.1111\/cpr.12621","volume":"52","author":"W Song","year":"2019","unstructured":"Song W, Gu Y, Lu S, Wu H, Cheng Z, Hu J, Qian Y, Zheng Y, Fan H. LncRNA TRERNA1 facilitates hepatocellular carcinoma metastasis by dimethylating H3K9 in the CDH1 promoter region via the recruitment of the EHMT2\/SNAI1 complex. Cell Prolif. 2019;52(4):e12621.","journal-title":"Cell Prolif"},{"issue":"11","key":"1019_CR286","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1111\/cas.14173","volume":"110","author":"Y Hu","year":"2019","unstructured":"Hu Y, Zheng Y, Dai M, Wang X, Wu J, Yu B, Zhang H, Cui Y, Kong W, Wu H, et al. G9a and histone deacetylases are crucial for Snail2-mediated E-cadherin repression and metastasis in hepatocellular carcinoma. Cancer Sci. 2019;110(11):3442\u201352.","journal-title":"Cancer Sci"},{"issue":"20","key":"1019_CR287","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1158\/0008-5472.CAN-10-0833","volume":"70","author":"MW Chen","year":"2010","unstructured":"Chen MW, Hua KT, Kao HJ, Chi CC, Wei LH, Johansson G, Shiah SG, Chen PS, Jeng YM, Cheng TY, et al. H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res. 2010;70(20):7830\u201340.","journal-title":"Cancer Res"},{"issue":"4","key":"1019_CR288","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jhep.2017.05.015","volume":"67","author":"L Wei","year":"2017","unstructured":"Wei L, Chiu DK, Tsang FH, Law CT, Cheng CL, Au SL, Lee JM, Wong CC, Ng IO, Wong CM. Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3. J Hepatol. 2017;67(4):758\u201369.","journal-title":"J Hepatol"},{"issue":"6","key":"1019_CR289","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/s41419-021-03853-y","volume":"12","author":"S Xia","year":"2021","unstructured":"Xia S, Wu J, Zhou W, Zhang M, Zhao K, Liu J, Tian D, Liao J. SLC7A2 deficiency promotes hepatocellular carcinoma progression by enhancing recruitment of myeloid-derived suppressors cells. Cell Death Dis. 2021;12(6):570.","journal-title":"Cell Death Dis"},{"key":"1019_CR290","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1476-4598-11-27","volume":"11","author":"M Tandon","year":"2012","unstructured":"Tandon M, Gokul K, Ali SA, Chen Z, Lian J, Stein GS, Pratap J. Runx2 mediates epigenetic silencing of the bone morphogenetic protein-3B (BMP-3B\/GDF10) in lung cancer cells. Mol Cancer. 2012;11:27.","journal-title":"Mol Cancer"},{"issue":"1","key":"1019_CR291","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41392-022-00896-1","volume":"7","author":"Y Fu","year":"2022","unstructured":"Fu Y, Zhang X, Liu X, Wang P, Chu W, Zhao W, Wang Y, Zhou G, Yu Y, Zhang H. The DNMT1-PAS1-PH20 axis drives breast cancer growth and metastasis. Signal Transduct Target Ther. 2022;7(1):81.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1019_CR292","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/onc.2013.522","volume":"34","author":"Y Yang","year":"2015","unstructured":"Yang Y, Liu R, Qiu R, Zheng Y, Huang W, Hu H, Ji Q, He H, Shang Y, Gong Y, et al. CRL4B promotes tumorigenesis by coordinating with SUV39H1\/HP1\/DNMT3A in DNA methylation-based epigenetic silencing. Oncogene. 2015;34(1):104\u201318.","journal-title":"Oncogene"},{"key":"1019_CR293","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.canlet.2018.02.023","volume":"422","author":"W Shuai","year":"2018","unstructured":"Shuai W, Wu J, Chen S, Liu R, Ye Z, Kuang C, Fu X, Wang G, Li Y, Peng Q, et al. SUV39H2 promotes colorectal cancer proliferation and metastasis via tri-methylation of the SLIT1 promoter. Cancer Lett. 2018;422:56\u201369.","journal-title":"Cancer Lett"},{"issue":"24","key":"1019_CR294","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1038\/s41388-022-02345-3","volume":"41","author":"S Ueshima","year":"2022","unstructured":"Ueshima S, Fang J. Histone H3K9 methyltransferase SETDB1 augments invadopodia formation to promote tumor metastasis. Oncogene. 2022;41(24):3370\u201380.","journal-title":"Oncogene"},{"issue":"24","key":"1019_CR295","doi-asserted-by":"crossref","first-page":"7333","DOI":"10.1158\/0008-5472.CAN-13-3572","volume":"74","author":"PC Wu","year":"2014","unstructured":"Wu PC, Lu JW, Yang JY, Lin IH, Ou DL, Lin YH, Chou KH, Huang WF, Wang WP, Huang YL, et al. H3K9 histone methyltransferase, KMT1E\/SETDB1, cooperates with the SMAD2\/3 pathway to suppress lung cancer metastasis. Cancer Res. 2014;74(24):7333\u201343.","journal-title":"Cancer Res"},{"issue":"5","key":"1019_CR296","doi-asserted-by":"crossref","first-page":"e70486","DOI":"10.1111\/jcmm.70486","volume":"29","author":"X Li","year":"2025","unstructured":"Li X, Shen Y, Lang J, Wu J, Qian Z, Shen G, Shen Y. CD39 Contributes to the Ability of Cell Invasion in Heterogeneity of Colorectal Cancer. J Cell Mol Med. 2025;29(5):e70486.","journal-title":"J Cell Mol Med"},{"key":"1019_CR297","doi-asserted-by":"crossref","first-page":"117114","DOI":"10.1016\/j.lfs.2019.117114","volume":"241","author":"HS Zhang","year":"2020","unstructured":"Zhang HS, Liu HY, Zhou Z, Sun HL, Liu MY. TSPAN8 promotes colorectal cancer cell growth and migration in LSD1-dependent manner. Life Sci. 2020;241:117114.","journal-title":"Life Sci"},{"issue":"15","key":"1019_CR298","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1073\/pnas.1614664114","volume":"114","author":"J Carnesecchi","year":"2017","unstructured":"Carnesecchi J, Forcet C, Zhang L, Tribollet V, Barenton B, Boudra R, Cerutti C, Billas IM, Serandour AA, Carroll JS, et al. ERRalpha induces H3K9 demethylation by LSD1 to promote cell invasion. Proc Natl Acad Sci U S A. 2017;114(15):3909\u201314.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1019_CR299","doi-asserted-by":"crossref","first-page":"830","DOI":"10.17305\/bb.2025.11251","volume":"26","author":"B Shi","year":"2025","unstructured":"Shi B, Wang Z, Xiu L, Li L, Yang X, Wang G, Li J, Wang H, Han Y. KDM3A drives NSCLC proliferation and metastasis via H3K9 demethylation, EMT activation and MMP-9 upregulation. Biomol Biomed. 2025;26(5):830\u201343.","journal-title":"Biomol Biomed"},{"issue":"29","key":"1019_CR300","doi-asserted-by":"publisher","first-page":"4150","DOI":"10.1038\/onc.2017.44","volume":"36","author":"M Sechler","year":"2017","unstructured":"Sechler M, Parrish JK, Birks DK, Jedlicka P. The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis. Oncogene. 2017;36(29):4150\u201360.","journal-title":"Oncogene"},{"issue":"12","key":"1019_CR301","doi-asserted-by":"crossref","first-page":"114262","DOI":"10.1016\/j.isci.2025.114262","volume":"28","author":"J Li","year":"2025","unstructured":"Li J, Sun S, Wang X, Li Y, Zhang H, Fu X, Zhao X, Chen G. KDM3B promotes neural invasion in colorectal cancer through TrkA upregulation by inhibiting H3K9 dimethylation. iScience. 2025;28(12):114262.","journal-title":"iScience"},{"issue":"18","key":"1019_CR302","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1038\/onc.2016.412","volume":"36","author":"C Wilson","year":"2017","unstructured":"Wilson C, Qiu L, Hong Y, Karnik T, Tadros G, Mau B, Ma T, Mu Y, New J, Louie RJ, et al. The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer. Oncogene. 2017;36(18):2565\u201376.","journal-title":"Oncogene"},{"issue":"27","key":"1019_CR303","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1038\/onc.2017.30","volume":"36","author":"L Yu","year":"2017","unstructured":"Yu L, Di Y, Xin L, Ren Y, Liu X, Sun X, Zhang W, Yao Z, Yang J. SND1 acts as a novel gene transcription activator recognizing the conserved Motif domains of Smad promoters, inducing TGFbeta1 response and breast cancer metastasis. Oncogene. 2017;36(27):3903\u201314.","journal-title":"Oncogene"},{"issue":"1","key":"1019_CR304","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s12967-023-04305-1","volume":"21","author":"X Gu","year":"2023","unstructured":"Gu X, Min W, Zeng Y, Fan N, Qian Q. Aberrant KAT2A accumulations render TRIM22-low melanoma sensitive to Notch1 inhibitors via epigenetic reprogramming. J Transl Med. 2023;21(1):443.","journal-title":"J Transl Med"},{"key":"1019_CR305","doi-asserted-by":"publisher","first-page":"5406","DOI":"10.1038\/ncomms6406","volume":"5","author":"C Gong","year":"2014","unstructured":"Gong C, Qu S, Lv XB, Liu B, Tan W, Nie Y, Su F, Liu Q, Yao H, Song E. BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10. Nat Commun. 2014;5:5406.","journal-title":"Nat Commun"},{"issue":"6","key":"1019_CR306","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.7150\/jca.66914","volume":"13","author":"Y Wen","year":"2022","unstructured":"Wen Y, Zhang X, Li X, Tian L, Shen S, Ma J, Ai F. Histone deacetylase (HDAC) 11 inhibits matrix metalloproteinase (MMP) 3 expression to suppress colorectal cancer metastasis. J Cancer. 2022;13(6):1923\u201332.","journal-title":"J Cancer"},{"issue":"8","key":"1019_CR307","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/onc.2016.286","volume":"36","author":"Y Xu","year":"2017","unstructured":"Xu Y, Qin L, Sun T, Wu H, He T, Yang Z, Mo Q, Liao L, Xu J. Twist1 promotes breast cancer invasion and metastasis by silencing Foxa1 expression. Oncogene. 2017;36(8):1157\u201366.","journal-title":"Oncogene"},{"issue":"1","key":"1019_CR308","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","volume":"10","author":"M Tufail","year":"2025","unstructured":"Tufail M, Jiang CH, Li N. Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduct Target Ther. 2025;10(1):227.","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"1019_CR309","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.trecan.2020.02.003","volume":"6","author":"J Cao","year":"2020","unstructured":"Cao J, Yan Q. Cancer Epigenetics, Tumor Immunity, and Immunotherapy. Trends Cancer. 2020;6(7):580\u201392.","journal-title":"Trends Cancer"},{"key":"1019_CR310","doi-asserted-by":"crossref","unstructured":"Seetharam D, Chandar J, Ramsoomair CK, Desgraves JF, Alvarado Medina A, Hudson AJ, et al. Activating antiviral immune responses potentiates immune checkpoint inhibition in glioblastoma models. J Clin Invest. 2025;135(6):e183745.","DOI":"10.1172\/JCI183745"},{"key":"1019_CR311","doi-asserted-by":"crossref","unstructured":"Guo E, Xiao R, Wu Y, Lu F, Liu C, Yang B, et al. WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway. J Exp Med. 2022;219(1):e20210789.","DOI":"10.1084\/jem.20210789"},{"issue":"11","key":"1019_CR312","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1158\/2326-6066.CIR-21-0543","volume":"9","author":"H Hu","year":"2021","unstructured":"Hu H, Khodadadi-Jamayran A, Dolgalev I, Cho H, Badri S, Chiriboga LA, Zeck B, Lopez De Rodas Gregorio M, Dowling CM, Labbe K, et al. Targeting the Atf7ip-Setdb1 Complex Augments Antitumor Immunity by Boosting Tumor Immunogenicity. Cancer Immunol Res. 2021;9(11):1298\u2013315.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1019_CR313","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41392-023-01626-x","volume":"8","author":"Y Fang","year":"2023","unstructured":"Fang Y, Zhang MC, He Y, Li C, Fang H, Xu PP, Cheng S, Zhao Y, Feng Y, Liu Q, et al. Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma. Signal Transduct Target Ther. 2023;8(1):381.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"1019_CR314","doi-asserted-by":"crossref","first-page":"e1598","DOI":"10.1002\/ctm2.1598","volume":"14","author":"M Sun","year":"2024","unstructured":"Sun M, Han X, Li J, Zheng J, Li J, Wang H, Li X. Targeting KDM4 family epigenetically triggers antitumour immunity via enhancing tumour-intrinsic innate sensing and immunogenicity. Clin Transl Med. 2024;14(2):e1598.","journal-title":"Clin Transl Med"},{"issue":"21","key":"1019_CR315","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1016\/j.scib.2025.08.023","volume":"70","author":"Y Wang","year":"2025","unstructured":"Wang Y, Zhao J, Wang Y, Chen G, Zhao S, Xu J, Yin C, Xu Y, Kang Y, Dong Y, et al. G9a-mediated H3K9 di-methylation protects centromere integrity and chromosome stability. Sci Bull (Beijing). 2025;70(21):3489\u201393.","journal-title":"Sci Bull (Beijing)"},{"issue":"41","key":"1019_CR316","doi-asserted-by":"crossref","first-page":"e07904","DOI":"10.1002\/advs.202507904","volume":"12","author":"C Mao","year":"2025","unstructured":"Mao C, Fan W, Liu J, Yang F, Li W, Li L, Shi Z, Li Q, Yuan Z, Jiang Y, et al. Targeting HDAC and PARP Enhances STING-Dependent Antitumor Immunity in STING-Deficient Tumor. Adv Sci (Weinh). 2025;12(41):e07904.","journal-title":"Adv Sci (Weinh)"},{"issue":"11","key":"1019_CR317","doi-asserted-by":"crossref","first-page":"eabf8627","DOI":"10.1126\/sciadv.abf8627","volume":"8","author":"AM Hansen","year":"2022","unstructured":"Hansen AM, Ge Y, Schuster MB, Pundhir S, Jakobsen JS, Kalvisa A, Tapia MC, Gordon S, Ambri F, Bagger FO, et al. H3K9 dimethylation safeguards cancer cells against activation of the interferon pathway. Sci Adv. 2022;8(11):eabf8627.","journal-title":"Sci Adv"},{"issue":"7","key":"1019_CR318","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/ijc.70284","volume":"158","author":"X Chai","year":"2026","unstructured":"Chai X, Chen J, Zhao Y, Chu W, Zhou J, Zhao Y, Hu Z, Zhu J, Zhu Y, Xu Z, et al. G9a epigenetically suppresses CXCL10 expression and inhibits anti-tumor immunity in hepatocellular carcinoma. Int J Cancer. 2026;158(7):1960\u201374.","journal-title":"Int J Cancer"},{"issue":"1","key":"1019_CR319","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/HEP.0000000000000704","volume":"81","author":"C Yin","year":"2025","unstructured":"Yin C, Zhang C, Wang Y, Liu G, Wang N, Liang N, Zhang L, Tu Q, Lv J, Jiang H, et al. ALDOB\/KAT2A interactions epigenetically modulate TGF-beta expression and T cell functions in hepatocellular carcinogenesis. Hepatology. 2025;81(1):77\u201393.","journal-title":"Hepatology"},{"issue":"1","key":"1019_CR320","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s13046-023-02885-w","volume":"42","author":"J Wang","year":"2023","unstructured":"Wang J, Zhang X, Ma X, Chen D, Cai M, Xiao L, Li J, Huang Z, Huang Y, Lian Y. Blockage of CacyBP inhibits macrophage recruitment and improves anti-PD-1 therapy in hepatocellular carcinoma. J Exp Clin Cancer Res. 2023;42(1):303.","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"1019_CR321","doi-asserted-by":"crossref","first-page":"114686","DOI":"10.1016\/j.celrep.2024.114686","volume":"43","author":"R Wang","year":"2024","unstructured":"Wang R, Li C, Cheng Z, Li M, Shi J, Zhang Z, Jin S, Ma H. H3K9 lactylation in malignant cells facilitates CD8(+) T cell dysfunction and poor immunotherapy response. Cell Rep. 2024;43(9):114686.","journal-title":"Cell Rep"},{"key":"1019_CR322","doi-asserted-by":"crossref","unstructured":"Chen W, Liao Y, Yao H, Zou Y, Fang J, Zhang J, Guo Z, Tu J, Chen J, Huo Z et al. Multiomics integration analysis identifies tumor cell-derived MIF as a therapeutic target and potentiates anti-PD-1 therapy in osteosarcoma. J Immunother Cancer. 2025;13(8).","DOI":"10.1136\/jitc-2024-011091"},{"issue":"3","key":"1019_CR323","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1158\/2326-6066.CIR-18-0126","volume":"7","author":"C Lu","year":"2019","unstructured":"Lu C, Yang D, Klement JD, Oh IK, Savage NM, Waller JL, Colby AH, Grinstaff MW, Oberlies NH, Pearce CJ, et al. SUV39H1 Represses the Expression of Cytotoxic T-Lymphocyte Effector Genes to Promote Colon Tumor Immune Evasion. Cancer Immunol Res. 2019;7(3):414\u201327.","journal-title":"Cancer Immunol Res"},{"key":"1019_CR324","doi-asserted-by":"crossref","unstructured":"Lu C, Yang D, Klement JD, Colson YL, Oberlies NH, Pearce CJ, et al. G6PD functions as a metabolic checkpoint to regulate granzyme B expression in tumor-specific cytotoxic T lymphocytes. J Immunother Cancer. 2022;10(1):e003543.","DOI":"10.1136\/jitc-2021-003543"},{"issue":"11","key":"1019_CR325","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1038\/s41590-024-01985-9","volume":"25","author":"D Raychaudhuri","year":"2024","unstructured":"Raychaudhuri D, Singh P, Chakraborty B, Hennessey M, Tannir AJ, Byregowda S, Natarajan SM, Trujillo-Ocampo A, Im JS, Goswami S. Histone lactylation drives CD8(+) T cell metabolism and function. Nat Immunol. 2024;25(11):2140\u201351.","journal-title":"Nat Immunol"},{"issue":"5","key":"1019_CR326","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1084\/jem.20100363","volume":"207","author":"B Lehnertz","year":"2010","unstructured":"Lehnertz B, Northrop JP, Antignano F, Burrows K, Hadidi S, Mullaly SC, Rossi FM, Zaph C. Activating and inhibitory functions for the histone lysine methyltransferase G9a in T helper cell differentiation and function. J Exp Med. 2010;207(5):915\u201322.","journal-title":"J Exp Med"},{"issue":"5","key":"1019_CR327","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1172\/JCI69592","volume":"124","author":"F Antignano","year":"2014","unstructured":"Antignano F, Burrows K, Hughes MR, Han JM, Kron KJ, Penrod NM, Oudhoff MJ, Wang SK, Min PH, Gold MJ, et al. Methyltransferase G9A regulates T cell differentiation during murine intestinal inflammation. J Clin Invest. 2014;124(5):1945\u201355.","journal-title":"J Clin Invest"},{"issue":"7406","key":"1019_CR328","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature11173","volume":"487","author":"RS Allan","year":"2012","unstructured":"Allan RS, Zueva E, Cammas F, Schreiber HA, Masson V, Belz GT, Roche D, Maison C, Quivy JP, Almouzni G, et al. An epigenetic silencing pathway controlling T helper 2 cell lineage commitment. Nature. 2012;487(7406):249\u201353.","journal-title":"Nature"},{"issue":"6","key":"1019_CR329","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.immuni.2016.05.013","volume":"44","author":"X Xiao","year":"2016","unstructured":"Xiao X, Shi X, Fan Y, Wu C, Zhang X, Minze L, Liu W, Ghobrial RM, Lan P, Li XC. The Costimulatory Receptor OX40 Inhibits Interleukin-17 Expression through Activation of Repressive Chromatin Remodeling Pathways. Immunity. 2016;44(6):1271\u201383.","journal-title":"Immunity"},{"issue":"3","key":"1019_CR330","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.immuni.2019.01.003","volume":"50","author":"V Adoue","year":"2019","unstructured":"Adoue V, Binet B, Malbec A, Fourquet J, Romagnoli P, van Meerwijk JPM, Amigorena S, Joffre OP. The Histone Methyltransferase SETDB1 Controls T Helper Cell Lineage Integrity by Repressing Endogenous Retroviruses. Immunity. 2019;50(3):629\u2013e644628.","journal-title":"Immunity"},{"issue":"11","key":"1019_CR331","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.4049\/jimmunol.2300023","volume":"211","author":"Y Song","year":"2023","unstructured":"Song Y, Zhao X, Qu H, Su Y, He R, Chen L, Fang L, Li J, Zou Z, He J, et al. Epigenetic Regulation of IL-23 by E3 Ligase FBXW7 in Dendritic Cells Is Critical for Psoriasis-like Inflammation. J Immunol. 2023;211(11):1701\u201313.","journal-title":"J Immunol"},{"issue":"4","key":"1019_CR332","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.molcel.2012.05.011","volume":"46","author":"Y Zhu","year":"2012","unstructured":"Zhu Y, van Essen D, Saccani S. Cell-type-specific control of enhancer activity by H3K9 trimethylation. Mol Cell. 2012;46(4):408\u201323.","journal-title":"Mol Cell"},{"issue":"10","key":"1019_CR333","doi-asserted-by":"crossref","first-page":"7893","DOI":"10.1074\/jbc.M110.165431","volume":"286","author":"MA Smith","year":"2011","unstructured":"Smith MA, Wright G, Wu J, Tailor P, Ozato K, Chen X, Wei S, Piskurich JF, Ting JP, Wright KL. Positive regulatory domain I (PRDM1) and IRF8\/PU.1 counter-regulate MHC class II transactivator (CIITA) expression during dendritic cell maturation. J Biol Chem. 2011;286(10):7893\u2013904.","journal-title":"J Biol Chem"},{"issue":"7","key":"1019_CR334","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.4049\/jimmunol.2001003","volume":"206","author":"S Chikuma","year":"2021","unstructured":"Chikuma S, Yamanaka S, Nakagawa S, Ueda MT, Hayabuchi H, Tokifuji Y, Kanayama M, Okamura T, Arase H, Yoshimura A. TRIM28 Expression on Dendritic Cells Prevents Excessive T Cell Priming by Silencing Endogenous Retrovirus. J Immunol. 2021;206(7):1528\u201339.","journal-title":"J Immunol"},{"key":"1019_CR335","doi-asserted-by":"publisher","first-page":"28845","DOI":"10.1038\/srep28845","volume":"6","author":"R Hachiya","year":"2016","unstructured":"Hachiya R, Shiihashi T, Shirakawa I, Iwasaki Y, Matsumura Y, Oishi Y, Nakayama Y, Miyamoto Y, Manabe I, Ochi K, et al. The H3K9 methyltransferase Setdb1 regulates TLR4-mediated inflammatory responses in macrophages. Sci Rep. 2016;6:28845.","journal-title":"Sci Rep"},{"issue":"2","key":"1019_CR336","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.immuni.2019.06.015","volume":"51","author":"AS Kimball","year":"2019","unstructured":"Kimball AS, Davis FM, denDekker A, Joshi AD, Schaller MA, Bermick J, Xing X, Burant CF, Obi AT, Nysz D, et al. The Histone Methyltransferase Setdb2 Modulates Macrophage Phenotype and Uric Acid Production in Diabetic Wound Repair. Immunity. 2019;51(2):258\u201371. e255.","journal-title":"Immunity"},{"issue":"10","key":"1019_CR337","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/ni.3257","volume":"16","author":"K Yoshida","year":"2015","unstructured":"Yoshida K, Maekawa T, Zhu Y, Renard-Guillet C, Chatton B, Inoue K, Uchiyama T, Ishibashi K, Yamada T, Ohno N, et al. The transcription factor ATF7 mediates lipopolysaccharide-induced epigenetic changes in macrophages involved in innate immunological memory. Nat Immunol. 2015;16(10):1034\u201343.","journal-title":"Nat Immunol"},{"issue":"2","key":"1019_CR338","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/imm.13183","volume":"160","author":"Z Dong","year":"2020","unstructured":"Dong Z, Li R, Xu L, Xin K, Xu Y, Shi H, Sun A, Ge J. Histone hyperacetylation mediates enhanced IL-1beta production in LPS\/IFN-gamma-stimulated macrophages. Immunology. 2020;160(2):183\u201397.","journal-title":"Immunology"},{"key":"1019_CR339","doi-asserted-by":"crossref","first-page":"122879","DOI":"10.1016\/j.biomaterials.2024.122879","volume":"314","author":"NC Wu","year":"2025","unstructured":"Wu NC, Quevedo R, Nurse M, Hezaveh K, Liu H, Sun F, Muffat J, Sun Y, Simmons CA, McGaha TL, et al. The use of a multi-metric readout screen to identify EHMT2\/G9a-inhibition as a modulator of cancer-associated fibroblast activation state. Biomaterials. 2025;314:122879.","journal-title":"Biomaterials"},{"issue":"1","key":"1019_CR340","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41392-025-02266-z","volume":"10","author":"J Song","year":"2025","unstructured":"Song J, Yang P, Chen C, Ding W, Tillement O, Bai H, Zhang S. Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance. Signal Transduct Target Ther. 2025;10(1):219.","journal-title":"Signal Transduct Target Ther"},{"key":"1019_CR341","doi-asserted-by":"crossref","first-page":"101285","DOI":"10.1016\/j.drup.2025.101285","volume":"83","author":"RE Farrell","year":"2025","unstructured":"Farrell RE, Stelzer KA, Liu GJ, Skropeta D. Emerging role of sialylation in cancer therapy resistance: Mechanisms and therapeutic implications. Drug Resist Updat. 2025;83:101285.","journal-title":"Drug Resist Updat"},{"issue":"7658","key":"1019_CR342","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature22794","volume":"546","author":"SM Shaffer","year":"2017","unstructured":"Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, Beqiri M, Sproesser K, Brafford PA, Xiao M, et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature. 2017;546(7658):431\u20135.","journal-title":"Nature"},{"issue":"22","key":"1019_CR343","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1111\/bph.14467","volume":"175","author":"C Ye","year":"2018","unstructured":"Ye C, Han K, Lei J, Zeng K, Zeng S, Ju H, Yu L. Inhibition of histone deacetylase 7 reverses concentrative nucleoside transporter 2 repression in colorectal cancer by up-regulating histone acetylation state. Br J Pharmacol. 2018;175(22):4209\u201317.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"1019_CR344","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1349-7006.2012.02215.x","volume":"103","author":"M Toth","year":"2012","unstructured":"Toth M, Boros IM, Balint E. Elevated level of lysine 9-acetylated histone H3 at the MDR1 promoter in multidrug-resistant cells. Cancer Sci. 2012;103(4):659\u201369.","journal-title":"Cancer Sci"},{"key":"1019_CR345","doi-asserted-by":"crossref","unstructured":"Duan L, Perez RE, Chastain PD 2nd, Mathew MT, Bijukumar DR, Maki CG. JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells. Oncogene. 2019;38(28):5643\u201357.","DOI":"10.1038\/s41388-019-0814-6"},{"issue":"7","key":"1019_CR346","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.7150\/thno.104858","volume":"15","author":"C Sun","year":"2025","unstructured":"Sun C, Li X, Teng Q, Liu X, Song L, Schioth HB, Wu H, Ma X, Zhang Z, Qi C, et al. Targeting platinum-resistant ovarian cancer by disrupting histone and RAD51 lactylation. Theranostics. 2025;15(7):3055\u201375.","journal-title":"Theranostics"},{"issue":"3","key":"1019_CR347","doi-asserted-by":"crossref","first-page":"e14649","DOI":"10.1111\/cns.14649","volume":"30","author":"L Ye","year":"2024","unstructured":"Ye L, Gu L, Wang Y, Xing H, Li P, Guo X, Wang Y, Ma W. Identification of TMZ resistance-associated histone post-translational modifications in glioblastoma using multi-omics data. CNS Neurosci Ther. 2024;30(3):e14649.","journal-title":"CNS Neurosci Ther"},{"issue":"15","key":"1019_CR348","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1158\/1078-0432.CCR-12-0560","volume":"18","author":"GJ Kitange","year":"2012","unstructured":"Kitange GJ, Mladek AC, Carlson BL, Schroeder MA, Pokorny JL, Cen L, Decker PA, Wu W, Lomberk GA, Gupta SK, et al. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts. Clin Cancer Res. 2012;18(15):4070\u20139.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"1019_CR349","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1038\/s41388-018-0596-2","volume":"38","author":"E Nie","year":"2019","unstructured":"Nie E, Miao F, Jin X, Wu W, Zhou X, Zeng A, Yu T, Zhi T, Shi Z, Wang Y, et al. Fstl1\/DIP2A\/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma. Oncogene. 2019;38(15):2706\u201321.","journal-title":"Oncogene"},{"issue":"Pt 1","key":"1019_CR350","doi-asserted-by":"crossref","first-page":"147332","DOI":"10.1016\/j.ijbiomac.2025.147332","volume":"327","author":"L Zou","year":"2025","unstructured":"Zou L, Liu Z, Peng L, Wu B, Huang Y, Wen X, Han D, Tan W, Zhou Y. Delactylation of H3K9 by Sirtuin6 inhibits MGMT transcription and reverses temozolomide resistance in glioblastoma. Int J Biol Macromol. 2025;327(Pt 1):147332.","journal-title":"Int J Biol Macromol"},{"key":"1019_CR351","doi-asserted-by":"crossref","first-page":"102166","DOI":"10.1016\/j.tranon.2024.102166","volume":"51","author":"X Tian","year":"2025","unstructured":"Tian X, Liu G, Ji L, Shen Y, Gu J, Wang L, Ma J, Xia Z, Li X. Histone-acetyl epigenome regulates TGF-beta pathway-associated chemoresistance in colorectal cancer. Transl Oncol. 2025;51:102166.","journal-title":"Transl Oncol"},{"key":"1019_CR352","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12935-019-0982-z","volume":"19","author":"R Wang","year":"2019","unstructured":"Wang R, Cheng L, Yang X, Chen X, Miao Y, Qiu Y, Zhou Z. Histone methyltransferase SUV39H2 regulates cell growth and chemosensitivity in glioma via regulation of hedgehog signaling. Cancer Cell Int. 2019;19:269.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"1019_CR353","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ccell.2017.07.002","volume":"32","author":"GD Guler","year":"2017","unstructured":"Guler GD, Tindell CA, Pitti R, Wilson C, Nichols K, KaiWai Cheung T, Kim HJ, Wongchenko M, Yan Y, Haley B, et al. Repression of Stress-Induced LINE-1 Expression Protects Cancer Cell Subpopulations from Lethal Drug Exposure. Cancer Cell. 2017;32(2):221\u201337. e213.","journal-title":"Cancer Cell"},{"key":"1019_CR354","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.acr.2022.12.002","volume":"158","author":"PC Moore","year":"2023","unstructured":"Moore PC, Henderson KW, Classon M. The epigenome and the many facets of cancer drug tolerance. Adv Cancer Res. 2023;158:1\u201339.","journal-title":"Adv Cancer Res"},{"issue":"12","key":"1019_CR355","doi-asserted-by":"crossref","first-page":"6093","DOI":"10.1016\/j.apsb.2025.09.019","volume":"15","author":"J Song","year":"2025","unstructured":"Song J, Ye L, Ding WQ, Qiao H, Dai J, Bai H, Zhang S. How histone modifications influence cellular radiosensitivity: Pharmaceutically targeting epigenetic regulators as a promising avenue to overcome radioresistance. Acta Pharm Sin B. 2025;15(12):6093\u2013140.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"1019_CR356","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13148-019-0800-4","volume":"12","author":"A Sharda","year":"2020","unstructured":"Sharda A, Rashid M, Shah SG, Sharma AK, Singh SR, Gera P, Chilkapati MK, Gupta S. Elevated HDAC activity and altered histone phospho-acetylation confer acquired radio-resistant phenotype to breast cancer cells. Clin Epigenetics. 2020;12(1):4.","journal-title":"Clin Epigenetics"},{"key":"1019_CR357","doi-asserted-by":"crossref","first-page":"115879","DOI":"10.1016\/j.ejmech.2023.115879","volume":"262","author":"Y Pan","year":"2023","unstructured":"Pan Y, Hou H, Zhou B, Gao J, Gao F. Hydroxamic acid hybrids: Histone deacetylase inhibitors with anticancer therapeutic potency. Eur J Med Chem. 2023;262:115879.","journal-title":"Eur J Med Chem"},{"key":"1019_CR358","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.2147\/OTT.S296937","volume":"14","author":"Y Li","year":"2021","unstructured":"Li Y, Chen Z, Cao K, Zhang L, Ma Y, Yu S, Jin H, Liu X, Li W. G9a Regulates Cell Sensitivity to Radiotherapy via Histone H3 Lysine 9 Trimethylation and CCDC8 in Lung Cancer. Onco Targets Ther. 2021;14:3721\u20138.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"1019_CR359","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41420-025-02805-1","volume":"11","author":"J Hu","year":"2025","unstructured":"Hu J, Qiu Y, Yuan W, Li G, Huang D, Zhang X, Liu Y, Lu S, Liu C. G9a deficiency activates TMEM27 to promote ferroptosis and enhances radiosensitivity in head and neck squamous cell carcinoma. Cell Death Discov. 2025;11(1):517.","journal-title":"Cell Death Discov"},{"issue":"7","key":"1019_CR360","first-page":"530","volume":"42","author":"HJ Ahn","year":"2019","unstructured":"Ahn HJ, Hwang SY, Nguyen NH, Lee IJ, Lee EJ, Seong J, Lee JS. Radiation-Induced CXCL12 Upregulation via Histone Modification at the Promoter in the Tumor Microenvironment of Hepatocellular Carcinoma. Mol Cells. 2019;42(7):530\u201345.","journal-title":"Mol Cells"},{"issue":"16","key":"1019_CR361","doi-asserted-by":"crossref","first-page":"E1490","DOI":"10.1073\/pnas.1219992110","volume":"110","author":"L Magnani","year":"2013","unstructured":"Magnani L, Stoeck A, Zhang X, Lanczky A, Mirabella AC, Wang TL, Gyorffy B, Lupien M. Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proc Natl Acad Sci U S A. 2013;110(16):E1490\u20131499.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7\u20138","key":"1019_CR362","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1101\/gad.352982.125","volume":"40","author":"L Garcia-Martinez","year":"2026","unstructured":"Garcia-Martinez L, Zha M, Borges RL, Liu T, Gonzalez-Blanco G, Martinez Alonso A, Stransky S, Sidoli S, Zhu H, Wang Z, et al. Chromatin architecture reprogramming reveals novel epigenetic dependencies in breast cancer. Genes Dev. 2026;40(7\u20138):429\u201343.","journal-title":"Genes Dev"},{"issue":"4","key":"1019_CR363","doi-asserted-by":"crossref","first-page":"522","DOI":"10.7150\/ijbs.4164","volume":"8","author":"J Fu","year":"2012","unstructured":"Fu J, Zhang L, He T, Xiao X, Liu X, Wang L, Yang L, Yang M, Zhang T, Chen R, et al. TWIST represses estrogen receptor-alpha expression by recruiting the NuRD protein complex in breast cancer cells. Int J Biol Sci. 2012;8(4):522\u201332.","journal-title":"Int J Biol Sci"},{"issue":"21","key":"1019_CR364","doi-asserted-by":"crossref","first-page":"e2114324119","DOI":"10.1073\/pnas.2114324119","volume":"119","author":"M Baratchian","year":"2022","unstructured":"Baratchian M, Tiwari R, Khalighi S, Chakravarthy A, Yuan W, Berk M, Li J, Guerinot A, de Bono J, Makarov V, et al. H3K9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancer. Proc Natl Acad Sci U S A. 2022;119(21):e2114324119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"1019_CR365","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/path.5495","volume":"252","author":"DE Tang","year":"2020","unstructured":"Tang DE, Dai Y, He JX, Lin LW, Leng QX, Geng XY, Fu DX, Jiang HW, Xu SH. Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer. J Pathol. 2020;252(2):101\u201313.","journal-title":"J Pathol"},{"key":"1019_CR366","first-page":"4012920","volume":"2022","author":"J Tian","year":"2022","unstructured":"Tian J, Wang W, Zhu J, Zhuang Y, Qi C, Cai Z, Yan W, Lu W, Shang A. Histone Methyltransferase SETDB1 Promotes Immune Evasion in Colorectal Cancer via FOSB-Mediated Downregulation of MicroRNA-22 through BATF3\/PD-L1 Pathway. J Immunol Res. 2022;2022:4012920.","journal-title":"J Immunol Res"},{"issue":"7866","key":"1019_CR367","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41586-021-03520-4","volume":"595","author":"GK Griffin","year":"2021","unstructured":"Griffin GK, Wu J, Iracheta-Vellve A, Patti JC, Hsu J, Davis T, Dele-Oni D, Du PP, Halawi AG, Ishizuka JJ, et al. Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. Nature. 2021;595(7866):309\u201314.","journal-title":"Nature"},{"issue":"1","key":"1019_CR368","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41420-025-02702-7","volume":"11","author":"M Qiu","year":"2025","unstructured":"Qiu M, Zhang Q, Li R, Wei R, Zhao J, Tan J, Zhang H, Qiao W. CRISPR\/Cas9 screening identifies SUV39H2 as a key regulator of oHSV-1 resistance in oral squamous cell carcinoma. Cell Death Discov. 2025;11(1):402.","journal-title":"Cell Death Discov"},{"issue":"2","key":"1019_CR369","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ccell.2018.01.002","volume":"33","author":"Y Yu","year":"2018","unstructured":"Yu Y, Schleich K, Yue B, Ji S, Lohneis P, Kemper K, Silvis MR, Qutob N, van Rooijen E, Werner-Klein M, et al. Targeting the Senescence-Overriding Cooperative Activity of Structurally Unrelated H3K9 Demethylases in Melanoma. Cancer Cell. 2018;33(2):322\u201336. e328.","journal-title":"Cancer Cell"},{"issue":"1","key":"1019_CR370","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41573-024-01074-4","volume":"24","author":"D McHugh","year":"2025","unstructured":"McHugh D, Duran I, Gil J. Senescence as a therapeutic target in cancer and age-related diseases. Nat Rev Drug Discov. 2025;24(1):57\u201371.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"1019_CR371","doi-asserted-by":"crossref","first-page":"e70194","DOI":"10.1111\/acel.70194","volume":"24","author":"B Zhang","year":"2025","unstructured":"Zhang B, Long Q, Wu S, Xu Q, Song S, Han L, Qian M, Ren X, Liu H, Jiang J, et al. KDM4 Orchestrates Epigenomic Remodeling of Senescent Cells and Potentiates the Senescence-Associated Secretory Phenotype. Aging Cell. 2025;24(10):e70194.","journal-title":"Aging Cell"},{"issue":"4","key":"1019_CR372","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.4049\/jimmunol.1402243","volume":"195","author":"AV Paschall","year":"2015","unstructured":"Paschall AV, Yang D, Lu C, Choi JH, Li X, Liu F, Figueroa M, Oberlies NH, Pearce C, Bollag WB, et al. H3K9 Trimethylation Silences Fas Expression To Confer Colon Carcinoma Immune Escape and 5-Fluorouracil Chemoresistance. J Immunol. 2015;195(4):1868\u201382.","journal-title":"J Immunol"},{"issue":"16","key":"1019_CR373","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.7150\/thno.24284","volume":"8","author":"Z Chen","year":"2018","unstructured":"Chen Z, Li W, Qiu F, Huang Q, Jiang Z, Ye J, Cheng P, Low C, Guo Y, Yi X, et al. Aspirin cooperates with p300 to activate the acetylation of H3K9 and promote FasL-mediated apoptosis of cancer stem-like cells in colorectal cancer. Theranostics. 2018;8(16):4447\u201361.","journal-title":"Theranostics"},{"issue":"12","key":"1019_CR374","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41568-025-00864-1","volume":"25","author":"A Wahida","year":"2025","unstructured":"Wahida A, Conrad M. Decoding ferroptosis for cancer therapy. Nat Rev Cancer. 2025;25(12):910\u201324.","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"1019_CR375","doi-asserted-by":"crossref","first-page":"102292","DOI":"10.1016\/j.xcrm.2025.102292","volume":"6","author":"J Li","year":"2025","unstructured":"Li J, Ma C, Cao P, Guo W, Wang P, Yang Y, Ding B, Yin F, Li Z, Wang Y, et al. A CD147-targeted small-molecule inhibitor potentiates gemcitabine efficacy by triggering ferroptosis in pancreatic ductal adenocarcinoma. Cell Rep Med. 2025;6(8):102292.","journal-title":"Cell Rep Med"},{"issue":"2","key":"1019_CR376","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.apsb.2020.09.015","volume":"11","author":"J Wang","year":"2021","unstructured":"Wang J, Yin X, He W, Xue W, Zhang J, Huang Y. SUV39H1 deficiency suppresses clear cell renal cell carcinoma growth by inducing ferroptosis. Acta Pharm Sin B. 2021;11(2):406\u201319.","journal-title":"Acta Pharm Sin B"},{"issue":"2","key":"1019_CR377","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s12072-022-10459-9","volume":"17","author":"X Cui","year":"2023","unstructured":"Cui X, Yun X, Sun M, Li R, Lyu X, Lao Y, Qin X, Yu W. HMGCL-induced beta-hydroxybutyrate production attenuates hepatocellular carcinoma via DPP4-mediated ferroptosis susceptibility. Hepatol Int. 2023;17(2):377\u201392.","journal-title":"Hepatol Int"},{"issue":"5","key":"1019_CR378","doi-asserted-by":"crossref","first-page":"tfae164","DOI":"10.1093\/toxres\/tfae164","volume":"13","author":"Z Shi","year":"2024","unstructured":"Shi Z, Jiang T, Sun X, Peng L, Cao B, Wang Y. HDAC10 inhibits non-small-cell lung cancer cell ferroptosis through the microRNA-223-5p-SLC7A11 axis. Toxicol Res (Camb). 2024;13(5):tfae164.","journal-title":"Toxicol Res (Camb)"},{"issue":"3","key":"1019_CR379","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.molcel.2007.01.017","volume":"25","author":"S Kubicek","year":"2007","unstructured":"Kubicek S, O\u2019Sullivan RJ, August EM, Hickey ER, Zhang Q, Teodoro ML, Rea S, Mechtler K, Kowalski JA, Homon CA, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell. 2007;25(3):473\u201381.","journal-title":"Mol Cell"},{"key":"1019_CR380","doi-asserted-by":"crossref","first-page":"173827","DOI":"10.1016\/j.ejphar.2020.173827","volume":"893","author":"S Jan","year":"2021","unstructured":"Jan S, Dar MI, Wani R, Sandey J, Mushtaq I, Lateef S, Syed SH. Targeting EHMT2\/ G9a for cancer therapy: Progress and perspective. Eur J Pharmacol. 2021;893:173827.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"1019_CR381","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/med.22119","volume":"45","author":"M Hajar","year":"2025","unstructured":"Hajar M, Werner T, Gajic M, Stark H, Sadek B. Targeting Histone H3K9 Methyltransferase G9a as a Potential Therapeutic Strategy for Neuropsychiatric Disorders. Med Res Rev. 2025;45(6):1547\u201363.","journal-title":"Med Res Rev"},{"issue":"8","key":"1019_CR382","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nchembio.599","volume":"7","author":"M Vedadi","year":"2011","unstructured":"Vedadi M, Barsyte-Lovejoy D, Liu F, Rival-Gervier S, Allali-Hassani A, Labrie V, Wigle TJ, Dimaggio PA, Wasney GA, Siarheyeva A, et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nat Chem Biol. 2011;7(8):566\u201374.","journal-title":"Nat Chem Biol"},{"issue":"21","key":"1019_CR383","doi-asserted-by":"crossref","first-page":"8931","DOI":"10.1021\/jm401480r","volume":"56","author":"F Liu","year":"2013","unstructured":"Liu F, Barsyte-Lovejoy D, Li F, Xiong Y, Korboukh V, Huang XP, Allali-Hassani A, Janzen WP, Roth BL, Frye SV, et al. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP. J Med Chem. 2013;56(21):8931\u201342.","journal-title":"J Med Chem"},{"issue":"7","key":"1019_CR384","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1021\/cb300139y","volume":"7","author":"Y Yuan","year":"2012","unstructured":"Yuan Y, Wang Q, Paulk J, Kubicek S, Kemp MM, Adams DJ, Shamji AF, Wagner BK, Schreiber SL. A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma. ACS Chem Biol. 2012;7(7):1152\u20137.","journal-title":"ACS Chem Biol"},{"issue":"15","key":"1019_CR385","doi-asserted-by":"crossref","first-page":"10506","DOI":"10.1021\/acs.jmedchem.2c00652","volume":"65","author":"KS Park","year":"2022","unstructured":"Park KS, Xiong Y, Yim H, Velez J, Babault N, Kumar P, Liu J, Jin J. Discovery of the First-in-Class G9a\/GLP Covalent Inhibitors. J Med Chem. 2022;65(15):10506\u201322.","journal-title":"J Med Chem"},{"issue":"8","key":"1019_CR386","doi-asserted-by":"crossref","first-page":"6397","DOI":"10.1021\/acs.jmedchem.3c02394","volume":"67","author":"J Velez","year":"2024","unstructured":"Velez J, Han Y, Yim H, Yang P, Deng Z, Park KS, Kabir M, Kaniskan HU, Xiong Y, Jin J. Discovery of the First-in-Class G9a\/GLP PROTAC Degrader. J Med Chem. 2024;67(8):6397\u2013409.","journal-title":"J Med Chem"},{"issue":"61","key":"1019_CR387","doi-asserted-by":"crossref","first-page":"31820","DOI":"10.18632\/oncotarget.25806","volume":"9","author":"T Vougiouklakis","year":"2018","unstructured":"Vougiouklakis T, Saloura V, Park JH, Takamatsu N, Miyamoto T, Nakamura Y, Matsuo Y. Development of novel SUV39H2 inhibitors that exhibit growth suppressive effects in mouse xenograft models and regulate the phosphorylation of H2AX. Oncotarget. 2018;9(61):31820\u201331.","journal-title":"Oncotarget"},{"key":"1019_CR388","doi-asserted-by":"crossref","first-page":"1073713","DOI":"10.3389\/fphar.2022.1073713","volume":"13","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Feng L, Peng X, Ma T, Tong R, Zhong L. Role of histone methyltransferase SETDB1 in regulation of tumourigenesis and immune response. Front Pharmacol. 2022;13:1073713.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1019_CR389","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1080\/14756366.2021.1900160","volume":"36","author":"YJ Hwang","year":"2021","unstructured":"Hwang YJ, Hyeon SJ, Kim Y, Lim S, Lee MY, Kim J, Londhe AM, Gotina L, Kim Y, Pae AN, et al. Modulation of SETDB1 activity by APQ ameliorates heterochromatin condensation, motor function, and neuropathology in a Huntington\u2019s disease mouse model. J Enzyme Inhib Med Chem. 2021;36(1):856\u201368.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"17","key":"1019_CR390","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1016\/j.bmc.2019.07.020","volume":"27","author":"P Mader","year":"2019","unstructured":"Mader P, Mendoza-Sanchez R, Iqbal A, Dong A, Dobrovetsky E, Corless VB, Liew SK, Houliston SR, De Freitas RF, Smil D, et al. Identification and characterization of the first fragment hits for SETDB1 Tudor domain. Bioorg Med Chem. 2019;27(17):3866\u201378.","journal-title":"Bioorg Med Chem"},{"issue":"16","key":"1019_CR391","doi-asserted-by":"crossref","first-page":"8760","DOI":"10.1002\/anie.202017200","volume":"60","author":"Y Guo","year":"2021","unstructured":"Guo Y, Mao X, Xiong L, Xia A, You J, Lin G, Wu C, Huang L, Wang Y, Yang S. Structure-Guided Discovery of a Potent and Selective Cell-Active Inhibitor of SETDB1 Tudor Domain. Angew Chem Int Ed Engl. 2021;60(16):8760\u20135.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"7","key":"1019_CR392","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.cell.2004.12.012","volume":"119","author":"Y Shi","year":"2004","unstructured":"Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell. 2004;119(7):941\u201353.","journal-title":"Cell"},{"issue":"7057","key":"1019_CR393","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature04020","volume":"437","author":"E Metzger","year":"2005","unstructured":"Metzger E, Wissmann M, Yin N, Muller JM, Schneider R, Peters AH, Gunther T, Buettner R, Schule R. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature. 2005;437(7057):436\u20139.","journal-title":"Nature"},{"key":"1019_CR394","doi-asserted-by":"crossref","unstructured":"Bauer TM, Besse B, Martinez-Marti A, Trigo JM, Moreno V, Garrido P, Ferron-Brady G, Wu Y, Park J, Collingwood T, et al. Phase I, open-label, dose-escalation study of the safety, pharmacokinetics, pharmacodynamics, and efficacy of GSK2879552 in relapsed\/refractory SCLC. J Thorac Oncol. 2019;14(10):1828\u20131838.","DOI":"10.1016\/j.jtho.2019.06.021"},{"issue":"36","key":"1019_CR395","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1200\/JCO.19.03250","volume":"38","author":"O Salamero","year":"2020","unstructured":"Salamero O, Montesinos P, Willekens C, Perez-Simon JA, Pigneux A, Recher C, Popat R, Carpio C, Molinero C, Mascaro C, et al. First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. J Clin Oncol. 2020;38(36):4260\u201373.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1019_CR396","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.tips.2025.01.006","volume":"46","author":"Y Song","year":"2025","unstructured":"Song Y, Yu B. Leveraging non-enzymatic functions of LSD1 for novel therapeutics. Trends Pharmacol Sci. 2025;46(3):204\u201319.","journal-title":"Trends Pharmacol Sci"},{"issue":"11","key":"1019_CR397","doi-asserted-by":"crossref","first-page":"e15535","DOI":"10.1371\/journal.pone.0015535","volume":"5","author":"ON King","year":"2010","unstructured":"King ON, Li XS, Sakurai M, Kawamura A, Rose NR, Ng SS, Quinn AM, Rai G, Mott BT, Beswick P, et al. Quantitative high-throughput screening identifies 8-hydroxyquinolines as cell-active histone demethylase inhibitors. PLoS ONE. 2010;5(11):e15535.","journal-title":"PLoS ONE"},{"issue":"8","key":"1019_CR398","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1039\/c3sc51122g","volume":"4","author":"RJ Hopkinson","year":"2013","unstructured":"Hopkinson RJ, Tumber A, Yapp C, Chowdhury R, Aik W, Che KH, Li XS, Kristensen JBL, King ONF, Chan MC, et al. 5-Carboxy-8-hydroxyquinoline is a Broad Spectrum 2-Oxoglutarate Oxygenase Inhibitor which Causes Iron Translocation. Chem Sci. 2013;4(8):3110\u20137.","journal-title":"Chem Sci"},{"issue":"3","key":"1019_CR399","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s41417-025-00874-z","volume":"32","author":"FM Schwarz","year":"2025","unstructured":"Schwarz FM, Klotz DM, Yang R, Brux M, Buchholz F, Harb H, Link T, Wimberger P, Theis M, Kuhlmann JD. Methylstat sensitizes ovarian cancer cells to PARP-inhibition by targeting the histone demethylases JMJD1B\/C. Cancer Gene Ther. 2025;32(3):286\u201396.","journal-title":"Cancer Gene Ther"},{"issue":"9","key":"1019_CR400","doi-asserted-by":"crossref","first-page":"8852","DOI":"10.1021\/acsnano.4c16542","volume":"19","author":"J Liu","year":"2025","unstructured":"Liu J, Zhao Z, Zanni R, Jiang X, Weichselbaum RR, Lin W. Nanoparticle-Mediated Toll-Like Receptor Activation and Dual Immune Checkpoint Downregulation for Potent Cancer Immunotherapy. ACS Nano. 2025;19(9):8852\u201366.","journal-title":"ACS Nano"},{"issue":"11","key":"1019_CR401","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1039\/D4MD00122B","volume":"15","author":"SU Zaman","year":"2024","unstructured":"Zaman SU, Pagare PP, Ma H, Hoyle RG, Zhang Y, Li J. Novel PROTAC probes targeting KDM3 degradation to eliminate colorectal cancer stem cells through inhibition of Wnt\/beta-catenin signaling. RSC Med Chem. 2024;15(11):3746\u201358.","journal-title":"RSC Med Chem"},{"key":"1019_CR402","doi-asserted-by":"crossref","unstructured":"Tsimberidou AM, Dayyani F, Sommerhalder D, Vandross AL, Pelster MS, Henry JT, Perez CA, Chakraborty A, Baysal MA, Chandhasin C, et al. Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumors. Oncologist. 2025;30(7).","DOI":"10.1093\/oncolo\/oyaf169"},{"key":"1019_CR403","doi-asserted-by":"crossref","unstructured":"Lee KH, Kim BC, Jeong SH, Jeong CW, Ku JH, Kim HH, et al. Histone demethylase KDM7A regulates androgen receptor activity, and its chemical inhibitor TC-E 5002 overcomes cisplatin-resistance in bladder cancer cells. Int J Mol Sci. 2020;21(16):5658.","DOI":"10.3390\/ijms21165658"},{"issue":"11","key":"1019_CR404","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1002\/ijc.31843","volume":"143","author":"KH Lee","year":"2018","unstructured":"Lee KH, Hong S, Kang M, Jeong CW, Ku JH, Kim HH, Kwak C. Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancer. Int J Cancer. 2018;143(11):2849\u201361.","journal-title":"Int J Cancer"},{"issue":"18","key":"1019_CR405","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1016\/j.febslet.2006.06.092","volume":"580","author":"Y Sun","year":"2006","unstructured":"Sun Y, Jiang X, Chen S, Price BD. Inhibition of histone acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiation. FEBS Lett. 2006;580(18):4353\u20136.","journal-title":"FEBS Lett"},{"issue":"9","key":"1019_CR406","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1158\/1535-7163.MCT-07-0159","volume":"6","author":"ED Eliseeva","year":"2007","unstructured":"Eliseeva ED, Valkov V, Jung M, Jung MO. Characterization of novel inhibitors of histone acetyltransferases. Mol Cancer Ther. 2007;6(9):2391\u20138.","journal-title":"Mol Cancer Ther"},{"issue":"32","key":"1019_CR407","doi-asserted-by":"crossref","first-page":"33716","DOI":"10.1074\/jbc.M402839200","volume":"279","author":"K Balasubramanyam","year":"2004","unstructured":"Balasubramanyam K, Altaf M, Varier RA, Swaminathan V, Ravindran A, Sadhale PP, Kundu TK. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J Biol Chem. 2004;279(32):33716\u201326.","journal-title":"J Biol Chem"},{"issue":"3","key":"1019_CR408","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1097-2765(00)80452-9","volume":"5","author":"OD Lau","year":"2000","unstructured":"Lau OD, Kundu TK, Soccio RE, Ait-Si-Ali S, Khalil EM, Vassilev A, Wolffe AP, Nakatani Y, Roeder RG, Cole PA. HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol Cell. 2000;5(3):589\u201395.","journal-title":"Mol Cell"},{"issue":"15","key":"1019_CR409","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1016\/S0968-0896(03)00265-7","volume":"11","author":"M Cebrat","year":"2003","unstructured":"Cebrat M, Kim CM, Thompson PR, Daugherty M, Cole PA. Synthesis and analysis of potential prodrugs of coenzyme A analogues for the inhibition of the histone acetyltransferase p300. Bioorg Med Chem. 2003;11(15):3307\u201313.","journal-title":"Bioorg Med Chem"},{"issue":"2","key":"1019_CR410","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/1078-0432.CCR-11-0579","volume":"18","author":"D Trisciuoglio","year":"2012","unstructured":"Trisciuoglio D, Ragazzoni Y, Pelosi A, Desideri M, Carradori S, Gabellini C, Maresca G, Nescatelli R, Secci D, Bolasco A, et al. CPTH6, a thiazole derivative, induces histone hypoacetylation and apoptosis in human leukemia cells. Clin Cancer Res. 2012;18(2):475\u201386.","journal-title":"Clin Cancer Res"},{"issue":"30","key":"1019_CR411","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1002\/anie.200453879","volume":"43","author":"M Biel","year":"2004","unstructured":"Biel M, Kretsovali A, Karatzali E, Papamatheakis J, Giannis A. Design, synthesis, and biological evaluation of a small-molecule inhibitor of the histone acetyltransferase Gcn5. Angew Chem Int Ed Engl. 2004;43(30):3974\u20136.","journal-title":"Angew Chem Int Ed Engl"},{"issue":"1","key":"1019_CR412","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1038\/s41467-017-01657-3","volume":"8","author":"JL Dahlin","year":"2017","unstructured":"Dahlin JL, Nelson KM, Strasser JM, Barsyte-Lovejoy D, Szewczyk MM, Organ S, Cuellar M, Singh G, Shrimp JH, Nguyen N, et al. Assay interference and off-target liabilities of reported histone acetyltransferase inhibitors. Nat Commun. 2017;8(1):1527.","journal-title":"Nat Commun"},{"issue":"1","key":"1019_CR413","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1042\/CS20200986","volume":"135","author":"ME Haque","year":"2021","unstructured":"Haque ME, Jakaria M, Akther M, Cho DY, Kim IS, Choi DK. The GCN5: its biological functions and therapeutic potentials. Clin Sci (Lond). 2021;135(1):231\u201357.","journal-title":"Clin Sci (Lond)"},{"issue":"11","key":"1019_CR414","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.7150\/thno.73223","volume":"12","author":"Q Chen","year":"2022","unstructured":"Chen Q, Yang B, Liu X, Zhang XD, Zhang L, Liu T. Histone acetyltransferases CBP\/p300 in tumorigenesis and CBP\/p300 inhibitors as promising novel anticancer agents. Theranostics. 2022;12(11):4935\u201348.","journal-title":"Theranostics"},{"issue":"12","key":"1019_CR415","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.ccell.2023.11.001","volume":"41","author":"L Nicosia","year":"2023","unstructured":"Nicosia L, Spencer GJ, Brooks N, Amaral FMR, Basma NJ, Chadwick JA, Revell B, Wingelhofer B, Maiques-Diaz A, Sinclair O, et al. Therapeutic targeting of EP300\/CBP by bromodomain inhibition in hematologic malignancies. Cancer Cell. 2023;41(12):2136\u2013e21532113.","journal-title":"Cancer Cell"},{"key":"1019_CR416","doi-asserted-by":"crossref","first-page":"116130","DOI":"10.1016\/j.biopha.2024.116130","volume":"171","author":"P Gou","year":"2024","unstructured":"Gou P, Zhang W. Protein lysine acetyltransferase CBP\/p300: A promising target for small molecules in cancer treatment. Biomed Pharmacother. 2024;171:116130.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"1019_CR417","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40364-025-00803-0","volume":"13","author":"Q Zhang","year":"2025","unstructured":"Zhang Q, Song Y, Zhou K, Lin Q. Emerging therapeutic agents in multiple myeloma: highlights from the 2024 ASH annual meeting. Biomark Res. 2025;13(1):90.","journal-title":"Biomark Res"},{"issue":"7717","key":"1019_CR418","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41586-018-0387-5","volume":"560","author":"JB Baell","year":"2018","unstructured":"Baell JB, Leaver DJ, Hermans SJ, Kelly GL, Brennan MS, Downer NL, Nguyen N, Wichmann J, McRae HM, Yang Y, et al. Inhibitors of histone acetyltransferases KAT6A\/B induce senescence and arrest tumour growth. Nature. 2018;560(7717):253\u20137.","journal-title":"Nature"},{"issue":"9","key":"1019_CR419","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1021\/acs.jmedchem.9b02071","volume":"63","author":"DL Priebbenow","year":"2020","unstructured":"Priebbenow DL, Leaver DJ, Nguyen N, Cleary B, Lagiakos HR, Sanchez J, Xue L, Huang F, Sun Y, Mujumdar P, et al. Discovery of Acylsulfonohydrazide-Derived Inhibitors of the Lysine Acetyltransferase, KAT6A, as Potent Senescence-Inducing Anti-Cancer Agents. J Med Chem. 2020;63(9):4655\u201384.","journal-title":"J Med Chem"},{"issue":"3","key":"1019_CR420","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1080\/13543784.2026.2634346","volume":"35","author":"T Mukohara","year":"2026","unstructured":"Mukohara T. KAT6 inhibitors under investigation for solid tumors: the preclinical and early phase progress. Expert Opin Investig Drugs. 2026;35(3):215\u201321.","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"1019_CR421","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1038\/s41591-024-03060-0","volume":"30","author":"T Mukohara","year":"2024","unstructured":"Mukohara T, Park YH, Sommerhalder D, Yonemori K, Hamilton E, Kim SB, Kim JH, Iwata H, Yamashita T, Layman RM, et al. Inhibition of lysine acetyltransferase KAT6 in ER(+)HER2(-) metastatic breast cancer: a phase 1 trial. Nat Med. 2024;30(8):2242\u201350.","journal-title":"Nat Med"},{"issue":"10","key":"1019_CR422","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","volume":"12","author":"BS Mann","year":"2007","unstructured":"Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12(10):1247\u201352.","journal-title":"Oncologist"},{"issue":"40","key":"1019_CR423","doi-asserted-by":"crossref","first-page":"67891","DOI":"10.18632\/oncotarget.18910","volume":"8","author":"JF Hay","year":"2017","unstructured":"Hay JF, Lappin K, Liberante F, Kettyle LM, Matchett KB, Thompson A, Mills KI. Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy. Oncotarget. 2017;8(40):67891\u2013903.","journal-title":"Oncotarget"},{"issue":"10","key":"1019_CR424","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3324\/haematol.2009.009217","volume":"94","author":"EW Schaefer","year":"2009","unstructured":"Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, Wu W, Laumann K, Espinoza-Delgado I, Gore SD, et al. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica. 2009;94(10):1375\u201382.","journal-title":"Haematologica"},{"issue":"3","key":"1019_CR425","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1007\/s10637-020-01038-6","volume":"39","author":"DI Quinn","year":"2021","unstructured":"Quinn DI, Tsao-Wei DD, Twardowski P, Aparicio AM, Frankel P, Chatta G, Wright JJ, Groshen SG, Khoo S, Lenz HJ, et al. Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879. Invest New Drugs. 2021;39(3):812\u201320.","journal-title":"Invest New Drugs"},{"issue":"2","key":"1019_CR426","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.13016","volume":"167","author":"M Kirschbaum","year":"2014","unstructured":"Kirschbaum M, Gojo I, Goldberg SL, Bredeson C, Kujawski LA, Yang A, Marks P, Frankel P, Sun X, Tosolini A, et al. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. Br J Haematol. 2014;167(2):185\u201393.","journal-title":"Br J Haematol"},{"issue":"1","key":"1019_CR427","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3324\/haematol.2013.096545","volume":"99","author":"RB Walter","year":"2014","unstructured":"Walter RB, Medeiros BC, Gardner KM, Orlowski KF, Gallegos L, Scott BL, Hendrie PC, Estey EH. Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I\/II study. Haematologica. 2014;99(1):54\u20139.","journal-title":"Haematologica"},{"issue":"1","key":"1019_CR428","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/bjh.13517","volume":"171","author":"DH Vesole","year":"2015","unstructured":"Vesole DH, Bilotti E, Richter JR, McNeill A, McBride L, Raucci L, Anand P, Bednarz U, Ivanovski K, Smith J, et al. Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and\/or refractory multiple myeloma. Br J Haematol. 2015;171(1):52\u20139.","journal-title":"Br J Haematol"},{"issue":"2","key":"1019_CR429","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3324\/haematol.2023.283002","volume":"109","author":"J Godfrey","year":"2024","unstructured":"Godfrey J, Mei M, Chen L, Song JY, Bedell V, Budde E, Armenian S, Puverel S, Nikolaenko L, Chen R, et al. Results from a phase I trial of pembrolizumab plus vorinostat in relapsed\/refractory B-cell non-Hodgkin lymphoma. Haematologica. 2024;109(2):533\u201342.","journal-title":"Haematologica"},{"issue":"16","key":"1019_CR430","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1182\/blood.2023020485","volume":"142","author":"M Mei","year":"2023","unstructured":"Mei M, Chen L, Godfrey J, Song J, Egelston C, Puverel S, Budde LE, Armenian S, Nikolaenko L, Nwangwu M, et al. Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade. Blood. 2023;142(16):1359\u201370.","journal-title":"Blood"},{"issue":"1","key":"1019_CR431","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41375-023-02073-x","volume":"38","author":"G Garcia-Manero","year":"2024","unstructured":"Garcia-Manero G, Podoltsev NA, Othus M, Pagel JM, Radich JP, Fang M, Rizzieri DA, Marcucci G, Strickland SA, Litzow MR, et al. A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia. 2024;38(1):58\u201366.","journal-title":"Leukemia"},{"issue":"7","key":"1019_CR432","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1038\/s41375-024-02288-6","volume":"38","author":"MY Zhang","year":"2024","unstructured":"Zhang MY, Othus M, McMillen K, Erba HP, Garcia-Manero G, Pagel JM, Sorror ML, Percival MM. Association between class III obesity and overall survival in previously untreated younger patients with acute myeloid leukemia enrolled on SWOG S1203. Leukemia. 2024;38(7):1488\u201393.","journal-title":"Leukemia"},{"issue":"4","key":"1019_CR433","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/neuonc\/nox161","volume":"20","author":"E Galanis","year":"2018","unstructured":"Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF Jr., Nebozhyn M, et al. Phase I\/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874\/ABTC 02. Neuro Oncol. 2018;20(4):546\u201356.","journal-title":"Neuro Oncol"},{"issue":"5","key":"1019_CR434","doi-asserted-by":"crossref","first-page":"e31619","DOI":"10.1002\/pbc.31619","volume":"72","author":"LM Stitzlein","year":"2025","unstructured":"Stitzlein LM, Baig MU, Chandra J, McGovern S, Paulino A, Ketonen LM, Khatua S, Zaky W. Phase I Study of Vorinostat and Temsirolimus in Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma. Pediatr Blood Cancer. 2025;72(5):e31619.","journal-title":"Pediatr Blood Cancer"},{"issue":"31","key":"1019_CR435","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.21.00703","volume":"39","author":"SG DuBois","year":"2021","unstructured":"DuBois SG, Granger MM, Groshen S, Tsao-Wei D, Ji L, Shamirian A, Czarnecki S, Goodarzian F, Berkovich R, Shimada H, et al. Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. J Clin Oncol. 2021;39(31):3506\u201314.","journal-title":"J Clin Oncol"},{"issue":"22","key":"1019_CR436","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1200\/JCO-24-02612","volume":"43","author":"T Cash","year":"2025","unstructured":"Cash T, Marachelian A, DuBois SG, Chi YY, Baregamyan A, Groshen SG, Jonus HC, Shamirian A, Crowley M, Goodarzian F, et al. Phase I Study of (131)I-Metaiodobenzylguanidine With Dinutuximab +\/- Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial. J Clin Oncol. 2025;43(22):2490\u2013501.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1019_CR437","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2967\/jnumed.114.144741","volume":"56","author":"RM Connolly","year":"2015","unstructured":"Connolly RM, Leal JP, Goetz MP, Zhang Z, Zhou XC, Jacobs LK, Mhlanga J, O JH, Carpenter J, Storniolo AM, et al. TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer. J Nucl Med. 2015;56(1):31\u20137.","journal-title":"J Nucl Med"},{"issue":"1","key":"1019_CR438","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10549-017-4503-2","volume":"167","author":"RM Connolly","year":"2018","unstructured":"Connolly RM, Fackler MJ, Zhang Z, Zhou XC, Goetz MP, Boughey JC, Walsh B, Carpenter JT, Storniolo AM, Watkins SP, et al. Tumor and serum DNA methylation in women receiving preoperative chemotherapy with or without vorinostat in TBCRC008. Breast Cancer Res Treat. 2018;167(1):107\u201316.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"1019_CR439","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/s43018-025-01004-2","volume":"6","author":"E Borcoman","year":"2025","unstructured":"Borcoman E, Cabarrou B, Francisco M, Bigot F, Ghiringhelli F, Vansteene D, Legrand F, Halladjian M, Dupain C, Le Saux O, et al. Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and\/or metastatic squamous cell carcinomas: a phase 2 basket trial. Nat Cancer. 2025;6(8):1370\u201383.","journal-title":"Nat Cancer"},{"issue":"22","key":"1019_CR440","doi-asserted-by":"crossref","first-page":"6623","DOI":"10.1158\/1078-0432.CCR-19-1305","volume":"25","author":"JE Gray","year":"2019","unstructured":"Gray JE, Saltos A, Tanvetyanon T, Haura EB, Creelan B, Antonia SJ, Shafique M, Zheng H, Dai W, Saller JJ, et al. Phase I\/Ib Study of Pembrolizumab Plus Vorinostat in Advanced\/Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res. 2019;25(22):6623\u201332.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1019_CR441","doi-asserted-by":"crossref","first-page":"106024","DOI":"10.1016\/j.esmoop.2025.106024","volume":"11","author":"DM Filippini","year":"2026","unstructured":"Filippini DM, Cabarrou B, Dupain C, Halladjian M, Coquan E, Sablin MP, Mazzarella L, Francisco M, Servant N, Tonini MM, et al. HPV circulating tumor DNA to monitor response to pembrolizumab and vorinostat combination in patients with advanced HPV-related squamous-cell carcinomas. ESMO Open. 2026;11(1):106024.","journal-title":"ESMO Open"},{"issue":"1","key":"1019_CR442","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s00280-024-04742-9","volume":"95","author":"KR Maher","year":"2025","unstructured":"Maher KR, Shafer D, Schaar D, Bandyopadhyay D, Deng X, Wright J, Piekarz R, Rudek MA, Harvey RD, Grant S. A phase I study of MLN4924 and belinostat in relapsed\/refractory acute myeloid leukemia or myelodysplastic syndrome. Cancer Chemother Pharmacol. 2025;95(1):24.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"1019_CR443","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3390\/tomography8020057","volume":"8","author":"K Xu","year":"2022","unstructured":"Xu K, Ramesh K, Huang V, Gurbani SS, Cordova JS, Schreibmann E, Weinberg BD, Sengupta S, Voloschin AD, Holdhoff M, et al. Final Report on Clinical Outcomes and Tumor Recurrence Patterns of a Pilot Study Assessing Efficacy of Belinostat (PXD-101) with Chemoradiation for Newly Diagnosed Glioblastoma. Tomography. 2022;8(2):688\u2013700.","journal-title":"Tomography"},{"issue":"11","key":"1019_CR444","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"JF San-Miguel","year":"2014","unstructured":"San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Gunther A, Nakorn TN, Siritanaratkul N, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195\u2013206.","journal-title":"Lancet Oncol"},{"issue":"11","key":"1019_CR445","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1007\/s12325-016-0413-7","volume":"33","author":"JF San-Miguel","year":"2016","unstructured":"San-Miguel JF, Einsele H, Moreau P. The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective. Adv Ther. 2016;33(11):1896\u2013920.","journal-title":"Adv Ther"},{"issue":"6","key":"1019_CR446","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood-2015-09-665018","volume":"127","author":"PG Richardson","year":"2016","unstructured":"Richardson PG, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Guenther A, Nakorn TN, Siritanaratkul N, et al. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016;127(6):713\u201321.","journal-title":"Blood"},{"issue":"11","key":"1019_CR447","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1016\/S2352-3026(16)30147-8","volume":"3","author":"JF San-Miguel","year":"2016","unstructured":"San-Miguel JF, Hungria VT, Yoon SS, Beksac M, Dimopoulos MA, Elghandour A, Jedrzejczak WW, Gunther A, Nakorn TN, Siritanaratkul N, et al. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematol. 2016;3(11):e506\u201315.","journal-title":"Lancet Haematol"},{"issue":"1","key":"1019_CR448","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41408-018-0154-8","volume":"9","author":"JL Kaufman","year":"2019","unstructured":"Kaufman JL, Mina R, Jakubowiak AJ, Zimmerman TL, Wolf JJ, Lewis C, Gleason C, Sharp C, Martin T, Heffner LT, et al. Combining carfilzomib and panobinostat to treat relapsed\/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study. Blood Cancer J. 2019;9(1):3.","journal-title":"Blood Cancer J"},{"issue":"4","key":"1019_CR449","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/ajh.26088","volume":"96","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Gregory TK, Faber EA, Hart LL, Mace JR, Arrowsmith ER, Flinn IW, Matous JV. A phase I\/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed\/refractory multiple myeloma: Final analysis of second dose-expansion cohort. Am J Hematol. 2021;96(4):428\u201335.","journal-title":"Am J Hematol"},{"issue":"5","key":"1019_CR450","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3324\/haematol.2014.119735","volume":"100","author":"JG Berdeja","year":"2015","unstructured":"Berdeja JG, Hart LL, Mace JR, Arrowsmith ER, Essell JH, Owera RS, Hainsworth JD, Flinn IW. Phase I\/II study of the combination of panobinostat and carfilzomib in patients with relapsed\/refractory multiple myeloma. Haematologica. 2015;100(5):670\u20136.","journal-title":"Haematologica"},{"issue":"2","key":"1019_CR451","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41408-021-00407-5","volume":"11","author":"JP Laubach","year":"2021","unstructured":"Laubach JP, Tuchman SA, Rosenblatt JM, Mitsiades CS, Colson K, Masone K, Warren D, Redd RA, Grayson D, Richardson PG. Phase 1 open-label study of panobinostat, lenalidomide, bortezomib\u2009+\u2009dexamethasone in relapsed and relapsed\/refractory multiple myeloma. Blood Cancer J. 2021;11(2):20.","journal-title":"Blood Cancer J"},{"issue":"1","key":"1019_CR452","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S1470-2045(20)30680-X","volume":"22","author":"JP Laubach","year":"2021","unstructured":"Laubach JP, Schjesvold F, Mariz M, Dimopoulos MA, Lech-Maranda E, Spicka I, Hungria VTM, Shelekhova T, Abdo A, Jacobasch L, et al. Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. Lancet Oncol. 2021;22(1):142\u201354.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1019_CR453","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.1016\/S2352-3026(15)00097-6","volume":"2","author":"D Tan","year":"2015","unstructured":"Tan D, Phipps C, Hwang WY, Tan SY, Yeap CH, Chan YH, Tay K, Lim ST, Lee YS, Kumar SG, et al. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. Lancet Haematol. 2015;2(8):e326\u2013333.","journal-title":"Lancet Haematol"},{"issue":"2","key":"1019_CR454","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood-2016-02-699520","volume":"128","author":"SE Assouline","year":"2016","unstructured":"Assouline SE, Nielsen TH, Yu S, Alcaide M, Chong L, MacDonald D, Tosikyan A, Kukreti V, Kezouh A, Petrogiannis-Haliotis T, et al. Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood. 2016;128(2):185\u201394.","journal-title":"Blood"},{"issue":"10","key":"1019_CR455","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3324\/haematol.2015.129577","volume":"100","author":"EM Ocio","year":"2015","unstructured":"Ocio EM, Herrera P, Olave MT, Castro N, Perez-Simon JA, Brunet S, Oriol A, Mateo M, Sanz MA, Lopez J, et al. Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib\/II panobidara study. Haematologica. 2015;100(10):1294\u2013300.","journal-title":"Haematologica"},{"issue":"12","key":"1019_CR456","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1038\/leu.2017.159","volume":"31","author":"G Garcia-Manero","year":"2017","unstructured":"Garcia-Manero G, Sekeres MA, Egyed M, Breccia M, Graux C, Cavenagh JD, Salman H, Illes A, Fenaux P, DeAngelo DJ, et al. A phase 1b\/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with \u2a7d30% blasts. Leukemia. 2017;31(12):2799\u2013806.","journal-title":"Leukemia"},{"issue":"12","key":"1019_CR457","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/neuonc\/noad141","volume":"25","author":"M Monje","year":"2023","unstructured":"Monje M, Cooney T, Glod J, Huang J, Peer CJ, Faury D, Baxter P, Kramer K, Lenzen A, Robison NJ, et al. Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047). Neuro Oncol. 2023;25(12):2262\u201372.","journal-title":"Neuro Oncol"},{"issue":"4","key":"1019_CR458","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1007\/s10637-019-00864-7","volume":"38","author":"A Wood","year":"2020","unstructured":"Wood A, George S, Adra N, Chintala S, Damayanti N, Pili R. Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma. Invest New Drugs. 2020;38(4):1108\u201316.","journal-title":"Invest New Drugs"},{"issue":"6","key":"1019_CR459","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/neuonc\/nou350","volume":"17","author":"EQ Lee","year":"2015","unstructured":"Lee EQ, Reardon DA, Schiff D, Drappatz J, Muzikansky A, Grimm SA, Norden AD, Nayak L, Beroukhim R, Rinne ML, et al. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol. 2015;17(6):862\u20137.","journal-title":"Neuro Oncol"},{"issue":"7","key":"1019_CR460","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1634\/theoncologist.2016-0060","volume":"21","author":"N Jin","year":"2016","unstructured":"Jin N, Lubner SJ, Mulkerin DL, Rajguru S, Carmichael L, Chen H, Holen KD, LoConte NK. A Phase II Trial of a Histone Deacetylase Inhibitor Panobinostat in Patients With Low-Grade Neuroendocrine Tumors. Oncologist. 2016;21(7):785\u20136.","journal-title":"Oncologist"},{"issue":"4","key":"1019_CR461","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00280-014-2501-1","volume":"74","author":"C Xia","year":"2014","unstructured":"Xia C, Leon-Ferre R, Laux D, Deutsch J, Smith BJ, Frees M, Milhem M. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide). Cancer Chemother Pharmacol. 2014;74(4):691\u20137.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"1019_CR462","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/bjc.2013.442","volume":"109","author":"PA Cassier","year":"2013","unstructured":"Cassier PA, Lefranc A, Amela EY, Chevreau C, Bui BN, Lecesne A, Ray-Coquard I, Chabaud S, Penel N, Berge Y, et al. A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group. Br J Cancer. 2013;109(4):909\u201314.","journal-title":"Br J Cancer"},{"issue":"1","key":"1019_CR463","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2165\/11208520-000000000-00000","volume":"13","author":"KA Lyseng-Williamson","year":"2012","unstructured":"Lyseng-Williamson KA, Yang LP. Romidepsin: a guide to its clinical use in cutaneous T-cell lymphoma. Am J Clin Dermatol. 2012;13(1):67\u201371.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"1019_CR464","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30(6):631\u20136.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1019_CR465","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.21.01815","volume":"40","author":"E Bachy","year":"2022","unstructured":"Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas RO, Ysebaert L, Damaj G, Guidez S, Pica GM, Kim WS, et al. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). J Clin Oncol. 2022;40(3):242\u201351.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1019_CR466","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1200\/JCO.23.01687","volume":"42","author":"V Camus","year":"2024","unstructured":"Camus V, Thieblemont C, Gaulard P, Cheminant M, Casasnovas RO, Ysebaert L, Damaj GL, Guidez S, Pica GM, Kim WS, et al. Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial. J Clin Oncol. 2024;42(14):1612\u20138.","journal-title":"J Clin Oncol"},{"issue":"17","key":"1019_CR467","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.2019001285","volume":"134","author":"OA O\u2019Connor","year":"2019","unstructured":"O\u2019Connor OA, Falchi L, Lue JK, Marchi E, Kinahan C, Sawas A, Deng C, Montanari F, Amengual JE, Kim HA, et al. Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study. Blood. 2019;134(17):1395\u2013405.","journal-title":"Blood"},{"issue":"16","key":"1019_CR468","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood.2020009004","volume":"137","author":"L Falchi","year":"2021","unstructured":"Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, Deng C, Kim HA, Rada A, Jacob AT, et al. Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. Blood. 2021;137(16):2161\u201370.","journal-title":"Blood"},{"issue":"19","key":"1019_CR469","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1182\/bloodadvances.2023009767","volume":"7","author":"J Ruan","year":"2023","unstructured":"Ruan J, Zain J, Palmer B, Jovanovic B, Mi X, Swaroop A, Winter JN, Gordon LI, Karmali R, Moreira J, et al. Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma. Blood Adv. 2023;7(19):5771\u20139.","journal-title":"Blood Adv"},{"issue":"9","key":"1019_CR470","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/s41591-024-03076-6","volume":"30","author":"SM Horwitz","year":"2024","unstructured":"Horwitz SM, Nirmal AJ, Rahman J, Xu R, Drill E, Galasso N, Ganesan N, Davey T, Hancock H, Perez L, et al. Duvelisib plus romidepsin in relapsed\/refractory T cell lymphomas: a phase 1b\/2a trial. Nat Med. 2024;30(9):2517\u201327.","journal-title":"Nat Med"},{"issue":"1","key":"1019_CR471","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1038\/s41467-021-24532-8","volume":"12","author":"T Montavon","year":"2021","unstructured":"Montavon T, Shukeir N, Erikson G, Engist B, Onishi-Seebacher M, Ryan D, Musa Y, Mittler G, Meyer AG, Genoud C, et al. Complete loss of H3K9 methylation dissolves mouse heterochromatin organization. Nat Commun. 2021;12(1):4359.","journal-title":"Nat Commun"},{"issue":"20","key":"1019_CR472","doi-asserted-by":"crossref","first-page":"11178","DOI":"10.1093\/nar\/gkad796","volume":"51","author":"S Park","year":"2023","unstructured":"Park S, Cho JH, Kim JH, Park M, Park S, Kim SY, Kim SK, Kim K, Park SG, Park BC, et al. Hypoxia stabilizes SETDB1 to maintain genome stability. Nucleic Acids Res. 2023;51(20):11178\u201396.","journal-title":"Nucleic Acids Res"},{"issue":"15","key":"1019_CR473","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/0008-5472.CAN-21-3523","volume":"82","author":"D Pan","year":"2022","unstructured":"Pan D, Bao X, Hu M, Jiao M, Li F, Li CY. SETDB1 Restrains Endogenous Retrovirus Expression and Antitumor Immunity during Radiotherapy. Cancer Res. 2022;82(15):2748\u201360.","journal-title":"Cancer Res"},{"issue":"2","key":"1019_CR474","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1158\/2326-6066.CIR-23-0514","volume":"13","author":"MK McGeary","year":"2025","unstructured":"McGeary MK, Damsky W, Daniels AJ, Lang SM, Xu Q, Song E, Huet-Calderwood C, Lou HJ, Paradkar S, Micevic G, et al. Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma. Cancer Immunol Res. 2025;13(2):245\u201357.","journal-title":"Cancer Immunol Res"},{"key":"1019_CR475","doi-asserted-by":"crossref","unstructured":"Zhou L, Wu Y, Kang T. H3K9 trimethylation homeostasis: mechanisms, crosstalk, and cancer relevance. Trends Cell Biol. 2026;36(8):707\u201320.","DOI":"10.1016\/j.tcb.2026.02.002"},{"issue":"7","key":"1019_CR476","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.tig.2025.04.011","volume":"41","author":"X Li","year":"2025","unstructured":"Li X, Liu N. Advances in understanding LINE-1 regulation and function in the human genome. Trends Genet. 2025;41(7):577\u201389.","journal-title":"Trends Genet"},{"issue":"10","key":"1019_CR477","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1002\/cac2.70048","volume":"45","author":"T Wu","year":"2025","unstructured":"Wu T, Zhao Y, Zhang X, Wang Y, Chen Q, Zhang M, Sheng H, Zhang Y, Guo J, Li J, et al. Short-chain acyl post-translational modifications in cancers: Mechanisms, roles, and therapeutic implications. Cancer Commun (Lond). 2025;45(10):1247\u201384.","journal-title":"Cancer Commun (Lond)"},{"issue":"7","key":"1019_CR478","doi-asserted-by":"crossref","first-page":"107235","DOI":"10.1016\/j.isci.2023.107235","volume":"26","author":"T Tsusaka","year":"2023","unstructured":"Tsusaka T, Oses-Prieto JA, Lee C, DeFelice BC, Burlingame AL, Goldberg EL. Non-specific recognition of histone modifications by H3K9bhb antibody. iScience. 2023;26(7):107235.","journal-title":"iScience"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-01019-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-01019-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-01019-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:48:15Z","timestamp":1792190895000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-01019-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":478,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1019"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-01019-6","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"15 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"143"}}